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Abstract 
Carbohydrates are important feed stocks in synthesis of natural products 
and so attract the interest of many organic researchers throughout the 
world, most notably in the last 10 years. The work described within explores 
the manipulation of the glucose-derived glucal. The addition of a reactive 
substituted cyclopropane across the alkene has been employed 
synthetically for many years, the subsequent ring breaking/expansion has 
been identified in the lab as slow and needing the support of catalysts. 
We ask the question, “Will cyclopropanated carbohydrates undergo the 
slow ring breaking/expansion in the presence of proteins, and are we able 
to identify which of the two types of mechanisms the reaction is going 
through?” The cyclopropane will act as a warhead to bind to proteins 
through Ferrier like rearrangements, resulting in irreversible inhibition. To 
identify the potential of such compounds, a combination of techniques 
are used to identify potential pathways, protein targets and reactivity 
through structure activity relationships. 
The key steps involved in finding out the potential of cyclopropanated 
carbohydrates are to determine biological activities through bio-assays, 
structure activity relationships, selective binding, chemical genetics and 
chemical proteomics. The bio-assays together with structure activity 
relationships provides evidence on which chemical mechanism is 
occurring when the biological target is interacting with the bioactive 
cyclopropanated carbohydrates. The most active compound, benzose 
(7), was subjected to chemical genetic analysis to determine the 
pathways and processes that are involved with the mode of action. The 
chemical genetic analysis was complimented by chemical proteomics to 
identify the direct biological target. Analogues of benzose were 
synthesised by the addition of azide groups to undergo a Huisgen 
Cyclisation within a cell lysate to facilitate binding to an alkyne-substituted 
matrix.  
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Abbreviation list 
1H NMR Proton nuclear magnetic resonance 
13C NMR Carbon nuclear magnetic resonance  
   Chemical Shift (ppm) 
ABC  ATP-binding cassette 
Ac2O  Acetic anhydride 
Ally  CH2CHCH2- 
AIBN  Azobisisobutyronitrile 
Bn  Benzyl 
Bz  Benzoyl  
bs  Broad singlet 
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ddd  Doublet of doublets of doublets 
ddH2O Double distilled water 
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DMF  N,N-dimethylformamide 
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PDR  Pleiotropic drug resistance 
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q  Quartet 
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SD  Synthetic dropout media 
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t  Triplet 
TEBAC Benzyltriethylammonium chloride 
TFA  Trifluoroacetic acid 
THF  Tetrahydrofuran 
TLC  Thin layer chromatography 
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1.0 INTRODUCTION  
 
We introduce here the background to cyclopropanes and carbohydrates 
and how these can be utilised in the field of drug development. 
This introduction shows the importance of enzymes in drug development, 
and how this information can be used in designing drugs to prevent or 
alleviate health related diseases. A method in drug development is 
introduced that has not been used to the potential we believe it presents. 
Finally, the use of yeast as a model organism in identifying potential 
pathways and processes that bioactive compounds target is presented, 
along with the use of yeast in identifying potential lead drugs for further 
optimisation.  
 
1.1 Enzymes in drug development 
 
Enzymes are crucial for existence of all forms of life. Without the ability to 
catalyse reactions, life would not exist (Szostak et al. 2001). These 
biological catalysts have evolved to exhibit a high degree of specificity 
and catalyse reactions with highly conserved mechanisms. Enzymes have 
been a point of focus for drug development, due to their role in metabolic 
pathways and potential for manipulation in diseases that involve 
abnormal protein expression (Neurath & Walsh, 1976; Marik et al. 2011). 
 
Drugs that inhibit over-expressed proteins are used to decrease, delay or 
prevent the progression of the related disease (Arnoldo, 2008). For 
example, a large area of cancer research is focused on designing novel 
anticancer drugs that are based on the normal substrate of enzymes. 
These enzymes are normally highly expressed in cancerous cells (Shah et 
al. 2004), and it has been shown that inhibiting these proteins can cause a 
decrease in cancerous growth (Marik et al. 2011). To be therapeutically 
2 | P a g e  
 
useful, an inhibitor must suppress the activity of a protein that is essential 
for disease progression, with limited adverse effects (Dombernowsky et al. 
1998; Semenza, 2002). A well designed inhibitor typically has a Kd value in 
the nanomolar (nM) range (Friedman et al. 1993).  
 
Common practise in drug development is to identify a protein target that 
is over-expressed in a related health problem. For example, up regulation 
of the HER-mediated signalling network has been implicated in breast 
cancer, resulting from the amplification of the HER-2 gene (Slamon et al. 
1987). HER-2 has been found to have a specific activity of 11 nmol/min/ 
mg and protein over-expression is present in approximately 20% of human 
breast cancers and is associated with decreased survival (Slamon et al. 
1989). A successful strategy to decease the effect of overexpressed HER-2 
protein involved the development of inhibitors that decrease the HER-2 
signalling pathways which play a role in the cancer cell proliferation. The 
extracellular binding domain F of HER-2 by trastuzumab, a humanized 
monoclonal antibody, has been shown to decrease cell proliferation 
(Vogel et al. 2002; Cameron et al. 2008). HER-2 is also targeted by the 
small-molecule inhibitor Lapatinib, the structure is shown in figure 1.1 
(Cameron et al. 2008).  
Enzymes can be targeted in not just humans. Bacterial related health 
Figure 1.1. Lapatinib a bioactive small molecule inhibitor of HER-2. 
3 | P a g e  
 
problems are also being researched to develop new methods of inhibiting 
enzymes associated with antibiotic resistant infections. 
Antibiotic-resistant infections have become a major challenge for 
healthcare professionals (Neidell et al. 2012). More die as a result from 
methicillin-resistant Staphylococcus aureus (MRSA) (approximately 19,000 
a year) than complications assocaited AIDS in USA (Klevens et al. 2008). To 
overcome drug resistance, a new drug target or new drug classes are 
needed. Multiple approaches will then increase the rate of the discovery 
of new target proteins to combat antibiotic-resistant infections (Smith, 
2005; Lizawa et al. 2004; Van Bambeke et al. 2008). One unexploited 
target in antibacterial drug design is present in the de novo purine 
biosynthetic pathway, 5-(carboxylamino)imidazole ribonucleotide 
synthase (CAIR-synthase). This pathway is a useful antibacterial target as it 
is different to that of humans (Firestine et al. 2009; Thoden et al. 2008). This 
gives an important potential target for an enzyme inhibiting drug and 
demonstrates the importance of designing single target inhibitors for drug 
discovery. The next step of finding bioactive compounds that can 
selectively inhibit CAIR-synthase can be achieved by synthesising a 
compound (based on the pre-existing knowledge of the CAIR-synthase 
active site) or testing a library of compounds against the protein. Firestine 
et al. (2009) tested 48 000 drug-like compounds against CAIR-synthase at 
inhibitor concentrations between 5- 27 µM and initially found 212 potential 
inhibitors. Of these 14 showed dose-response relationships. Thoden et al. 
(2008) were also the first research group to find selective, non-nucleotide 
inhibitors for CAIR-synthase. 
 
In order to achieve advances in drug design and identification of 
bioactive compounds it is vital to adopt multiple approaches (Balani et al. 
2005). 
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1.2 Approaches to drug design and discovery:  
 
Drug design has been approached from many angles and each angle 
has its advantages and disadvantages (Patani & LaVoie, 1996; Wolber et 
al. 2008). The approaches to drug design can be broken down to three 
common methods. 
 
1) Ligand-Based Drug Design 
Designing a compound that interacts with a target, based on knowledge 
of existing ligands that interact with the target site. Typically this approach 
uses quantitative structure activity relationship (QSAR) analysis and 
requires activity profiles of many ligands (Yang & Huang, 2006). It is 
especially valuable when high quality target site information is sparse, as 
can often be the case with membrane-associated target proteins. 
 
2) High Throughput Screening 
Discovery of a lead compound, typically from natural products or libraries 
of combinatorially synthesised compounds. For example the Maybridge, 
ChemDic, Chembridge and MS Spectrum Libraries consisting of over 
49,000+ drug like compounds, are commercially available libraries that 
can be used for high throughput screens. Depending on the screening 
methodology adopted, this approach does not require any prior 
knowledge of either target or drug-target interactions. The library screens 
can then be spilt up into three types: 
 
1) Structure based screens;  
2) Activity based screens; and 
3) High throughput libraries screens. 
 
Once a lead compound is discovered, it will then be optimised through 
medicinal chemistry (Costantino & Barlocco, 2006; Kolb & Sharpless, 2003) 
and/or QSAR approaches as described above. 
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3) Target-Based Drug Design 
Designing a compound that interacts with a target, based on existing 
knowledge of the target’s active site (Ricci et al. 2005; Skulnick et al. 1995). 
Typically this approach is used for the design of mechanism-based drugs. 
 
The three methods of drug discovery are different, however, all drug 
development approaches follow a similar path: 
 
1. Synthesis, extraction or compound library;   
2. screening against a cell line/target to find activity; 
3. identification of targets or interactions if unknown; and 
4. optimisation.       
 
A fourth method will be presented and discussed in this thesis. This method 
is based around well-known organic mechanisms and how they could be 
catalysed by enzymes. In most cases the approach to drug design is 
completed against a biological target, ie a protein of interest. However, 
when the target is unknown, it is essential to identify what the bioactive 
compound is interacting with.  
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1.3 Methods of target identification 
 
One of the most important steps in drug development is the identification 
of the protein target of the bioactive molecule (Phillip, 2002). Knowledge 
of the interaction between the protein target and the bioactive molecule 
is essential for understanding the mechanism of the bioactive molecule 
within a cell (Cho & Kwon, 2012).   
 
A classical method of target identifying is genetic based, involving 
mutations introduced into living cells (James et al. 1996). The introduced 
mutations can include knockout genes or over-expression of certain 
proteins. When this is done on a large scale with multiple permutations it is 
referred to as a genomic library (James et al. 1996). A genomic library 
screened against a drug-like compound will identify resistant or sensitive 
strains, where particular genes that are knocked out or up-regulated may 
play a pivotal role in the mechanism of action of the drug-like compound. 
For example, a deletion library in Saccharomyces cerevisiae treated with 
rapamycin was able to identify resistant and sensitive strains (Xie et al. 
2005). This information was then used to identify that the TOR (target of 
rapamycin) pathways were being affected. Further studies identified that 
rapamycin inhibits downstream signalling from the target TOR proteins 
inhibiting protein synthesis. Chemical genomics together with other 
approaches of identification can be used to generate strong evidence 
towards identifying a bioactive compound’s target and function (Huang 
et al. 2004).   
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A direct approach for drug target identification involves proteomic 
profiling, which identifies proteins by peptides. Identification of a target 
can be completed in forward or reverse chemical proteomic methods, 
both of which can utilise affinity based interactions (Kramer & Cohen, 
2004). Forward chemical proteomics involves the identification of the 
target protein of a newly-discovered bioactive molecule (Lokey, 2003). 
The compound of interest is attached to a resin, then a cell lysate or 
protein mixture is washed past the resin (affinity pull-down) as shown in 
figure 1.2. The proteins are then removed by washing or tryptic digest 
(Bantscheff et al. 2012). The interacting targets can then be identified by 
mass spectrometry (von Rechenberg et al. 2005; Cho & Kwon, 2012).  
 
 
 
 
Figure 1.2. Classic affinity purification for drug target discovery, involving direct 
immobilization of the bioactive compound onto a solid resin. (Figure adapted from 
Sleno & Emili, 2008) 
Protein 
lysate 
Immobilized 
ligand 
Target 
protein 
Peptide 
chains 
Load protein 
lysate 
Non-binding 
proteins 
Wash non-covalent  
binders 
Trypsin treat covalent 
binders 
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If the bioactive compound of interest does not contain a suitable 
functional group (most commonly; an amine, carboxyl, or hydroxyl group) 
to attach to the resin, chemical synthesis of an appropriate functionalised 
analogue of the compound is required. The resulting analogue will then 
need to be evaluated as to whether it retains the required target affinity 
or biological activity (Bantscheff, 2012).  
With a method that is successfully able to identify a biologically active 
compound’s target, it is then possible to identify what type of interactions 
are occurring. Using methods like mechanism-based design, it is possible 
to design a compound to interact with a biological target in a certain 
way, giving you an idea of the interactions that could possibly occur. 
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1.4 Mechanism-based inhibitors  
 
Mechanism-based inhibition is a lesser-used method in drug discovery, but 
has become an essential method in identifying irreversible inhibitors of 
target enzymes (Walsh, 1982; Silverman, 1988).   
 
The mechanism-based design approach is split into two types, one is 
based on having understanding of how a compound undergoes a 
reaction in the chemistry lab. Applying that idea in context with cells and 
asking the question, “Is it possible for this mechanism to be catalysed by 
an enzyme within a cellular environment”? This type will be explored within 
this thesis.  
 
The second type, which is the reverse of above was used by Borthwick et 
al. (1998) to identify novel inhibitors of Human Herpes Virus Retinitis 
Pneumonitis (HHVRP), where Borthwick designed an inhibitor based on the 
active site of HHVRP. The information generated from the structure and 
interactions of HHVRP with its substrate, gave Borthwick the required 
information to identify what chemical mechanism would achieve a 
covalent mechanism-based attachment to the HHVRP. Borthwick was 
then able to design a compound with all the requirements shown to be 
needed to inhibit HHVRP.  
 
Cyclopropanes have been employed frequently in this field due to their 
high ring strain and their propensity to ring open when exposed to 
nucleophiles. Nucleophiles are able to attack, breaking the cyclopropane 
to irreversibly form covalent bonds (Hanzlik et al. 1979; Wiseman & Abeles, 
1979; Paech et al. 1980; Silverman & Hoffman, 1980).  
 
Mechanism-based design of inhibitors has many challenges to overcome 
to become a more commonly used method. Understandably, a major 
challenge is the fear of unexpected side effects through build-up of 
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covalently bound non-targets (Overall & Kleifeld, 2006). This has led to the 
majority of drug development focusing on non-covalent inhibitors. 
Interestingly, 35% of the currently licensed enzyme inhibitors for human use 
in the USA covalently modify the target or enzyme-substrate complex 
(Robertson, 2005). These drugs have proven efficacy by targeting binding 
but more importantly the catalytic mechanism. Since the active moiety of 
the bioactive molecule is only active to the target enzyme, it proves to be 
highly specific (Overall & Kleifeld, 2006). 
 
The interactions between enzymes and substrates or inhibitors are usually 
non-covalent, for example through hydrogen bonding, electrostatic and 
hydrophobic interactions, but irreversible covalent modifications can also 
occur. Suicide inhibitors are a class of inhibitors that utilise an enzyme’s 
catalytic mechanism, to leave the inhibitor covalently attached to the 
enzyme. These inhibitors are most often used when cell death is the 
desired outcome, as in the potential treatment of cancers (Ricci et al. 
2005). Suicide inhibitors are also used to trigger cell death in the case of 
antibiotics. The -lactam-based antibiotics are a good example of this. 
Scheme 1.1 shows a ring opening of the penicillin -lactams (Labischinski, 
1992). The attack at the carbonyl group of the -lactam ring, typically by 
an active site serine of a bacterial transpeptidase, results in the nitrogen-
carbon bond breaking, and the binding of penicillin through an ester to 
the enzyme.  
ENZ-OH
Scheme 1.1. Ring opening of penicillin by transpeptidase  
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The work proposed in this thesis will be looking at a class of potential 
suicide inhibitors that utilise the reactivity of strained functionalised 
cyclopropanes.  
 
 
1.4.1 Cyclopropanated compounds 
 
Freund reported the first synthesis of cyclopropane (C3H6) in 1881 (Freund, 
1881). The compound was discovered to be highly flammable and 
reactive to nucleophilic attack (Blomberg et al. 1987). Cyclopropanes 
have also been found to have an anaesthetic effect (Waters & Schmidt, 
1934) as well as some other interesting properties. For example, a 
cyclopropane has a higher degree of general similarity to an alkene than 
a cyclobutane (Meijere, 1979; Meijere, 2003). An alkene is usually more 
reactive than a cyclopropane, but there are no fundamental differences 
in behaviour (Baeyer, 1885; Meijere, 2003).  
 
Three years after Freund’s synthesis of cyclopropane, the first synthesis of a 
cyclopropane derivative was reported (Perkin, 1884). Current research on 
the chemical and biological uses of cyclopropanes continues to provide 
advances in understanding their utility (Meijere, 2003). The cyclopropane 
ring has biological relevance as it has high torsional strain and is 
susceptible to nucleophillic attack, for example by proteins (Wong et al. 
1989).  
 
Thousands of cyclopropane containing compounds have been 
characterised (Brandt & Wessjohann, 2003), with many being biologically 
active. Cyclopropane moieties appear to be involved in some interesting 
enzyme catalysed reactions, including the inhibition of methanol 
dehydrogenase (Frank et al. 1989). These biologically active 
cyclopropanated structures found naturally makes them useful tools for 
enzyme inhibitor design. Cyclopropanes are found in several natural 
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product classes, including hormones, amino acids, fatty acids, alkaloids, 
and terpenoids.  
 
The importance of cyclopropanes relates in part to the properties that 
they engender on their parent molecule. An increase in overall rigidity, 
activity through constraint in flexibility and also potential energy (created 
by torsional and ring strain) of cyclopropane-containing molecules, can 
be factors that help drive further reactions towards opening the 
cyclopropane (Chu-Moyer & Danushefsky, 1993). An enzymatic 
nucleophile can attack the cyclopropane and form a covalent bond, as 
occurs with dihydrofolate reductase with cyclopropane substituted 
pteridine and pyrimidine in schemes 1.3 & 1.4 (Haddow et al. 1987; 
Suckling, 1988). The resulting enzymatic attack on a cyclopropane causes 
inhibition by leading to the ring opening of the cyclopropane and 
irreversible inhibition as the enzyme is covalently attached. (Haddow et al. 
1987; Suckling, 1988 Chu-Moyer & Danushefsky; 1993).  
Harnessing cyclopropanes that undergo ring opening or breaking 
reactions that lead to irreversible inhibition is the ideal outcome in the 
research proposed here. The active compounds described in this chapter 
contain a cyclopropane with a carbohydrate backbone, together are 
known to undergo catalytic ring opening and ring breaking reactions. 
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Scheme 1.3. Cyclopropanated pyrimidine as a mechanism-based inhibitor of 
dihydrofolate reductase 
 
Scheme 1.2. Cyclopropanated pteridine as a mechanism-based inhibitor of 
dihydrofolate reductase 
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1.4.2 Carbohydrate-cyclopropanes   
 
The incorporation of cyclopropanes into carbohydrates provides 
interesting chemistry through the combination of the strained cyclopropyl 
ring with the chirality inherent to the parent carbohydrate. The literature in 
this field has been based mainly on such compounds as intermediates in 
the synthesis of bioactive compounds and new synthetic methods, 
focusing on the pyranoside- and furanoside-based carbohydrates 
(Meldgaard & Wengel, 2000; Hewitt & Harvey, 2010). Examples include the 
synthesis of seven-membered rings and their application in the synthesis of 
natural products and analogues (Brandt & Wessjohann, 2003).  
 
1,2-Cyclopropanated carbohydrates can be synthesised by the addition 
of a carbene to a glycal. Many (protected) glycals are commercially 
available, while they are also simply synthesised from the corresponding 
sugar. 1,2-Cyclopropanated carbohydrates are very interesting as they 
can undergo a range of ring expansion and ring breaking reactions. The 
ring expansion reactions provide oxepines and ring breaking leads to 2-C-
branched pyranosides (Hewitt & Harvey, 2010; Moore, 2012).  
 
Schemes 1.4 and 1.5 depict a reaction of a cyclopropanated 
carbohydrate with a nucleophile which attacks the C-1 of the sugar; the 
product is a 7-membered ring formed through ring expansion (Salaün, 
2000). The ring expansion can go by either of two pathways. The first 
(scheme 1.4) results in the loss of the C-3 substituent, which is promoted by 
a Lewis acid or electrophile, resulting in an unsaturated product. The 
second pathway results in the loss of a leaving group from the C-7 position 
(X=halogen, hydrogen), as shown in scheme 1.5. Several research groups 
have studied cyclopropane ring expansions of functionalised gem-
dichloro-1,2-cyclopropanated carbohydrates (Hewitt & Harvey, 2010), for 
example, leading to oxepines following ring expansion in refluxing toluene 
in the presence of a nucleophile under basic conditions (Jayaraman & 
Ganesh 2008; Jayaraman & Ganesh 2007). 
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Another method of cyclopropane ring opening results in the C-2-
branched pyranoside (Hewitt, 2008). Scheme 1.6 shows a generalised 
mechanism for this transformation as proposed by Hewitt. There are 
numerous potential rearrangement reactions that can then follow such 
reactions of the cyclopropanated sugar.  
 
The mechanisms described above have the potential of being able to be 
catalysed by an enzyme. A potential enzyme will need a nucleophile, 
electrophile a binding site that will accommodate the cyclopropanated 
sugar. If an enzyme has the right characteristics, these compounds may 
covalently bind to that enzyme (scheme 1.6). In the absence of an 
external nucleophile a cyclopropane sugar can react through an 
intermolecular cyclisation with the C-6, resulting in the generation of a 
bicyclic compound (Hoberg & Cousins, 2000). These reactions illustrate the 
general mechanisms associated with breaking of the cyclopropane ring. 
(Hoberg & Bozell, 1995). 
 
In summary, cyclopropanated sugar derivatives can undergo reactions 
with nucleophiles and electrophiles that lead to either:  
 
i) Ring-opening of the cyclopropane, giving carbohydrate-like pyrans  
with variant C-2 substitution or  
ii) Ring expansion of the pyran, giving oxepines.  
 
In both cases, either a catalyst, promoter or harsh reaction conditions are 
required and the nucleophile is covalently bonded to the C-1 position.  
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Scheme 1.5. Nucleophile-mediated ring expansion with the loss of C-3 substituent 
Nu:
E+
Scheme 1.4. Nucleophile-mediated ring expansion with the loss of C-7 substituent  
Nu:
1
2
3
4
5
7
6
Figure 1.3. Structure of   cyclopropanated carbohydrate, showing numbers of 
carbons. 
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Designing bioactive compounds based on carbohydrates offers many 
benefits including: cost effectiveness, pre-existing stereochemistry, and 
well known chemistry. Once a compound of this class has been identified 
to have bioactivity, it will then be optimised to increase the associated 
toxicity. 
Scheme 1.6. Nucleophile-mediated ring breaking with the loss of C-7 substituent 
through a stabilised carbanion intermediate. 
Nu:
H+
Base
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1.5 Yeast as a model organism  
 
Saccharomyces cerevisiae (baker’s yeast) is a valuable tool for the search 
of novel therapeutic agents. S. cerevisiae screens are inexpensive and 
often quicker and simpler to run compared to mammalian screens. The 
unicellular S. cerevisiae are small in size and are able to double in 90 min 
under optimum conditions. 
The yeast genome consists of 16 chromosomes; ~6400 open reading 
frames (ORFs) of which ~1000 genes are classed as “essential”. This term is 
given to genes that once deleted leaves the yeast non-viable. Over 4800 
genes are non-essential and have been replaced singly by integration of 
an antibiotic resistance marker and synthetic barcode sequence to 
create a comprehensive non-essential deletion mutant array (DMA). This 
has given rise to a yeast genome deletion set (YGDS) which comprises of 
~4800 strains that each have a single non-essential gene deleted. The 
deleted gene is replaced by a gene cassette (KanMX4) conferring 
resistance to kanamycin. The cassette is accompanied by a unique 
molecular bar code surrounding every gene deletion. The YGDS is a tool 
that can be used to determine pathways in which compounds may act, 
by identifying strains that are either hyper-sensitive or resistant compared 
to the wild type of yeast as described by Tong et al. (2004). High 
throughput drug assays make it possible to categorise compounds that 
can act on particular pathways or processes.  
 
The S. cerevisiae genome has been completely sequenced and has a 
relatively low number of genes and associated proteins compared to 
mammalian cells, making it a simple medium to use (Geoffeau et al. 
1996). S. cerevisiae also has other important factors that make it a model 
organism for the study of genetic disorders in humans. Almost 1,000 yeast 
genes have orthologs that are implicated in human disease.  S. cerevisiae 
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can also mimic multiple human disease, through genetic manipulation 
(Botstein et al. 1997; Kataoka et al. 1985). This fact has been a driving force 
in the importance of using yeast as the first stepping stone in the discovery 
of new drugs that can treat or prevent the progression of a human 
disease.  
 
A study by Andrade and colleagues identified 285 yeast proteins that are 
similar to 155 proteins associated to human disease (Andrade et al. 1998). 
If one is to inhibit a protein in yeast, then most likely, a similar protein in 
humans will also be inhibited (Bork et al. 2004). This gives a direct method 
for testing inhibitory drugs in a robust, easily cultured, simplified and well-
characterised system. One such example is the immunosuppressant 
compound FK506 that has an inhibitory concentration (IC50) of 9 nM and 
was found to inhibit calcinuerin function in yeast (Breuder et al. 1994). As 
well as human diseases, S. cerevisiae also represents an entry point for 
identifying antifungal agents (Joyce & Palsson, 2006). 
 
What has been presented here in this introduction gives a pathway to 
drug development; from synthesising a new compound, to identifying its 
potential in the future of drug design. All together this leads to a hypothesis 
that will be explored as part of my Masters in Biomedical Science based 
on carbohydrate-based cyclopropanes and their potential use in drug 
development.  
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1.6 Research hypothesis and objectives 
 
Cyclopropanated sugars that can undergo ring opening or ring expansion 
reactions have ideal characteristics for suicide inhibitors. The research 
hypothesis will be tested to determine whether these reactions (scheme 
1.4, 1.5 and/or 1.6) can be utilised in drug development. These reactions 
do not occur at a significant rate naturally without the use of strong 
nucleophiles, activators or high temperatures which make them ideal 
substrates for enzymes. Addition of a protein may provide nucleophilic 
and catalytic functionalities either ring opening or ring expansion, 
providing the products at ambient temperatures.  If the nucleophile was 
provided by the protein, this would leave the binding site alkylated by the 
bioactive substance. It is proposed that there will be a limited number of 
proteins that will provide the essential functionality and capacity to both 
bind the artificial substrate and complete the reaction, resulting in good 
target selectivity. 
 
The main objectives of this research are to 
1) Prepare a range of cyclopropanated glucal-derived compounds; 
2) Conduct a structure activity relationship (SAR) analysis to determine 
the most active compound against S. cerevisiae; 
3) Identify potential pathways of interactions by chemical genomics; 
and 
4) Determine protein targets by mass spectrometry 
 
1) Prepare a range of cyclopropanated compounds 
Starting with glucal, a range of cyclopropanated compounds will be 
synthesised to create a small library. The derivatives are designed to 
provide information on which proposed ring opening/ ring expansion 
mechanism is taking place within the cell. 
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2) SAR analysis to determine the most active compound against S. 
cerevisiae  
Each compound that is made will be subjected to an IC50 analysis in S. 
cerevisiae. In addition to identifying a lead compound, structural features 
that promote or supress activity will be determined and a likely 
mechanism for any covalent modification be proposed. 
 
3) Identify potential pathways of interactions by chemical genomics 
The lead compound from 2 (above) will be subjected to a chemical 
genomic screen to identify any pathways that are being affected in 
yeast. The lead compound will also be subjected to an assay to determine 
whether it is cytotoxic or cytostatic. 
 
4) Determine protein targets  
A parallel study to 3 (above) will be to modify the lead compound to 
allow for an attachment point of a matrix or molecular probe. Ideally this 
will be achieved without a decrease in activity. The lead compound-
probe will be then treated with S. cerevisiae cell lysate. Target proteins will 
be isolated by use of sepharose resin and identified by tryptic digest and 
MS/MS to determine the protein target.  
 
This thesis is split into two general threads, chapter two focuses on the 
chemistry aspect, and chapter three has the emphasis on the biological 
testing of the compounds synthesised in chapter two. 
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2.0 CHEMISTRY 
 
2.1 Aim and Objectives  
 
The aim of this chemistry was to design and synthesis a range of 
cyclopropanated carbohydrates in order to identify a lead compound. 
The lead compound would then be carried through to the biological 
testing which is discussed in chapter 3. The objectives outlined in section 
1.6 that will be addressed here include; 
1) To prepare a range of cyclopropanated compounds 
4) Determine protein targets  
 
The structure of each compound presented with this thesis is numbered as 
depicted in figure 2.1. This is in accordance to IUPAC recommendations. 
 
2
1
3
4
5
6
7
2
1
3
4
5
6
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2.2 Introduction 
 
2.2.1 Cyclopropanes 
 
In 1959 Simmons and Smith discovered a procedure that produced 
cyclopropanes from alkenes with carbenes without side products usually 
present in other methods current at the time (Simmons & Smith, 1959). Their 
method involves treatment of an alkene with CH2I2 and a zinc-copper 
couple, and is thought to go through an organozinc intermediate. A high 
degree of stereoselectivity can be achieved, for example when directed 
by a hydroxyl group. The zinc coordinates to the oxygen species which 
directs the reaction to occur on the same face as the oxygen 
functionality. This is shown in scheme 2.1, where the cyclic allylic alcohol 
(cyclopent-2-en-1-ol) is cyclopropanated forming the bicyclic alcohol 
(bicyclo[3.1.0]hexan-2-ol).  
 
gem-Dihalocyclopropyl groups are important functional groups in organic 
chemistry. They provide routes to functionalised and unfunctionalised 
cyclopropanes, including those found in natural products. gem-Dichloro/ 
gem-dibomocyclopropanes are synthesised by the addition of a carbene, 
through the treatment of an alkene with chloroform or bromoform. The 
Makosza dichlorocarbene addition is directed by steric bulk, such that 
Scheme 2.1. Synthesis of biocylo[3.1.0]hexan-1ol by Simmons and Smith 
methodology. 
CH2I2, Zn dust
CH2Cl2
(1R)-cyclopent-2-en-1-ol (1S,2R,5R)-bicyclo[3.1.0]hexan-2-ol
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addition occurs on the opposite face to the C-3 substituent, due to the C-
3 hydroxyl protecting group blocking the top face.  
Nagarajan demonstrated the preparation of a range of 1,2-
cyclopropanated sugars through the Simmons-Smith and Makosza 
methodologies as exemplified by the reaction of tri-O-benzyl-D-glucal 
shown in scheme 2.2 (Nagarajan et al. 1997). Firstly, the cyclopropane was 
synthesised using a zinc-copper couple, CH2I2 and acetyl chloride in 
refluxing diethyl ether, producing the “up facing” cyclopropane in 89% 
yield. Makosza cyclopropanation with chloroform provided the “down 
facing” dichlorocyclopropane in 85% yield. A modified Makosza 
cyclopropanation was used to synthesise the “down facing” 
dibromocyclopropane with an 84% yield, scheme 2.2. 
The above methodology was extended here to the formation of a library 
of cyclopropanated sugars, varying the oxygen substituents and 
cyclopropane stereoisomers. The library was created to identify a lead 
compound and give further evidence towards the likely mechanism 
introduced in section 1.4.2. The library was extended once the lead 
compound was identified to further optimise the inhibitory effect on S. 
cerevisiae. 
Scheme 2.2. Simmon-Smith cyclopropanation, Makosza dichlorocyclopropanation 
and modified Makosza dibromocyclopropanation cyclopropanation (Nagarajan et al. 
1997). 
CH2I2
ZnCu
CHCl3, 
50% NaOH
TEBAC
CHBr3, 
33% NaOH
TEBAC, KF
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2.2.2 Optimising inhibitors 
 
Once a lead inhibitor is found, it can then be altered to enhance any 
desirable effects. A study by Marik and colleagues (2011) shows a good 
example in optimisation of genistein, a known bioactive compound that 
inhibits breast cancer cell lines (Shah et al. 2004; Marik et al. 2011). To 
enhance the activity of the anticancer properties, seven derivatives of 
genistein were synthesised. Marik identified three derivatives that showed 
a 10-15 increase in toxicity (IC50 genistein 14 µM, MA-6 0.8 µM) against ER 
positive breast cancer cell lines.  
 
Designing bioactive compounds for biologically known and unknown 
targets is important to enhance the field of drug discovery. 
Cyclopropanes have already been shown to be important in mechanism-
based inhibition of proteins. However, with a carbohydrate backbone 
increased protein specificity may occur due to the associated 
stereochemistry, which is essential towards decreasing negative side 
effects. Identifying biological targets of these cyclopropane-containing 
compounds will determine the associated selectivity and, together with 
chemical genetics, would present a pathway to developing new 
commercial drugs. To fully utilise chemical genetics it is beneficial to 
compliment it with chemical proteomics. For this, it is crucial to have a 
molecular probe that is able to bind to the lead compound and then trap 
the protein target. Ideally, selective binding will occur.  
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2.2.3 Molecular probes 
 
The identification of a potential protein target of an active compound 
can be achieved by the use of a molecular probe (Jeffery & Bogyo, 2003). 
Resin-based probes consist of a water-insoluble matrix as well as a linker 
and a point of attachment, for example an epoxide. (Blanks & 
McLaughlin, 1988). Used together with mass spectrometry it is possible to 
identify proteins that are interacting with the resin; additionally, it is 
possible to attach the active compound of interest to the linker of the resin 
and to use that compound as “bait” for the proteins. 
 
Traditionally, a lead compound is developed through SAR, then the 
identification of the biological target is undertaken if unknown. However, 
achieving the attachment of an affinity resin without the lead compound 
losing its activity is a challenge, and in some circumstances impossible. In 
many situations the compound of interest has to be chemically modified 
to allow for the attachment of the resin (Leslie & Hergenrother, 2008). The 
modification ideally has to have no effect on binding to a target or there 
is a risk the protein pull-down maybe different to that of the target of the 
non-resin bound compound.   
 
The incorporation of an azide into the compound of interest allows a well-
known method of attachment to a probe, though the Huisgen Cyclisation 
chemistry (Huisgen et al. 1984; Moses & Moorhouse, 2007). Azides react 
with alkynes in the presence of a copper species, and ascorbic acid (only 
if CuII) through Huisgen-type cycloadditions. Typically, the copper-assisted 
Huisgen Cyclisation reaction is the ideal method to react azides with the 
corresponding alkyne, and is valuable as both azides and alkynes are inert 
within the cell. The identification of proteins using Huisgen-Cyclisation is 
shown in scheme 2.3.  
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Protein 
lysate 
Click 
reaction 
Mass spec  
Attached 
proteins 
Scheme 2.3. A proposed attachment of a glycoside by a Huisgen Cyclisation reaction 
to determine protein targets by mass spectrometry 
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2.4  Results and discussion 
 
2.4.1 Synthesis of cyclopropanated carbohydrates derivatives 4 to 10 and 
13 to 18  
 
The synthesis of cyclopropanes can be achieved in multiple ways, 
commonly by the addition of carbenes to alkenes (Simmons & Smith, 
1959). The use of 1,2-unsaturated sugars (glucals) as substrates extends the 
range of products to highly functionalised stereo-chemically pure systems. 
This application has been pioneered, based on the research by Simmons 
and Smith, Makosza (Makosza & Wawrsyniewicz, 1969), and Nagarajan 
(Nagarajan et al. 1997). For this project two main glucal substrates were 
used, 3,4-di-O-benzyl-6-O-trityl-D-glucal (4) and 3,4,6-tri-O-benzyl-D-glucal 
(28), both of which have a high degree of literature precedence for their 
cyclopropanation, and are easily made from D-glucose (Gammon et al. 
2007; Nagarajan et al. 1997). A general scheme is presented in scheme 
2.4. 
The pioneering work of Emil Fischer and Karl Zach (Fischer & Zach, 1912) 
was employed in the synthesis of tri-O-acetyl-D-glucal from D-glucose in 
three steps beginning with acetic anhydride and a catalytic amount of 
perchloric acid (scheme 2.5). Addition of HBr in acetic acid provided the 
-bromoglycoside as a white solid. This was dissolved in diethyl ether and 
reacted with zinc in the presence of aqueous acetic acid to provide 
crude 3,4,6-tri-O-acetyl-D-glucal in 93% over the three steps.  
Scheme 2.4. A general scheme of a cyclopropanation from D-glucose. R = Bn, Tr; 
R’R”= Bn 
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The acetyl groups were removed using catalytic sodium methoxide in 
methanol followed by purification as described by Risseeuw (Risseeuw et 
al. 2009): The crude product was dissolved in methanol and treated with 
portions of acetone and then diethyl ether which resulted in the impurities 
precipitating out; the resulting pure D-glucal was concentrated, providing 
a pleasing 99% yield. Selective re-protection of the C-6 hydroxyl with trityl 
chloride provided 3 in a good yield of 80% after purification by silica 
column chromatography. However, this yield was typically only achieved 
when a pink colour was seen on the addition of the trityl chloride to the 
pyridine, indicating the presence of the trityl cation. If this was not 
observed the yield was reduced to ca. 60% most likely due to wet 
pyridine. In all cases, the yield based on recovered starting material was 
typically 97%, indicating incomplete conversion with wet pyridine. 
Protection of C-3 and C-4 hydroxyl groups was then achieved with benzyl 
Scheme 2.6. Synthesis of 3,4-di-O-benzyl-6-O-trityl-D-glucal (4) 
Scheme 2.5. Synthesis of 3,4,6-Tri-O-acetyl-D-glucal 1 
1
i) Ac2O, cat. HCIO4
   30 min, 40-50 oC
ii) HBr, AcOH
    90 min, r.t.
Zn, AcOH aq)
0 oC to r.t. o/n
1 2 3
4
BnBr, Na
DMF
MeOH, 
Na
TrCl, Pyridine
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bromide in DMF and NaH which provided the desired product 4 as a white 
solid in a good yield of 93% (scheme 2.6).  
The next step in the synthesis was cyclopropanation, forming non-
halogenated or halogenated (bromide and chloride) cyclopropane 
derivatives. The Simmons-Smith reaction afforded the unsubstituted 
cyclopropane, while the halogenated derivatives were generated by 
Makosza cyclopropanation with bromoform or chloroform. The Simmons-
Smith method applied CH2I2, zinc dust and Cu(OAc)2, whereby the zinc 
carbenoid intermediate reacts with the alkene 4 with high stereoselectivity 
due to coordination to the C-3 oxygen substituent. Purification afforded 17 
as a white solid with yields from 75 to 84% with characteristic   H-1 and H-2 
signals in the 1H NMR spectrum and the two protons on the cyclopropane 
(H-7a, b) characteristic of the product.  
Dibromocyclopropanation was performed as reported by Hewitt and 
Harvey (Hewitt & Harvey, 2009) using a suspension of potassium fluoride in 
a 33% (w/w) solution of sodium hydroxide which resulted in yields of 
between 60- 80% of the major product 13 and yields of the minor isomer 
14 between 10-20%. The maximum yield of 80% was afforded after the 
reaction time was extended to 5 days. The characteristic H-1 and H-2 
signals in the 1H NMR spectrum were again as distinctive as in 17. An 
alternative cyclopropanation method with 33% sodium hydroxide, in the 
absence of potassium fluoride allowed preparation of the 
dichlorocyclopropane. Higher yields were achieved with chloroform, with 
yields between 70 to 85%. Purification by silica column chromatography 
yielded an off-white powder and colourless oil for the major and minor 
products, respectively. The 1H NMR spectrum of the major product 5 
matched the data of Moore (2012) (scheme 2.7). The diastereomer at C-1, 
C-2 of 5 and 13 were also prepared in yields of 10 to 20% 
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Removal of the trityl group from the C-6 position of 5, 6, 13, 14 and 17 was 
done with formic acid in diethyl ether resulted in the corresponding 
alcohols 7, 9, 15, 16, 18 in a range of yields between 20 and 60%. These 
low to moderate yields were due to the formation of a formate ester, 
which was unable to be converted to 6-OH due to the propensity of 
cyclopropane ring opening under formate deprotection conditions. The 
amount of formate ester formed depended on time of the reaction, but it 
was found that the dibromocyclopropanes did not form any formate 
esters if the reaction was limited to two hours. Concurrent biological 
testing of compounds 8 and 10 showed that the compounds were 
inactive (discussed in section 3.4.3) therefore the synthesis of the formate 
ester dibromocyclopropane was not pursued.  
The deprotection of compounds 5 and 6 (scheme 2.8) found that two 
hours provided a good balance of product to formate by-product, as 
shown in table 2.1. Purification of the mixture by silica column 
chromatography gave semi-pure dichloro- and dibromocyclopropanes 
products 7 and 13, further purification by -14 °C hexane recrystallisation 
resulted in pure white powder. The deprotection of 5 and the  
Scheme 2.7. Synthesis of 5 and 6, 13 and 14 and 17 
13 14
6517 
CH2I2, Zn
Cu(OAc)2
CHCl3, 33% NaOH(aq),
TEBAC
CHBr3, 33%
NaOH(aq), TEBAC
KF 
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Compound 
number 
Time 
hours 
Deprotected 
OH 
Formate 
ester 
Starting 
material 
7 2 45% 22% 20% 
7 4 39% 34% 13% 
7 6 21% 68% 10% 
13 2 17% 0% 58% 
  
characterisation of 7 and 8 was consistent with that of Moore: for 7 the 
characteristic H-1 signal at 3.87 (doublet, 3JH-H = 8.3 Hz) and H-2 at 1.84 
ppm (doublet of doublets, 3JH-H = 8.6, 3.9 Hz) peaks of the cyclopropane 
and the aromatic region (7.43 - 7.29 ppm) showing only 10 protons, 
consistent with two benzyl protecting groups (C-3 and C-4). The formate 
ester 8 displayed very similar peaks for H-1 and H-2 and the 10 aromatic 
protons. However, there was an H-8 formyl proton at 8.03 ppm (quartet, 
3JH-H = 0.7 Hz) which corresponded to the formate ester.  
The same characterization technique was used to identify 9 and 10, 
formed from the deprotection of dichlorocyclopropane 6. The 
characterization of 9 and 10 were again consistent with that of Moore 
(2012): for 9 the characteristic H-1 at 3.97 (doublet, 3JH-H = 9.4 Hz) and H-2 
at 2.13 ppm (triplet, 3JH-H = 8.2 Hz) peaks of the cyclopropane and the 
aromatic region (7.43-7.29 ppm) showing only 10 protons. The formate 
ester 10 displayed very similar peaks for H-1 and H-2 and the 10 aromatic 
protons. However, there was an H-8 proton at 8.00 ppm (singlet) which 
corresponded to the formate ester.  
In the interest of generating a library of compounds all side products 
where kept for the biological studies to determine SARs.  
 
 
Table 2.1. Rate of formate ester formation compared to recovered starting material 
and desired deprotection. 
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Et2O, 
HCO2H
Et2O, 
HCO2H
Et2O, 
HCO2H
Et2O, 
HCO2H
7 8
9 10
13 15
6
5
14 16
Scheme 2.8. Synthesis of compounds 7 and 8, 9 and 10, 15 and 16.Figure 2.1. Guide 
to numbering glucals (left), and carbohydrate-cyclopropanes (right). 
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2.4.2 Synthesis of cyclopropanated carbohydrate derivatives 29 to 33 
 
Compound 29 was has been reported in the literature to be active 
against HeLa cell lines (Sanhueza et al. 2007), it was decided to synthesise 
this compound to compare whether the activity can also be found in 
yeast. The dibromocyclopropane 32 was also synthesised to determine if 
the activity of 29 was related to the possible mechanism of inhibition. 
As described previously, the deprotection of the tri-O-acetyl-D-glucal was 
achieved by the use of catalytic sodium methoxide in methanol followed 
by purification. The resulting pure D-glucal 2 was obtained in a 98% yield. 
Subsequent re-protection with benzyl bromide provided the desired tri-O-
benzyl-D-glucal 28 as a white solid in a good yield of 80% (scheme 2.9). 
The tri-O-benzyl-D-glucal was then subjected to dichlorocyclopropanation 
which resulted in a 79% yield of the desired major product 29 with no minor 
30 product being observed initially. However, on repeating the reaction 
the minor isomer was observed in 12% yield along with the major isomer in 
82% yield. As previously mentioned the characteristic NMR signals of H-1 
and H-2 were used to identify the products of cyclopropanation reactions.  
The tri-O-benzyl-D-glucal was also subjected to dibromocyclopropanation 
providing a yield of 65% of the major isomer 32 and 14% of the minor 
isomer 33. Complete deprotection of the benzyl groups within 29 was 
accomplished by hydrogenation with H2 and catalytic Pd/C, in methanol 
with catalytic acetic acid, as described by Murali (Murali et al. 2007) albeit 
with alterations to the temperature. Heating of the reaction mixture was 
effective in dissolving the tribenzyl derivative more effectively. Purification 
through a silica plug afforded an 83% yield of the triol 31. Compound 31 
was used as a substrate in later reactions. 
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Scheme 2.9. Synthesis of 29 and 30, 31 and 32 and 33  
 
28
29
29 30
32 33
31
CHCl3, 
33% NaOH
TEBAC
CHBr3, 
33% NaOH
TEBAC, KF
MeOH, 
10% Pd/C
Acetic acid
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2.4.3 Synthesis of cyclopropanated carbohydrate derivatives 25, 26, 27 
and 31 
 
To increase the scope of the SAR study, a range of compounds were 
prepared with partial protection of the hydroxyl groups at C-3, C-4 and/or 
C-6. The conditions of the cyclopropanation required protecting groups 
on C-3, C-4 and C-6 to have partial protection this had to occur after the 
cyclopropanation steps. 
Compound 5 was subjected to deprotection of both the trityl and benzyl 
substituents by hydrogenolysis with catalytic Pd/C, in methanol, as 
described by Murali, but using warm ethanol as solvent, which provided 
higher levels of solubility than methanol. The deprotection yielded the triol 
31. After 24 hours of stirring under a H2 atmosphere, four spots developed 
on the TLC. These were separated by flash chromatography to yield fully 
and partially deprotected products 25, 27 and 31 (scheme 2.10). 
 
 
 
  
Scheme 2.10. Synthesis of 25, 27 and 31. 
5
MeOH,
10% Pd/C
Acetic acid
24 hrs
25
27
31
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2.4.4 Synthesis of cyclopropanated carbohydrate derivative 12 
 
Further derivatisations of the C-6 hydroxyl material were carried out in an 
attempt to attach either a fluorescent probe or matrix to aid in the 
identification of any potential protein targets (see section 3.3.10).   
A Swern oxidation, pioneered by Swern and Omura (1978) was attempted, 
with the aim of accessing the C-6 aldehyde. However, over-oxidation was 
observed, with the alcohol converting to the carboxylic acid 12 as shown 
in scheme 2.11. The expected aldehyde proton signal was not present in 
the 1H NMR spectra for either the crude or purified product. This was not 
the original intention but, due to the nature of this project, the carboxylic 
acid was in itself useful as it could be explored in biological testing and 
SAR studies, to date compound 12 has yet to be tested for biological 
activity. Further oxidations at this stage have yet to be attempted. 
 
 
 
 
 
Scheme 2.11. Synthesis of 12 
Oxalyl chloride, DMSO
TEA, CH2Cl2
127
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2.4.5 Synthesis of cyclopropanated carbohydrate derivative 11 
 
To further understand which of the proposed chemical mechanisms is 
occurring within the biological environment (see section 1.6), it was 
decided to remove one of the chlorides on the cyclopropane as this 
would decrease the level of carbanion stability. Therefore, the synthesis of 
11 was attempted (scheme 2.12). It is known that when gem-
dichlorocyclopropane carbohydrates are treated with excess LiAlH4, the 
des-halo product is formed. We attempted to synthesise the mono halide 
via use of limited equivalents of LiAlH4. Reduction of the chloride of 
compound 7 was decided. At this stage of the project 7 was the most 
biologically active compound. Reduction of the chloride was achieved 
using LiAlH4 in THF under N2, for three days. Although three products were 
noted in the TLC of the reaction mixture, only the monochloro derivative 
11 could be purified sufficiently for characterisation. The SAR analysis of 
this compound led to further indication of the mechanism that is occurring 
within the cell (section 3.4.3). 
 
 
 
 
 
  
 
 
 
 
Scheme 2.12. Synthesis of 11 
LiAlH4, THF
       N2
7 11
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2.4.6 Synthesis of compounds 36, 38 and 37; exploration of probe 
attachment  
 
With the knowledge that bioactivity may be completely lost if a probe is 
attached to the C-6 hydroxyl in compound 7, it was decided to attempt 
to selectively protect either the C-3 or C-4 hydroxyl to probe these sites as 
likely attachment points of a probe. 
Compounds 36 and 37 were synthesised in one step from 3 as described 
by Mereyala & Kulkarni (1989), shown in scheme 2.13. For 37 0.8 
equivalents of benzoyl chloride was added to a solution of 3 in DMF and 
pyridine. Selective protection of the C-3 hydroxyl was observed with a 
yield of 80% 37, 8% 36 and 12% recovered starting material. This method 
was repeated with 2.5 equivalents of benzoyl chloride with a yield of 95% 
36 was achieved in four hours with no mono protected glucal being 
observed. Compounds 36 and 37 were unable to be cyclopropanated as 
the conditions of the cyclopropanation (strong aqueous base) are ideal 
conditions to remove the ester functionalities. Research by Hewitt (2008) 
showed that under these conditions, the cyclopropanation of the triacetyl 
glucal 1 was unable to form the corresponding cyclopropane. It was then 
decided that 37 could be used to generate selectively a benzyl protected 
C-4 hydroxyl, this would then allow C-3 position to be deprotected and 
reprotected with a protecting group that would stay intact in under the 
cyclopropanation reaction conditions. However prior to this, 3 was 
reacted with one equivalent of benzyl chloride and one equivalent of 
sodium hydride to determine if there was any selectivity of between C-4 
36 37
BzCl, DMF
pyridine
3
Scheme 2.13. Synthesis of 36 and 37 
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and C-3 hydroxyl groups in the benzylation. This might occur if the acidity 
of the proton is influencing the selectivity.   
In several instances, different selectivity in mono protection of C-3 and C-4 
was observed. The alkylation of 6-O-trityl-D-glucal with one equivalent of 
benzyl bromide primarily led to the addition of a single benzyl group on 
the C-4 position of 3 to give 38 (scheme 2.14). This is in accordance with 
the computational and experimental findings of Hamann et al. (1999), 
who showed that this selectivity arises as a result of greater acidity of the 
hydroxyl group at C-4 over other positions. Hamann et al. focus their 
argument on the stability of the oxyanion at the C4 position. This is 
opposite to the outcome of the mono benzoylation of the C-3 and C-4 
hydroxyl with benzoyl chloride. The C-3 hydroxyl is preferred due to the 
accessibility of the site of acylation, the allylic C-3 hydroxyl is also more 
nucleophilic. It was found that the benzyl protection with one equivalent 
of benzyl bromide was not as selective as the benzoyl in a parallel 
experiment, 60% and 80% respectively. Although both reactions resulting in 
36 and 38 were more selective than that previously completed in literature 
(Mereyala & Kulkarni, 1989; Moore, 2012). 
 
Scheme 2.14. Selective synthesis of 5 and 38 
BnBr, NaH
DMF
3 4 38
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2.4.7 Synthesis of cyclopropanated carbohydrate derivative 24; the probe 
linker 
 
Initial reactions were attempted to attach a fluorescein to the C-6 
hydroxyl of 7 were unsuccessful. These results are not discussed within this 
thesis. Due to repeated failed attempts of attaching a probe to 7, it was 
decided to attempt attachment of a probe to the C-3 and/or C-4 position 
of an analogue of 7. To achieve this, a p-azidobenzyl protecting group 
was synthesised.  
The p-azidobenzyl bromide protecting group was synthesised in two steps 
from p-toluidine, as described by Kloss. (Kloss et al. 2011). p-Toluidine 
reacted with sodium nitrate in water and 37% HCl to form a diazonium salt 
that, upon treatment with sodium azide, afforded p-azidotoluene 19 as a 
bright orange liquid in a yield of 70%. The radical bromination of p-
azidotoluene was carried out as described by Mornet and colleagues 
(Mornet et al. 1984) utilising AIBN and NBS, and provided the desired 
product in 80% yield (scheme 2.15). Care was needed during purification 
by silica chromatography due to the nature of silica being nucleophilic 
and able to react with p-azidobenzyl bromide. As long as the column was 
completed within 10 min, pure p-azidobenzyl bromide 20 was obtained in 
a good yield of 79%. Personal care was taken due to the tendency of 20 
to act as an irritant (greater than that of benzyl bromide).  
i) NaNO2, HCl, 
H2O, 2 hrs r.t
ii) NaOAc
    NaN3, r.t
i) NBS, AIBN
Benzene, reflux
5 hrs, r.t
19 20
Scheme 2.15 Synthesis of 20 
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For selective p-azidobenzyl protection of the C-4 hydroxyl group of 3, two 
equivalents of 6-O-trityl-D-glucal 3 was added to one equivalent of p-
azidobenzyl bromide. Selective protection of C-4 hydroxyl group was 
observed and 22 was identified by proton NMR and HMBC. A modest 63% 
yield was achieved after purification by silica chromatography. p-Azido-
benzyl protection at the C-3 hydroxyl group of the 6-O-trityl-D-glucal was 
not observed in TLC or crude NMR. This observation was expected as 
previously discussed. Further protection of the C-3 hydroxyl was 
completed with the addition of NaH and BnBr in DMF as described 
previously (section 3.4.6), this resulted in the fully protected glucal required 
for the dichlorocyclopropanation reaction. However the 
cyclopropanated sugar did not form under Makosza cyclopropanation 
conditions. This may have been due to an impurity noted in the starting 
material glucal, which appeared as an aldehyde-like peak that at first was 
thought to have been DMF in the 1H NMR spectrum of the glucal 22. To 
overcome this, the trityl glucal 3 was subjected to four equivalents of p-
azidobenzyl bromide to form the di-p-azidobenzyl protected 21 in 65% 
yield (scheme 2.16).  
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It is speculated that the p-azidobenzyl bromide was reacting with DMF to 
form the aldehyde species, this side compound could not be separated 
by means of column chromatography or recrystallization. Due to time 
constraints, at this stage of the project it was decided to ignore this by-
product and carry on with a somewhat impure compound 21. The 
cyclopropanation yielded only the major species, with the cyclopropane 
opposite the C-3 substituent with a yield of 15%, consistent with previous 
cyclopropanations. It is likely that if the reaction had been high yielding a 
minor isomer would have also been seen. Subsequent removal of the trityl 
protecting group on C6-OH of 23 yielded 46% of pure alcohol 24. 
Compound 24 was then attached to an alkyne-substituted sepharose 
matrix through Huisgen Cyclisation chemistry in a cell lysate (section 
3.3.10). 
  
  
 
p-azidobenzyl 
bromide
NaH, DMF
CHCl3, NaOH
TEBAC
Formic acid
diethyl ether
3 21 23
24
Scheme 2.16. Synthesis of 21, 23, and 24. 
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2.4.8  Synthesis of Alkyne-substituted matrix; the probe 
 
To complement the synthesis of 24 an alkyne matrix was identified to allow 
the attachment of 24 via Huisgen Cyclisation. However, due to the cost of 
alkyne-substituted matrices, synthetic modifications of a standard epoxy-
activated sepharose matrix was attempted. A small number of alkynes 
were added to the epoxide to determine which would be used for the 
Huisgen Cyclisation conditions. Propargyl alcohol could not be linked 
directly to the epoxide, probably due to the weakly nucleophilic hydroxyl 
group. It was decided that a stronger nucleophile was needed, a 
secondary amine would provide the greater nucleophilicity and would 
also not require the addition of a strong base. To achieve this, it was 
decided to couple an amine to propargyl bromide. Use of N-propylamine 
and isopropylamine was attempted, but these amines were too volatile to 
give an acceptable yield of monopropargylated amine. 3-
Aminopropanol proved effective, resulting in 3-(prop-2-
ynylamino)propanol 37 in a yield of 85% along with 12% of the bis product 
38. The addition of 37 to the epoxide-activated sepharose is covered in 
section 3.3.10. 
 
 
 
 
 
 
 
 
3837
K2CO3, MeCN, N2, 
propargyl bromide
Scheme 2.17. Synthesis of 37 and 38 
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2.6  Experimental  
Unless otherwise stated, the following conditions apply. All reactions were 
performed under an atmosphere of N2 in oven-dried glassware using HPLC 
grade solvents.  
Reaction progress was monitored using thin layer chromatography (TLC) 
plates pre-coated with silica DC-Fertigfolien Polygram® SIL G/UV254 and 
visualised by either UV radiation (254 nm) or potassium permanganate dip. 
Purification by silica chromatography was conducted using a column 
filled with silica gel 60, with solvent systems indicated. 1H NMR and 13C 
NMR spectra were recorded on either a Varian Unity Inova 300 (300 MHz 
for 1H and 75 MHz for 13C), a 500 Varian Unity Inova 500 (500 MHz for 1H 
and 125 MHz for 13C). All chemical shifts () were referenced to solvent 
peaks (7.26 ppm 1H- residual CHCl3 and 77.2 ppm 13C- CDCl3 or 4.80 ppm 
1H- residual D2O. Infrared spectra were obtained on Bruker Tensor 27 FTIR 
spectrometer. High-resolution mass spectra were obtained on an Agilent 
Q-TOF LC/MS 6530 series. Optical rotations were recorded on a Perkin-
Elmer 241 polarimeter in DMSO unless otherwise stated.  
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Tri-O-acetyl-D-glucal (1) 
Using a modification of Fischer & Zach’s procedure (Fischer & Zach, 1912), 
acetic anhydride (200 mL) was added to a 500 mL flask, D-glucose (150 
mg, 0.83 mmol) was dissolved under stirring, followed by drop-wise 
addition of perchloric acid. Further D-glucose (19 g, 0.105 mol) was added 
slowly over 1.5 h at a rate such that the temperature of the reaction 
stayed between 40-50 °C. Once the reaction was cooled to r.t., fuming 
hydrogen bromide in an acetic adic solution (78 mL) was added and left 
to stir for 1.5 h at r.t. The solution was diluted with dichloromethane (200 
mL), the organic layer was washed with water (2 x 100 mL), then sat. 
sodium bicarbonate solution (6 x 80 mL). The organic layers were 
combined and dried with magnesium sulphate, filtered and concentrated 
to afford an off white powder. Recrystallization from ethyl 
acetate/hexanes, provided (1) (27.1 g, 93.1%) as a white solid. The 
spectral data matched those reported in the literature (Zhao et al. 2010) 
1) Rf = 0.3 (3:1 hexanes/ethyl acetate); 
; m.p. 50-51 °C (lit m.p. = 50-
52 °C); 1H NMR: (500 MHz, CDCl3)  6.46 (dd, J = 6.1, 1.2 
Hz, 1H, H-1), 5.33 (m, 1H, H-3), 5.22 (dd, J = 7.5, 5.6 Hz, 
1H, H-4), 4.84 (dd, J = 6.1, 3.2 Hz, 1H H-2), 4.39 (dd, J = 12.2, 5.9 Hz, 1H, H-
6a), 4.25 (m, 1H, H-5), 4.19 (dd, J = 12.2, 3.2 Hz, 1H, H-6b), 2.09 (s, 3H, 
CH3CO), 2.07 (s, 3H, CH3CO), 2.04 (s, 3H, CH3CO); 13C NMR: (500 MHz, 
CDCl3)  170.8 (CH3CO), 170.6 (CH3CO), 169.8 (CH3CO), 145.8 (CH, C-1), 
99.1 (CH, C-2), 74.1 (CH, C-5), 67.6 (CH, C-3), 67.3 (CH, C-4), 61.5 (CH2, C-
6), 21.1 (CH3, CH3CO), 20.94 (CH3, CH3CO), 20.88 (CH3, CH3CO); IR (Film 
from CH2Cl2): υmax 2961, 1738, 1650, 1369, 1215, 1032, 912, 730 cm-1. 
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D-Glucal (2)  
Solid sodium (62 mg, 2.70 mmol) was reacted with methanol (50 mL), then 
treated with a solution of 1 (2.32 g, 8.52 mmol) in methanol (20 mL). The 
reaction was stirred at r.t. for 10 min, the solution was concentrated to 
provide crude D-glucal. The crude product was purified by successive 
addition of methanol (3 mL), acetone (10 mL) and diethyl ether (20 mL), 
which lead to precipitation of impurities. The solution was filtered and 
concentrated to afford 2 (1.037 g, 84%) as a yellow solid/oil. The spectral 
data matched literature values (Moore, 2012).  
2)  1H NMR: (500 MHz, D2O)  
6.41 (dd, J = 6.1, 1.6 Hz, 1H, H-1), 4.82–4.81 (complex m, 
3H, 3 x OH), 4.80 (dd, J = 6.1, 2.4 Hz, 1H, H-2), 4.23 (ddd, 
J = 7.0, 2.3, 1.7 Hz, 1H, H-3), 3.92– 3.85 (complex m, 3H, 
H-5, H-6a, H-6b), 3.67 (dd, J = 9.0, 7.1 Hz, 1H, H-4); 13C NMR: (500 MHz, D2O) 
 143.6 (CH, C-1), 102.7 (CH, C-2), 78.1 (CH, C-5), 68.7 (CH, C-4), 68.2 (CH, 
C-3), 60.0 (CH2 , C-6); IR (KBr): υmax 3372, 2887, 1653, 1416, 1385,1232, 1137, 
1098, 1073, 1045, 1017 cm-1 
 
1,5-Anhydro-2-deoxy-6-O-trityl-D -arabino-hex-1-enitol (3)  
As reported by Esswein et al. (1990) 2 (1.81 g, 12.3 mmol) was added in a 
1:1 mixture of dichloromethane and pyridine (25 mL) trityl chloride (4.50 g, 
16.1 mmol) was then added over 3 min at room temperature. The solution 
was stirred for 18 h at r.t. before the solution was quenched with water, the 
resulting mixture was separated and the organic layer was washed with 
Sat. sodium bicarbonate solution (2 x 60 mL), dried over magnesium 
sulphate and concentrated to provide a crude yellow oil. The crude oil 
was purified by column chromatography (hexanes/ethyl acetate 1:1) to 
afford 3 as a white solid in 3.82 g (80%) yield. The spectral data matched 
to what had previously been reported (Moore, 2012). 
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3) Rf = 0.53 (2:1 Ethyl acetate/hexanes); 
; m.p. 61.0-63°C (lit m.p. = 62-
64 °C); 1H NMR (500 MHz, CDCl3):  7.20 - 7.45 (m, 15H, 
Ph), 6.40 (dd, J = 6.1, 1.6 Hz, 1H, H-1), 4.76 (dd, J = 6.1, 
2.2 Hz, 1H, H-2), 4.24 (m, 1H, H-3), 3.9 (ddd, J = 9.5, 7.1, 
3.5 Hz, 1H, H-4), 3.84 (dt, J = 9.5, 3.4 Hz, 1H, H-5), 3.57 (dd, J = 10.4, 3.5 Hz, 
1H, H-6a), 3.36 (dd, J = 10.4, 3.5 Hz, 1H, H-6b), 2.33 (d, J = 3.5 Hz, 1H, OH-4); 
13C NMR: (CDCl3)  144.7 (CH, C-1), 143.6 (C, Ph), 128.7(CH, Ph), 128.2 (CH, 
Ph), 127.4 (CH, Ph), 102.6 (CH, C-2), 87.1 (C, CPh3), 76.7(CH, C-5), 71.8 (CH, 
C-4), 69.6 (CH, C-3), 63.0 (CH2, C-6); IR (Film from CH2Cl2): υmax 3382, 3061, 
3033, 2920, 2882, 1647, 1491, 1449, 1229, 1099, 1056, 1032, 1002, 735, 702 
cm-1 
 
1,5-Anhydro-3,4-di-O-benzyl-2-deoxy-6-O-trityl-D-arabino-hex-1-enitol (4)  
In a slight modification of Esswein et al. (1990) procedure, 3 (0.440 g, 2.03 
mmol) was dissolved in dimethylformamide (20 mL) and cooled to -10 °C 
in an ice/salt bath. Sodium hydride (0.671 g, 16.78 mmol) was added, 
portion-wise over 1 min and the solution stirred at -10 °C for 15 min 
followed by addition of benzyl bromide (0.712 g, 4.2 mmol). The solution 
was allowed to warm to room temperature and stirred for 16 h. The 
reaction was then quenched with water (20 mL) and extracted with 
chloroform (3 x 25 mL). The organic fractions were combined, dried over 
magnesium sulphate and concentrated to give the crude product as a 
pale yellow solid. The crude product was purified by column 
chromatography (hexanes/ethyl acetate 9:1) to afforded 4 as a white 
solid. The spectral data matched to what had previously been reported 
(Nagarajan et al. 1997 & Moore, 2012). 
5) Rf = 0.40 (9:1 hexanes/ethyl acetate); 115-117 °C (lit 
m.p. = 116 °C); 1H NMR: (500 MHz, CDCl3)  7.51–7.04 
(complex m, 25H, Ph), 6.52 (dd, J = 6.1, 1.5 Hz, 1H, H-1), 
4.90 (dd, J = 6.1, 2.4 Hz, 1H, H-2), 4.76 (d, J = 11.0 Hz, 1H, 
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PhCH2), 4.65 (d, J = 11.6 Hz, 1H, PhCH2), 4.58 (d, J = 11.6 Hz, 1H, PhCH2), 
4.53 (d, J = 11.0 Hz, 1H, PhCH2), 4.20 (m, 1H, H-3), 4.04 (m, 1H, H-5), 4.01 (dd, 
J = 8.8, 5.9 Hz, 1H, H-4), 3.56 (dd, J = 10.2, 2.2 Hz, 1H, H-6a), 3.43 (dd, J = 
10.2, 4.1 Hz, 1H, H-6b); 13C NMR: (CDCl3 )  145.0 (CH, C-1), 144.0 (C, Ph), 
138.5 (C, Ph), 138.2 (C, Ph), 128.9 (CH, Ph), 128.6 (CH, Ph), 128.4 (CH, Ph), 
128.1 (CH, Ph), 127.96 (CH, Ph), 127.94 (CH, Ph), 127.8 (CH, Ph), 127.7 (CH, 
Ph), 127.1 (CH, Ph), 99.9 (CH, C-2), 86.6 (C, CPh3), 77.1 (CH, C-5), 76.2 (CH, 
C-3), 74.8 (CH, C-4), 74.0 (CH2 , PhCH2), 71.0 (CH2, PhCH2), 62.3 (CH2 , C-6); 
IR (Film from CH2Cl2): υmax 3061, 3031, 2927, 2878, 1647, 1491, 1449, 1095, 
1066, 1026, 908, 732, 695 cm-1. 
 
1,5-Anhydro-4-O-benzyl-2-deoxy-6-O-trityl-D-arabino-hex-1-enitol (36) 
In a slight modification of Schmidt et al. procedure, 3 (0.550 g, 4.1 mmol) 
was dissolved in dimethylformamide (20 mL) and cooled in an ice/salt 
bath to -10 °C. Sodium hydride (0.169 g, 4.25 mmol) was added slowly, 
portion-wise over 1 min and the solution stirred at -10 °C for 15 min 
followed by addition of benzyl bromide (0.712 g, 4.21 mmol). The solution 
was allowed to warm to room temperature and stirred for 16 h, followed 
by quenching with water (20 mL) and extraction with chloroform (3 x 25 
mL). The organic fractions were combined, dried over magnesium 
sulphate and concentrated to give the crude product as a pale yellow 
solid. The crude product was purified by column chromatography 
(hexanes/ethyl acetate gradient elution 9:1 to 0:1) afforded 38 as a yellow 
oil (64%). The spectral data matched to what had previously been 
reported (Moore, 2012). 
 38) Rf = 0.37 (3:1 hexanes/ethyl acetate); 1H NMR: 
(500 MHz, CDCl3)  7.51–7.07 (complex m, 20H, Ph), 
6.50 (dd, J = 6.1, 1.4 Hz, 1H, H-1), 4.76 (dd, J = 6.1, 2.4 
Hz, 1H, H-2), 4.62 (d, J = 11.5 Hz, 1H, PhCH2), 4.48 (d, J = 
11.5 Hz, 1H, PhCH2), 4.31 (m, 1H, H-3), 3.95 (apparent 
dt, J = 9.3, 2.9 Hz, 1H, H-5), 4.82 (dd, J = 9.3, 6.6 Hz, 1H, H-4), 3.65 (dd, J = 
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10.3, 2.4 Hz, 1H, H-6a), 3.29 (dd, J = 10.3, 3.4 Hz, 1H, H-6b), 1.96 (bs, 1H, OH-
3); 13C NMR: (CDCl3)  144.9 (CH, C-1), 143.9 (C, Ph), 138.3 (C, Ph), 128.9 
(CH, Ph), 128.6 (CH, Ph), 128.1 (CH, Ph), 127.99 (CH, Ph), 127.97 (CH, Ph), 
127.2 (CH, Ph), 102.5 (CH, C-2), 86.6 (C, CPh3), 77.5 (CH, C-4), 77.0 (CH, C-
5), 74.0 (CH2, PhCH2), 69.4 (CH, C-3), 62.3 (CH2, C-6); IR (Film from CH2Cl2): 
υmax 3372, 3061, 3030, 2927, 2879, 1650, 1492, 1449, 1091, 1029, 1001, 901, 
744, 696 cm-1. 
 
1,5-Anhydro-3,4-di-O-benzyl-6-O-(triphenylcarbinyl)-2-deoxy-1,2-C-
(dichloromethylene)-D-glycero-D-gulo-hexitol (5) and 1,5-anhydro-3,4-di-
O-benzyl-6-O-(triphenylcarbinyl)-2-deoxy-1,2-C-(dichloromethylene)-D-
glycero-D-talo-hexitol (6) 
As reported by Nagarajan et al. (1997), a solution of 4 (800 mg, 1.93 mmol) 
and benzyltriethylammonium chloride (10 mg, 0.044 mmol) in chloroform 
(5 mL) was treated drop-wise with 33% sodium hydroxide (10 mL) with 
rapid stirring. The biphasic mixture was stirred at r.t for 10 hrs. The biphasic 
mixture was then diluted with water (10 mL) and extracted with 
dichloromethane (3 x 20 mL). The organic fractions were combined and 
dried over magnesium sulphate and concentrated to provide a crude 
mixture of cyclopropanes 5 and 6. The crude product was purified by 
column chromatography (14:1 hexanes: ethyl acetate) liberated the 
major cyclopropane 5 as a white solid in a yield of 626 mg (62%) and the 
minor cyclopropane 6 as an oil in a yield of 151 mg (15%) The spectral 
data matched those previously reported (Nagarajan et al. 1997 & Moore, 
2012). 
5) Rf = 0.40 (9:1 hexanes/ethyl acetate); m.p. 
50.0–51.0 °C; 1H NMR: (500 MHz, CDCl3)  7.47–
7.22 (complex m, 25H, Ph), 4.81 (d, J = 11.6 Hz, 1H, 
PhCH2), 4.80 (d, J = 10.7 Hz, 1H, PhCH2), 4.70 (d, J 
= 11.6 Hz, 1H, PhCH2), 4.25 (d, J = 10.7 Hz, 1H, 
PhCH2), 4.06 (d, J = 8.0 Hz, 1H, H-1), 3.88–3.84 (complex m, 2H H-4, H-5), 
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3.78 (dd, J = 8.8, 4.9 Hz, 1H, H-3), 3.48 (dd, J = 10.2, 3.0 Hz, 1H, H-6a), 3.17 
(dd, J = 10.2, 3.0 Hz, 1H, H-6b), 1.87 (dd, J = 8.0, 4.9 Hz, 1H, H-2); 13C NMR: 
(CDCl3)  143.8 (C, Ph), 138.1 (C, Ph), 137.7 (C, Ph), 128.8 (CH, Ph), 128.7 
(CH, Ph), 128.4 (CH, Ph), 128.11 (CH, Ph), 128.10 (CH, Ph), 128.08 (CH, Ph), 
128.06 (CH, Ph), 127.8 (CH, Ph), 127.3 (CH, Ph), 86.9 (C, CPh3), 80.5 (CH, C-
5), 77.6 (CH, C-3), 75.9 (CH, C-4), 75.0 (CH2 , PhCH2), 72.2 (CH2 , PhCH2), 
63.7 (CH2 , C-6), 61.8 (C, C-7), 59.3 (CH, C-1), 34.7 (CH, C-2); IR (Film from 
CH2Cl2): υmax 3087, 3061, 3031, 2919, 2869, 1492, 1449, 1158, 1093, 1029, 736, 
698 cm-1. 
6) Rf = 0.30 (9:1 hexanes/ethyl acetate); m.p. 50-
51 °C; 1H NMR: (500 MHz, CDCl3)  7.51–7.17 
(complex m, 23H, Ph), 6.90–6.88 (complex m, 2H, 
Ph), 4.88 (d, J = 11.9 Hz, 1H, PhCH2), 4.75 (d, J = 
11.9 Hz, 1H, PhCH2), 4.70 (d, J = 10.6 Hz, 1H, 
PhCH2), 4.34 (d, J = 10.6 Hz, 1H, PhCH2), 4.14–4.08 (complex m, 2H, H-3, H-
4), 4.05 (d, J = 8.0 Hz, 1H, H-1), 3.56 (dd, J = 10.3, 2.0 Hz, 1H, H-6a), 3.41 
(ddd, J = 9.7, 3.9, 2.0 Hz, 1H, H-5), 3.19 (dd, J = 10.3, 3.9 Hz, 1H, H-6b), 2.12 
(apparent t, J = 7.7 Hz, 1H, H-2); 13C NMR: (CDCl3)  144.0 (C, Ph), 138.3 (C, 
Ph), 138.0 (C, Ph), 129.0 (CH, Ph), 128.7 (CH, Ph), 128.3 (CH, Ph), 128.2 (CH, 
Ph), 128.09 (CH, Ph), 128.08 (CH, Ph), 128.0 (CH, Ph), 127.9 (CH, Ph), 127.0 
(CH, Ph), 86.7 (C, CPh3), 78.4 (CH, C-5), 78.2 (CH, C-4), 76.6 (CH, C-3), 74.9 
(CH2 , PhCH2), 71.6 (CH2, PhCH2), 62.33 (CH2 , C-6), 62.25 (CH, C-1), 62.1 (C, 
C-7), 33.1 (CH, C-2); IR (Film from CH2Cl2): υmax 3061, 3031, 2930, 2875, 1492, 
1449, 1182, 1090,1023, 910, 736, 698 cm-1. 
 
1,5-Anhydro-3,4-di-O-benzyl-2-deoxy-1,2-C-(dichloromethylene)-D-
glycero-D-gulo-hexitol (7), and 1,5-anhydro-3,4-di-O-benzyl-6-O-(formyl)-
2-deoxy-1,2-C-(dichloromethylene)- D-glycero-D-gulo-hexitol (8)  
 
 A solution of 5 (50 mg, 0.09 mmol) in diethyl ether (0.3 mL) was treated 
with formic acid (0.4 mL) and stirred at room temperature for 1 h. The 
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reaction was diluted with diethyl ether (4 mL) and washed with sat. sodium 
bicarbonate solution (4 x 10 mL). The organic layer was dried over 
magnesium sulphate and concentrated. The crude product was purified 
by column chromatography (hexanes/ethyl acetate gradient 14:1 to 5:1) 
to give 7 in a yeild of 16.56 mg (45%) as a white solid and 8 in a yeild of 
8.65 mg (22%) as an oil. The spectral data matched reported (Moore 
20012).  
7) Rf = 0.45 (3:1 hexanes/ethyl acetate); 
; m.p. 80.0–81 °C; 1H 
NMR: (500 MHz, CDCl3)  7.43–7.29 (complex m, 
10H, Ph), 4.93 (d, J = 11.2 Hz, 1H, PhCH2), 4.81 (d, J 
= 11.7 Hz, 1H, PhCH2), 4.72 (d, J = 11.7 Hz, 1H, 
PhCH2), 4.67 (d, J = 11.2 Hz, 1H, PhCH2), 3.87 (d, J = 8.3 Hz, 1H, H-1), 3.81 
(dd, J = 9.5, 3.9 Hz, 1H, H-3), 3.87 (dt, J = 8.6, 3.9 Hz, 1H, H-5), 3.68 (d, J = 3.9, 
2H, H-6a,b), 3.60 (dd, J = 9.5, 8.6 Hz, 1H, H-4), 1.84 (dd, J = 8.6, 3.9 Hz, 1H, H-
2), 1.68 (s, 1H, 6-OH); 13C NMR: (CDCl3)  138.1 (C, Ph), 137.6 (C, Ph), 128.7 
(CH, Ph), 128.6 (CH, Ph), 128.3 (CH, Ph), 128.15 (CH, Ph), 128.12 (CH, Ph), 
79.6 (CH, C-5), 77.2 (CH, C-3), 75.0 (CH2, PhCH2), 74.8 (CH, C-4), 72.2 (CH2, 
PhCH2), 62.8 (CH2, C-6), 60.9 (C, C-7), 58.9 (CH, C-1), 33.9 (CH, C-2); IR (Film 
from CH2Cl2): υmax 3375, 3032, 2976, 2864, 1496, 1454, 1365, 1095, 1026, 733, 
696 cm-1. 
8) Rf = 0.30 (9:1 hexanes/ethyl acetate); 1H 
NMR: (500 MHz, CDCl3)  8.03 (q, J = 0.7 Hz, 
1H, HC(O)O), 7.43–7.27 (complex m, 10H, 
Ph), 4.95 (d, J = 11.2 Hz, 1H, PhCH2), 4.81 (d, J 
= 11.3 Hz, 1H, PhCH2), 4.70 (d, J = 11.3 Hz, 1H, 
PhCH2), 4.63 (d, J = 11.2 Hz, 1H, PhCH2), 4.30 ddd, J = 12.0, 5.1, 0.7, 1H, H-
6a), 4.15 (ddd, J = 12.0, 2.7, 0.7, 1H, H-6b), 3.87 (dddd, J = 8.3, 5.1, 2.7, 0.7 
Hz, 1H, H-5), 3.86 (d, J = 8.1 Hz, 1H, H-1), 3.80 (dd, J = 9.5, 4.4 Hz, 1H, H-3), 
3.57 (dd, J = 9.5, 8.3 Hz, 1H, H-4), 1.82 (dd, J = 8.1, 4.4 Hz, 1H, H-2); 13C NMR: 
(CDCl3)  160.6 (C, CHO), 137.7 (C, Ph), 137.5 (C, Ph), 105 128.73 (CH, Ph), 
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128.66 (CH, Ph), 128.5 (CH, Ph), 128.2 (CH, Ph), 128.13 (CH, Ph), 128.08 (CH, 
Ph), 77.9 (CH, C-5), 77.2 (CH, C-3), 74.9 (CH2 , PhCH2), 74.5 (CH, C-4), 72.1 
(CH2, PhCH2), 63.3 (CH2, C-6), 61.0 (C, C-7), 58.6 (CH, C-1), 34.1 (CH, C-2); 
IR (Film from CH2Cl2): υmax 3062, 3031, 2919, 2869, 1726, 1496, 1453, 1152, 
1128, 1089, 1027, 735, 697 cm-1. 
 
1,5-Anhydro-3,4-di-O-benzyl-2-deoxy-1,2-C-(dichloromethylene)- D-
glycero-D-gulo-hexitol (9), and1,5-anhydro-3,4-di-O-benzyl-6-O-(formyl)-
2-deoxy-1,2-C-(dichloromethylene)-D-glycero-D-talo-hexitol (10) 
 
 A solution of 6 (50 mg, 0.09 mmol) in diethyl ether (0.3 mL) was treated 
with formic acid (0.4 mL) and stirred at r.t. for 10 h. The mixture was diluted 
with diethyl ether (4 mL) and washed with saturated sodium bicarbonate 
solution (4 x 10 mL). The organic layer was dried over magnesium sulphate 
and concentrated. The crude product was purified by column 
chromatography (hexanes/ethyl acetate gradient 14:1 to 5:1) to give 19 in 
a yield of 17 mg (30%) of 9 a colourless oil and 5 mg (9%) of 10 as a yellow 
oil. The spectral data matched to what had previously been reported 
(Moore 2012).  
9) Rf = 0.38 (3:1 hexanes/ethyl acetate); 1H NMR: 
(500 MHz, CDCl3)  7.43–7.23 (complex m, 10H, 
Ph), 4.81 (d, J = 11.2 Hz, 1H, PhCH2), 4.78 (d, J = 
11.7 Hz, 1H, PhCH2), 4.72 (d, J = 11.7 Hz, 1H, 
PhCH2), 4.67 (d, J = 11.2 Hz, 1H, PhCH2), 4.05 (d, J = 8.3 Hz, 1H, H-3), 3.80 (t, 
J = 9.4 Hz, 1H, H-1), 3.59 (dt, J = 8.6, 3.9 Hz, 1H, H-5), 3.78 (d, J = 3.9, 2H, H-
6a,b), 3.58 (dd, J = 9.5, 8.6 Hz, 1H, H-4), 2.11 (t, J = 8.2 Hz, 1H, H-2); 13C NMR: 
(CDCl3)  140.1 (C, Ph), 137.6 (C, Ph), 128.9 (CH, Ph), 128.6 (CH, Ph), 128.3 
(CH, Ph), 128.2 (CH, Ph), 128.2 (CH, Ph), 79.7 (CH, C-5), 77.4 (CH, C-3), 75.0 
(CH2 , PhCH2), 75.1 (CH, C-4), 72.2 (CH2 , PhCH2), 62.9 (CH2 , C-6), 60.9 (C, 
C-7), 60.0 (CH, C-1), 33.1 (CH, C-2). IR (Film from CH2Cl2): υmax 3378, 3033, 
2979, 2862, 1494, 1454, 1365, 1098, 1030, 736, 697 cm-1. 
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10) Rf = 0.25 (9:1 hexanes/ethyl acetate); 1H 
NMR: (500 MHz, CDCl3)  8.0 (s, 1H, HC(O)O), 
7.42-7.23 (complex m, 10H, Ph), 4.88 (d, J = 
11.8 Hz, 1H, PhCH2), 4.85 (d, J = 11.0 Hz, 1H, 
PhCH2), 4.70 (d, J = 11.8 Hz, 1H, PhCH2),4.57 (d, J = 11.0 Hz, 1H, PhCH2), 4.47 
(dd, J = 12.0, 1.2 Hz,1H, H-6a), 4.22 (dd, J = 12.0, 5.1 Hz, 1H, H-6b), 4.19 
(apparent t, J = 7.8 Hz, 1H,H-3), 3.96 (d, J = 8.1 Hz, 1H, H-1), 3.80 (dd, J = 
10.4, 7.6 Hz, 1H, H-4), 3.50 (ddd, J = 10.4, 5.1, 1.7 Hz, 1H, H-5), 2.12 (t, J = 8.1 
Hz, 1H, H-2); 13C NMR: (CDCl3)  160.7 (C, COH), 137.8 (C, Ph), 137.7 (C, Ph), 
128.8 (CH, Ph), 128.6 (CH, Ph), 128.24 (CH, Ph), 128.19 (CH, Ph), 128.18 (CH, 
Ph), 128.1 (CH, Ph), 77.9 (CH, C-3), 76.2 (CH, C-5), 75.9 (CH, C-4, 74.7 (CH2, 
PhCH2), 71.3 (CH2, PhCH2), 62.5 (CH2, C-6), 62.2 (CH, C-1), 61.4 (C, C-7), 
32.8 (C, C-2); IR (Film from CH2Cl2): υmax 3065, 3031, 2918, 2870, 1724, 1497, 
1454, 1170, 1088, 1027, 734, 698 cm-1. 
 
1,5-Anhydro-3,4-di-O-benzyl-2-deoxy-1,2-C-(chloromethylene)-D-
glycero-D-gulo-hexitol (11),  
To a solution of 7 (40 mg, 0.10 mmol) in tetrahydrofuran (1 mL) was added 
lithium aluminium hydride (11.2 mg, 0.29 mmol) and stirred at r.t. under 
nitrogen for 3 days. The mixture was quenched with water (2 mL), 
extracted with ethyl acetate (3 x 5 mL). The combined organic layers were 
dried over magnesium sulphate and concentrated. The crude product 
was purified by column chromatography (hexanes/ethyl acetate 4:1) to 
give 11 in a yield of 19 mg (47.4 %) as an oil. 
11) Rf = 0.40 (3:1 hexanes/ethyl acetate) 1H NMR: 
(500 MHz, CDCl3)  7.42–7.30 (complex m, 10H, 
Ph), 4.79 (d, J = 11.4 Hz, 1H, PhCH2), 4.79 (d, J = 
11.7 Hz, 1H, PhCH2), 4.68 (d, J = 11.5 Hz, 2H, 
PhCH2), 3.92 (dd, J = 9.6, 4.4 Hz, 1H, H-1), 3.81 (m, 
1H, H-3), 3.72 (m, 1H, H-5), 3.69- 3.60 (m, 3H, H-4, H-6a,b), 3.15 (dd, J = 5.1, 
3.2 Hz, 1H, H-2), 1.83 (t, J =6.3 Hz, 1H, OH), 1.37- 1.33 (m, 1H, H-8); 13C NMR: 
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(CDCl3)  (C, Ph), (C, Ph), (CH, Ph), (CH, Ph), (CH, Ph), (CH, Ph), (CH, Ph), 
(CH, C-5), (CH, C-3), (CH2 , PhCH2), (CH, C-4), (CH2 , PhCH2), (CH2 , C-6), 
(C, C-7), (CH, C-1), (CH, C-2) IR (Film from CH2Cl3): υmax 3370, 3042, 2972, 
2864, 1499, 1456, 1369, 1092, 1027, 732, 696 cm-1; C21H23ClO4Na+ [M+Na]+ 
calculated 374.1285, found 374.1353. 
 
1,5-anhydro-3,4-di-O-benzyl-6-O-(carboxyl)-2-deoxy-1,2-C 
(dichloromethylene)- D-glycero-D-gulo-hexitol (12) 
 Dimethyl sulfoxide (86.17 mg, 1.103 mmol) and dichloromethane (3 mL), 
was cooled to – 78 oC. Oxalyl chloride (69.9 mg, 0.551 mmol) was then 
added and stirred for 40 min before 7 (150 mg, 0.362 mmol) was added 
and stirred for another 30 min before triethylamine (22.34 mg, 2.208 mmol) 
was added, stirred for another 30 min, quenched with Sat. sodium chloride 
(1 mL) and warmed to r.t. The organic layer was then dried over 
magnesium sulphate and concentrated to afford a crude material 170 
mg. The acid product was separated by a base wash to give 12 in a yield 
of 47 mg (30.5%). No further purification preformed. 
12) Rf = 0.1 (3:1 hexanes/ethyl acetate) 1H NMR: (500 
MHz, CDCl3)  11.87 (bs, 1H, COOH), 7.41–7.20 
(complex m, 10H, Ph), 4.92 (d, J = 11.3 Hz, 1H, 
PhCH2), 4.80 (d, J = 11.4 Hz, 1H, PhCH2), 4.65 (t, J = 
11.3 Hz, 2H, PhCH2), 3.98 (d, J = 9.6Hz, 1H, H-1), 3.84 
(m, 1H, H-3), 3.76 (m, 2H, H-4,5), 3.60 (d, J = 8.6 Hz 1H, H-6a), 3.34 (d, J = 8.6 
Hz 1H, H-6b) 1.78 (dd, J = 8.6, 4.4 Hz, 1H, H-2); further anaylsis is required. 
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1,5-Anhydro-3,4-di-O-benzyl-6-O-(triphenylcarbinyl)-2-deoxy-1,2-C-
(dibromomethylene)-D-glycero-D-gulo-hexitol (13) and 1,5-anhydro-3,4-
di-O-benzyl-6-O-(triphenylcarbinyl)-2-deoxy-1,2-C-(dibromomethylene)-
D-glycero-D-talo-hexitol (14) 
A solution of 4 (508 mg, 0.87 mmol) and benzyltriethylammonium chloride 
(23 mg, 0.101 mmol) in bromoform (1.5 mL) was treated with a drop-wise 
solution of 33% aqueous sodium hydroxide (3 mL) and potassium fluoride 
(2.0 g, 34.42 mmol) in water (2.0 mL). The biphasic mixture was stirred for 
five days at r.t. The mixture was diluted with water (6 mL), extracted with 
diethyl ether (3 x 15 mL). The combined organic layer was washed with 
brine (10 mL), dried over magnesium sulphate and concentrated. The 
crude product was purified by column chromatography (hexanes/ethyl 
acetate 9:1) to give the major stereoisomer 13 in a yeild of 300 mg (49.8%) 
as an oil, in addition to the minor stereoisomer 14 in a yield of 83 mg 
(12.8%) as a yellow oil with a combined yield of 63%. 
13) Rf = 0.35 (9:1 hexane/ethyl acetate) 1H NMR: 
(500 MHz, CDCl3)  7.43–7.21 (complex m, 23H, 
Ph), 7.02 (dd, 2H, Ph), 4.83 (t, J = 11.6 Hz, 2H, 
PhCH2), 4.73 (d, J = 11.8 Hz, 1H, PhCH2), 4.25 (d, J 
= 10.7 Hz, 1H, PhCH2), 4.14 (d, J = 7.8 Hz, 1H, H-1), 
3.90- 3.94 (m, 2H, H-3, H-4), 3.72 (dd, J = 8.8, 4.9 Hz, H-5) 3.52 (d, J = 1.5 Hz, 
1H, H-6a), 3.2 (d, J = 3.3 Hz, 1H, H-6b), 2.01 (dd, J = 7.8, 4.9 Hz, 1H, H-2), 13C 
NMR: (CDCl3)  143.8 (C, Ph), 138.1 (C, Ph), 137.9 (C, Ph), 128.8 (CH, Ph), 
128.6 (CH, Ph), 128.3 (CH, Ph), 128.1 (CH, Ph), 128.09 (CH, Ph), 128.08 (CH, 
Ph), 128.06 (CH, Ph), 127.8 (CH, Ph), 127.3 (CH, Ph), 86.9 (C, CPh3), 80.8 
(CH, C-5), 80.1 (CH, C-4), 75.7 (CH, C-3), 75.0 (CH2 , PhCH2), 72.1 (CH2, 
PhCH2), 63.7 (CH2, C-6), 59.7 (CH, C-1), 35.7 (C, C-2), 34.3 (CBr2, C-7), IR 
(Film from CHCl3): υmax 3434, 3081, 3012, 2918, 1710, 1449, 1364, 1084, 745, 
697, 632 cm-1; C40H23BrO4Na+ [M+Na]+ calculated 738.0980, found 
738.1185. 
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14) Rf = 0.28 (9:1 hexane/ethyl acetate) 1H NMR: 
(500 MHz, CDCl3)  7.53–7.31 (complex m, 23H, 
Ph), 6.91 (dd, J= 7.6, 1.8 Hz, 2H, Ph), 4.92 (d, J = 2 
Hz, 1H, PhCH2), 4.75 (d, J = 1.9 Hz, 1H, PhCH2), 
4.72 (d, J = 0.7 Hz, 1H, PhCH2), 4.37 (d, J = 10.8 Hz, 
1H, PhCH2), 4.22 (dd, J = 7.55, 10.25 Hz, 1H, H-1), 4.11-4.15 (m, 1H, H-3), 3.57 
(dd, J = 10.3, 1.7 Hz, H- 4) 3.42-3.46 (m, 1H, H-5), 3.31 (dd, J = 10.3, 1.7 Hz, 
1H, H-6a) 3.20 (dd, J = 10.3, 1.7 Hz, 1H, H-6b), 2.15 (t, J = 8.1 Hz, 1H, H-2), 13C 
NMR: (CDCl3)  144.1 (C, Ph), 138.8 (C, Ph), 138.1 (C, Ph), 128.9 (CH, Ph), 
128.8 (CH, Ph), 128.7 (CH, Ph), 128.1 (CH, Ph), 128.1 (CH, Ph), 128.1 (CH, 
Ph), 128.1 (CH, Ph), 128.1 (CH, Ph), 127.9 (CH, Ph), 87.4 (C, CPh3), 81.1 (CH, 
C-5), 80.5 (CH, C-4), 75.5 (CH, C-3), 75.1 (CH2 , PhCH2), 72.1 (CH2, PhCH2), 
63.9 (CH2 , C-6), 60.7 (CH, C-1), 37.5 (C, C-2), 36.3 (CBr2, C-7), IR (Film from 
CH2Cl2): υmax 3434, 3082, 3032, 2918, 1632, 1448, 1088, 1020, 913, 737, 697 
cm-1; C40H23BrO4Na+ [M+Na]+ calculated 738.0980, found 738.1000 
 
1,5-Anhydro-3,4-di-O-benzyl-2-deoxy-1,2-C-(dichloromethylene)-D-
glycero-D-gulo-hexitol (15) 
A solution of 13 (50 mg, 0.08 mmol) in diethyl ether (0.3 mL) was treated 
with formic acid (0.4 mL) and stirred at r.t. for 1 h. The mixture was diluted 
with diethyl ether (4 mL) and washed with saturated sodium bicarbonate 
solution (4 x 10 mL). The organic layer was dried over magnesium sulphate 
and concentrated. The crude product was purified by column 
chromatography (hexanes/ ethyl acetate gradient 14:1 to 5:1) to give 15 
in a yield of 12 mg (34%) as an oil. 
15) Rf =0.27 (3: 1 hexanes/ ethyl acetate) 1H NMR: 
(500 MHz, CDCl3)  7.43-4.25 (m, 10H, Ph), 4.94 (d, 
J = 11.4 Hz, 1H, Ph-CH2), 4.80 (d, J = 11.7 Hz, 1H, Ph-
CH2), 4.71 (d, J = 11.4 Hz, 1H, Ph-CH2), 4.60 (d, J = 
11.3 Hz, 1H, Ph-CH2), 3.90 (d, J = 8.4 Hz, 1H, H-1), 
3.89 (m, 1H, H-4), 3.71 (dd, J = 9.0, 4.1 Hz, 1H, H-3), 3.60 (d, J = 3.9 Hz, 2H, H-
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6a, H-6b), 3.64-3.60 (m, 1H, H-5), 1.99 (dd, J = 8.4, 4.5 Hz, 1H, H-2); 13C NMR: 
(CDCl3)  (C, COH), (C, Ph), (C, Ph), (CH, Ph), (CH, Ph), (CH, Ph), (CH, Ph), 
(CH, Ph), (CH, Ph), (CH, C-3), (CH, C-5), (CH, C-4), (CH2, PhCH2), (CH2, 
PhCH2), (CH2, C-6), (CH, C-1), (C, C-7), (C, C-2); 
 
1,5-Anhydro-3,4-di-O-benzyl-2-deoxy-1,2-C-(dichloromethylene)-D-
glycero-D-talo-hexitol (16) 
A solution of 14 (50 mg, 0.08 mmol) in diethyl ether (0.3 mL) was treated 
with formic acid (0.4 mL) and stirred at r.t. for one h. The mixture was 
diluted with diethyl ether (4 mL) and washed with saturated sodium 
bicarbonate solution (4 x 10 mL). The organic layer was dried over 
magnesium sulphate concentrated. The crude product was purified by 
flash chromatography (hexanes/ethyl acetate gradient 14:1 to 5:1) to give 
19 in a yeild of 6 mg (17%) as an oil. 
16) Rf =0.15 (3:1 hexanes/ethyl acetate) 1H NMR: 
(500 MHz, CDCl3)  7.43-4.25 (m, 10H, Ph), 4.94 (d, 
J = 11.4 Hz, 1H, Ph-CH2), 4.83 (d, J = 11.7 Hz, 1H, 
Ph-CH2), 4.71 (d, J = 11.4 Hz, 1H, Ph-CH2), 4.61 (d, J 
= 11.3 Hz, 1H, Ph-CH2), 4.00 (d, J = 8.4 Hz, 1H, H-1), 
3.90 (m, 1H, H-4), 3.77 (dd, J = 9.0, 4.1 Hz, 1H, H-3), 3.61 (d, J = 3.9 Hz, 2H, H-
6a, H-6b), 3.69-3.65 (m, 1H, H-5), 2.09 (t, J = 8.4 Hz, 1H, H-2); 13C NMR: 
(CDCl3)  (C, COH), (C, Ph), (C, Ph), (CH, Ph), (CH, Ph), (CH, Ph), (CH, Ph), 
(CH, Ph), (CH, Ph), (CH, C-3), (CH, C-5), (CH, C-4), (CH2, PhCH2), (CH2, 
PhCH2), (CH2, C-6), (CH, C-1), (C, C-7), (C, C-2) 
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1,5-Anhydro-3,4-di-O-benzyl-6-O-(triphenylcarbinyl)-2-deoxy-1,2-C-
(methylene)-D-glycero-D-gulo-hexitol (17)  
To a solution of zinc (0.314 g, 4.8 mmol), copper iodide (0.091 g, 0.48 
mmol) and methyl iodide (6.25 mL) in ether (3 mL) under nitrogen was 
treated with drop-wise with acetyl chloride (0.16 mL). The solution was 
heated in an oil bath for five min at 45 °C. A solution of 4 (300 mg, 0.53 
mmol) in ether (5 mL) was added drop-wise to the heated mixture over 30 
min, additional methyl iodide (6.25 mL) was added then the combined 
mixture was refluxed under nitrogen for 1 h. The reaction mixture was 
cooled in an ice bath then quenched drop-wise with saturated 
ammonium chloride then filtered. The filtrate was washed with hexanes (3 
x 5 mL). The combined organic fractions were washed with 10% sodium 
hydroxide (3 x 5 mL), combined organic fractions were dried over 
magnesium sulphate and concentrated. The crude product was purified 
by column chromatography (hexanes/ethyl acetate 5:1) to give 17 with a 
yield of 282 mg (89%) as a whit solid. The spectral data matched to what 
had previously been reported (Nagarajan et al. 1997). 
17) Rf = 0.25 (5:1 hexane/ethyl acetate) 1H NMR 
(500 MHz, CDCl3):  0.82 (app. dt, J = 9.8, 5.8 Hz, 
1H, H-8), 0.91 (dt, J = 6.8, 2.4 Hz, 1H, H-9), 1.33 
(app. dq, J = 9.7, 7.0 Hz, 1H, H-2), 3.12 (dd, J = 
10.1, 4.3 Hz, 1H, H-3), 3.33-3.43 (m, 3H, H-4, H-6, H-
7), 3.81 (ddd, J= 7.0, 5.8, 2.8 Hz 1H, H-1), 4.06 (t, J = 6.9 Hz, 1H, H-5), 4.38 (d, 
J = 10.8 Hz, 1H, CH2Ph), 4.61 (d, J = 11.7 Hz, 1H, CH2Ph), 4.70 (d, J = 10.7 Hz, 
1H, CH2Ph), 4.83 (d, J = 11.7 Hz, 1H, CH2Ph), 6.93 (dd, J = 7.5, 1.8 Hz, 2H, Ph), 
7.18-7.49 (m, 23H, Ph), 13C NMR: (CDCl3)  138.50 (C, Ph), 138.42, (CH, Ph), 
138.43 (CH, Ph) 128.43 (CH, Ph), 128.03 (CH, Ph), 127.87 (CH, Ph), 127.74 
(CH, Ph), 127.57 (CH, Ph), 78.74 (CH, C-3), 78.55 (CH, C-5), 77.92 (CH, C-4), 
74.21 (CH2, PhCH2), 70.0 (CH2, PhCH2), 62.52 (CH2, C-6), 55.10 (CH, C-1), 
15.69 (C, C-7), 11.98 (C, C-2). 
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1,5-Anhydro-3,4-di-O-benzyl-2-deoxy-1,2-C-(methylene)-D-glycero-D-
gulo-hexitol (18) 
A solution of 21 (50 mg, 0.08 mmol) in diethyl ether (0.3 mL) was treated 
with formic acid (0.4 mL) and stirred at r.t. for 1 h. The mixture was diluted 
with diethyl ether (4 mL) and washed with saturated sodium bicarbonate 
solution (4 x 10 mL). The organic layer was dried over magnesium sulphate 
and concentrated. The crude product was purified by column 
chromatography (hexanes/ethyl acetate gradient 14:1 to 5:1) to give 22 
with a yield of 18 mg (65%) as an oil. The spectral data matched to what 
had previously been reported (Nagarajan et al. 1997).  
18) Rf = 0.12 (3:1 hexane/ethyl acetate). 1HNMR 
(500 MHz, CDCl3):  7.35-7.29 (m, 10H, Ph), 4.89 (t, 
2H, CH2Ph), 4.74 (t, 2H, CH2Ph), 3.87 (m, 1H, C-1), 
3.40 (m, 3H, C-3, C-4, C-5), 2.11 (dd, 2H, C-6, C-6’), 
1.08-0.93 (m, 1H, C-2), 0.81-0.69 (m, 2H, C-7, CPH3); 
13C NMR: (CDCl3)  138.49 (C, COH), 138.35, (CH, Ph), 128.51 (CH, Ph), 
128.0 (CH, Ph), 127.79 (CH, Ph), 126.98 (CH, Ph), 79.61 (CH, C-3), 76.91 (CH, 
C-5), 76.53 (CH, C-4), 73.61 (CH2, PhCH2), 71.25 (CH2, PhCH2), 62.58 (CH2, 
C-6), 49.98 (CH, C-1), 14.43(C, C-7), 10.29 (C, C-2). 
 
p-Azidotoluene (19) 
p-Toluidine (1 g, 9.2 mmol) in water (12 mL) and hydrochloric acid (37%, 12 
mL) were reacted with sodium nitrite (0.756 g, 10.8 mmol) for 2 h of 0oC. 
The diazonium salt was then treated with sat. sodium acetate (15.1 g, 368 
mmol) and sodium azide (1.2 g, 18.4 mmol). The resulted mixture was 
extracted with portions of 2:1 ethyl acetate/hexane (20 mL) and the 
combined organic extracts were treated with brine (20 mL) and dried with 
magnesium sulphate. Resulting in p-azidotoluene as a yellow/orange oil 
with a distinct smell 23 (95% yield). The spectral data matched to what 
had previously been reported (Smith et al. 2011) 
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19) 1H NMR (300 MHz; CDCl3): δ = 6.91-7.18 (m, 4H, CH), 2.34 (s, 
3H, CH3) ppm. 13C NMR (500 MHz; CDCl3): δ = 20.8 (1C, N3-C-CH), 
118.8 (2C, N3-C-CH), 130.3 (2C, CH3-C-CH), 134.6 (1C, CH3-C), 
 
 
p-Azidobenzyl bromide (20) 
A solution of 19 (0.665 g, 5 mmol), N-bromosuccinimide (0.98 g, 5.5 mmol) 
and azobisisobutyronitrile (0.08 g) was heated in the dark under nitrogen in 
refluxing dry benzene for 5 h. The mixture was poured into water and 
diethyl ether. The organic layer was dried over magnesium sulphate and 
concentrated. The residue was dissolved in a small volume of light 
petroleum and purified by column chromatography (hexanes) resulting in 
p-azidobenzyl bromide with a yield of 65% as an orange liquid. The 
spectral data matched to what had been previously reported (Gubbens 
et al. 2009). Please note; p-azidobenzyl bromide is a strong irritant to the 
eyes that causes a high degree of discomfort and should kept in a closed 
system and prior to cleaning be quenched with water within the 
fumehood.  
20) 1H NMR (500 MHz, CDCl3): δ 7.38 (d, J = 8.5 Hz, 2H, Ph), 7.00 (d, 
J 8.5 Hz, 2H, Ph), 4.48 (s, 2H, CH2); 13C NMR (75.5 MHz, CDCl3) δ 
45.6 (1C, C-1), 119.1, 130.1, 134.1, 140.1. 
 
 
1,5-Anhydro-3,4-di-O-(p-azidophenyl)methoxy-2-deoxy-6-O-trityl-D- 
arabino-hex-1-enitol (21)  
Trityl-D-glucal (400 mg, 0.810 mmol) was dissolved in dimethylformamide 
(10 mL) and cooled in an ice bath to -10 °C. sodium hydride (48 mg, 2.20 
mmol) was then added portion-wise over 1 min and the solution was 
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stirred for 10 min, which was then followed by the addition of p-
azidobenzyl bromide (20) (400 mg, 1.89 mmol). The solution was warmed 
to r.t. and stirred for 16 h, followed by quenching with water (20 mL) and 
extraction with chloroform (3 x 10 mL). The organic layers were combined 
and reduced to 10 mL and washed with aqueous sat. copper sulphate (4 
x 10 mL). The organic layer was then dried with magnesium sulphate and 
concentrated, to provide a crude mixture that was purified by column 
chromatography (hexanes/ethyl acetate 9:1) resulting in 21 in a yield of 
250 mg (47.6%) as an oil. 
21) Rf = 0.7 (5:1 hexanes/ethyl acetate) 1H NMR: 
(500 MHz, CDCl3) δ 7.42- 7.30 (complex m, 7H, 
Ph), 7.30- 7.05 (complex m, 12H, Ph), 6.88 (d, J = 
8.4 Hz, 2H, PhN3), 6.79 (d, J = 8.4 Hz, 2H, PhN3), 
6.43 (d, J = 6.3 Hz, 1H, H-2), 4.79 (dd, J = 6.3, 3.1 
Hz, 1H, H-1), 4.69 (d, J = 11.3 Hz, 1H, PhCH2), 4.65 
(d, J = 11.4 Hz, 1H, PhCH2), 4.45 (d, J = 11.3 Hz, 
1H, PhCH2), 4.35 (d, J = 11.3 Hz, 1H, PhCH2), 4.15- 
4.00 (complex m, 2H, H-3,4), 3.90 (d, J = 6.3 Hz, 1H, H-5), 3.48 (dd, J = 10.2, 
2.4 Hz, 1H, H-6a), 3.25 (d, J = 10.1, 2.4 Hz, 1H, H-6b); 13C NMR (75.5 MHz, 
CDCl3) δ 144.9 (CH, C-1), 143.8 (C, Ph), 134.9 (C, Ph), 129.5 (C, Ph), 128.7 
(CH, Ph), 127.8 (CH, Ph), 127.0 (CH, Ph), 118.8 (C, CN3), 99.7 (CH, C-2), 76.9 
(C, CPh3), 76.3 (CH, C-5), 74.6 (CH, C-4), 73.2 (CH2, PhCH2), 70.8 (CH2, 
PhCH2), 62.0 (CH2, C-6); IR (Film from CH2Cl3) υmax 
 
1,5-Anhydro-4-O-(p-azidophenyl)-2-deoxy-6-O-trityl-D-arabino-hex-1-
enitol (22) 
Trityl-D-glucal 3 (1.8 g, 3.7 mmol) was dissolved in dimethylformamide (20 
mL) and cooled in an ice/calcium chloride bath to -10 °C. Sodium hydride 
(48 mg, 2.20 mmol) was then added portion-wise over 1 min and the 
solution was stirred for 10 min, which was then followed by the addition of 
p-azidobenzyl bromide (20) (400 mg, 1.89 mmol). The solution was warmed 
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to r.t and stirred for 16 h, followed by quenching with water (40 mL) and 
extraction with chloroform (3 x 20 mL) the organic layers were combined 
and reduced to 10 mL which was then washed by aqueous sat. copper 
sulphate (6 x 20 mL). The organic layer was then dried with magnesium 
sulphate and concentrated, to provide a crude mixture that was purified 
by column chromatography (hexanes/ethyl acetate 9:1) resulting in 21 in 
a yield of 439 mg (36.4%) as an oil. 
22) Rf = 0.28 (5:1 hexanes/ ethyl acetate) 1H 
NMR: (500 MHz, CDCl3) δ 7.51- 7.45 (m, 7H, Ph), 
7.33-7.23 (m, 8H, Ph), 7.04 (d, J = 8.3 Hz, 2H, 
PhN3), 6.90 (d, J = 8.5 Hz, 2H, PhN3), 6.51 (d, J = 
6.1 Hz, 1H, H-2), 4.77 (dd, J = 6.1, 2.4 Hz, 1H, H-
1), 4.62 (d, J = 11.2 Hz, 1H, PhCH2), 4.45 (d, J = 
11.2 Hz, 1H, PhCH2), 4.32 (t, J = 6.1 Hz, 1H, H-3), 
3.93 (dd, J = 9.3, 3.0 Hz, 1H, H-4), 3.82 (dd, J = 9.2, 6.7 Hz, 1H, H-5), 3.65 (dd, 
J = 10.3, 2.2 Hz, 1H, H-6a), 3.27 (dd, J = 10.3, 3.4 Hz, 1H, H-6b), 1.91 
(apparent t, 1H, OH);  
 
1,5-Anhydro-3,4-di-O-(p-azidophenyl)methoxyl-6-O-(triphenyl-c-arbinyl)-
2-deoxy-1,2-C-(dichloromethylene)-D-glycero-D-gulo-hexitol 
Following the methodology of Nagarajan et al. (1997) a solution of 21 (200 
mg, 0.3 mmol) and benzyltriethylammonium chloride (10 mg, 0.04 mmol) in 
chloroform (5 mL) was treated drop-wise with 33% aqueous sodium 
hydroxide (10 mL) with rapid stirring. The biphasic mixture was stirred at r.t. 
for 10 h. The Biphasic mixture was then diluted with water (10 mL) and 
extracted with dichloromethane (3 x 20 mL). The organic fractions were 
combined and dried by magnesium sulphate and concentrated to 
provide a crude mixture. The crude product was purified by column 
chromatography (hexanes/ethyl acetate 14:1) giving the major 
cyclopropane 23 in a yield of 20 mg (9%) as a colourless oil.  
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23) Rf = 0.3 (9:1 hexanes /ethyl acetate); 1H 
NMR: (500 MHz, CDCl3) δ 7.47 (d, J = 8.3 Hz, 2H, 
PhN3), 7.22 (d, J = 8.3 Hz, 2H, PhN3, 7.05 (d, J = 
8.3 Hz, 2H, PhN3), 7.95 (d, J = 8.0 Hz, 2H, PhN3), 
4.81 (d, J = 11.6 Hz, 1H, PhCH2), 4.78 (d, J = 10.7 
Hz, 1H, PhCH2), 4.70 (d, J = 11.6 Hz, 1H, PhCH2), 4.30 (d, J = 10.7 Hz, 1H, 
PhCH2), 4.10 (d, J = 8.0 Hz, 1H, H-1), 3.88–3.80 (complex m, 2H H-4,5), 3.75 
(dd, J = 8.4, 4.2 Hz, 1H, H-3), 3.49 (dd, J = 10.2, 3.0 Hz, 1H, H-6a), 3.23 (dd, J 
= 10.2, 3.0 Hz, 1H, H-6b), 1.90 (dd, J = 8.0, 4.9 Hz, 1H, H-2); 13C NMR: (CDCl3) 
δ (C, Ph), (C, Ph), (CH, Ph), (CH, Ph), (CH, Ph), (CH, Ph), (CH, Ph), (CH, C-5), 
(CH, C-3), (CH2 , PhCH2), (CH, C-4), (CH2 , PhCH2), (CH2 , C-6), (C, C-7), 
(CH, C-1), (CH, C-2); IR (Film from CH2Cl3) υmax 3016, 2970, 2113, 1444, 1365, 
1092, 1025, 900, 760, 701 cm-1 
 
1,5-Anhydro-3,4-di-O-(p-azidophenyl)methoxy-2-deoxy-1,2-C-
(dichloromethylene)-D-glycero-D-gulo-hexitol 
A solution of 23 (20 mg, 0.027 mmol) in diethyl ether (0.3 mL) was treated 
with formic acid (0.4 mL) and stirred at r.t. for one h. The mixture was 
diluted with diethyl ether (4 mL) and washed with saturated sodium 
bicarbonate solution (4 x 10 mL). The organic layer was dried over 
magnesium sulphate and concentrated. The crude product was purified 
by column chromatography (hexanes/ethyl acetate gradient 14:1 to 5:1) 
to give 24 in a yield of 6.5 mg (48%) as an oil, and 25 (1 mg 7%). 
24) Rf = 0.30 (3:1 hexanes/ethyl acetate) 1H 
NMR: (500 MHz, CDCl3) δ 7.45 (d, J = 8.3 Hz, 2H, 
PhN3), 7.36 (d, J = 8.3 Hz, 2H, PhN3, 7.14 (d, J = 
8.3 Hz, 2H, PhN3), 7.10 (d, J = 8.0 Hz, 2H, PhN3), 
4.91 (d, J = 11.3 Hz, 1H, PhCH2), 4.79 (d, J = 12 
Hz, 1H, PhCH2), 4.68 (t, J = 11.1 Hz, 1H, PhCH2), 3.89 (d, J = 9.5 Hz, 1H, H-1), 
3.79 (dd, J = 9.3, 3.9 Hz, 1H, H-4), 3.75 (m, 1H, H-3), 3.71 (m, 2H, H-6a,b), 3.62 
(t, J = 9.2, Hz, 1H, H-5), 1.82 (dd, J = 8.3, 3.9 Hz, 1H, H-2); 13C NMR: (CDCl3) δ 
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135.8 (C, Ph), 135.8 (C, Ph), 135.1 (CH, Ph), 134.5 (CH, Ph),129.1 (CH, Ph), 
129.1 (CH, Ph), 118.8 (CN3, Ph), 118.7 (CN3, Ph), 79.5 (CH, C-5), 76.1 (CH2 , 
PhCH2),  74.9 (CH, C-4), 74.2 (CH2, PhCH2), 71.4 (CH, C-3), 62.6 (CH2 , C-6), 
60.8 (C, C-7), 58.8 (CH, C-1), 33.7 (CH, C-2); IR (Film from CH2Cl3) υmax 3415, 
2980, 2358, 2346, 2340, 1611, 1512, 1359, 1095, 841, 670 cm-1. 
 
1,5-Anhydro-6-O-(triphenylcarbinyl)-2-deoxy-1,2-(dichloromethylene)-D-
glycero-D-gulo-hexitol (25) 1,5-Anhydro-4-O-benzyl-2-deoxy-1,2-C-
(dichloromethylene)-D-glycero-D-gulo-hexitol (27) 
Compound 5 (920 g, 1.45 mmol) was taken up in warm ethanol (30 mL) 
under nitrogen flow and 10% Pd/C (~80 mg) and three drops of acetic 
acid were added to the mixture. The reaction vessel was purged with 
hydrogen gas and the mixture was vigorously stirred for 24 h. The reaction 
mixture was filtered through celite and concentrated. The crude product 
was purified by column chromatography (hexanes/ethyl acetate gradient 
9:1 to 1:1) resulting in four colourless oils 7 in a yield of 180 mg (30%), 25 in 
30 mg (5%), 26 in 103 mg (31%) and 27 in 103 mg (31%). 
25) Rf = 0.8 (1:1 hexanes/ethyl acetate) 1H NMR: 
(500 MHz, CDCl3) δ 7.51- 7.23 (m, 15H, Ph), 3.86 
(d, J = 8.6 Hz, 1H, H-1), 3.80- 3.65 (m, 2H, H-3, 4), 
3.62- 3.58 (m, 1H, H-5), 3.41 (dd, J = 6.8, 1.5 Hz, 
1H, H-6a), 3.31 (dd, J = 1.4, 6.9 Hz, 1H, H-6b), 3.12 
(bs, 2H, OH), 1.89 (dd, J = 8.6, 3.6 Hz, 1H, H-2), 13C NMR: (CDCl3) 146.9 (C, 
Ph), 144.4 (C, Ph), 143.5 (C, Ph), 128.6 (CH, Ph), 128.6 (CH, Ph), 128.0 (CH, 
Ph), 127.7 (CH, Ph), 127.3 (CH, Ph), 126.8 (CH, Ph), 82.0 (C, C-Ph3), 78.2 (CH, 
C-5), 69.4 (CH, C-4), 68.9 (CH, C-3), 68.5 (CCl2, C-7), 62.5 (CH2, C-6), 58.9 
(CH, C-1), 34.1 (CH, C-2); IR (Film from CH2Cl3) υmax 3460, 3058, 3021, 1591, 
1492, 1444, 1328, 1156, 1010, 758, 706, 638 cm-1; C26H24Cl2O4Na+ [M+Na]+ 
calculated 470.1052, found 470.1046 
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27) Rf = 0.2 (1:1 hexanes/ethyl acetate) 1H NMR: 
(500 MHz, CDCl3) δ 7.40- 7.30 (m, 5H, Ph), 4.79 (d, J 
= 11.7 Hz, 1H, PhCH2), 4.76 (d, J = , 1H, PhCH2), 3.89 
(d, J = 11.5 Hz, 1H, H-1), 3.78 (s, 1H, H-3), 3.69 (m, 
2H, H-4, 5), 3.60 (dd, J = 8.6, 3.8 Hz, 2H, H-6a, 6b) 
2.62 (bs, 1H, OH), 2.0 (bs, 1H, OH), 1.79 ( dd, J = 8.5, 3.6 Hz, 1H, H-2). 13C 
NMR: (CDCl3) 136.9 (C, Ph), 128.7 (CH, Ph), 128.4 (CH, Ph), 128.3 (CH, Ph), 
79.1 (CH, C-5), 76.1 (CH2, PhCH2), 72.1 (CH, C-4), 68.2 (CH, C-3), 63.1 (CH2, 
C-6), 61.1 (CCl2, C-7), 58.8 (CH, C-1), 29.7 (CH, C-2); IR (Film from CH2Cl3) 
υmax 3375, 2016, 2928, 1635, 1384, 1161, 1110, 1053, 987 cm-1 
 
1,5-Anhydro-2-deoxy-1,2-C-(dichloromethylene)-D-glycero-D-gulo-hexitol 
(31) 
Compound 30 (626 mg, 1.2 mmol) was taken up in warm methanol (30 
mL) under nitrogen flow and 10% Pd/C (80 mg) and three drops of acetic 
acid were added to the mixture. The reaction vessel was purged with 
hydrogen gas and the mixture was vigorously stirred for 36 h. The reaction 
mixture was filtered through celite and concentrated. The crude product 
was purified by column chromatography (hexanes/ethyl acetate 1:1) 
resulting in a colourless oil 26 in a yield of 241.2 mg (87.5%). 
26) Rf = 0.05 (1:1 hexanes/ ethyl acetate) 1H NMR: 
(500 MHz, CDCl3) δ 3.88 (d, J = 8.5 Hz, 1H, H-1), 
3.85 (dd, J = 9.0, 3.3 Hz, 1H, H-4), 3.80 (d, J = 3.2 
Hz, 2H, H-6a, H-6b), 3.69- 3.61 ( complex m, 2H, H-
3, H-5), 1.92 (dd, J = 8.6, 3.3 Hz, 1H, H-2); 13C NMR: 
(CDCl3) 80.9 (CH, C-5), 70.0 (CH, C-4), 68.9 (CH, C-3), 62.9 (CH2, C-6), 62.0 
(CCl2, C-7), 58.8 (CH, C-1), 34.0 (CH, C-2); IR (Film from CH2Cl3) υmax 3376, 
3016, 2928, 1635, 1061, 1010, 953, 785 cm-1 
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Tri-O-benzyl-D-glucal (28) 
A solution of 2 (1.54 g, 9.72 mmol) in dimethylformamide (20 mL) was 
cooled to 0 °C and then treated with sodium hydride (1.5 g, 62.5 mmol). 
The solution was stirred at 0 °C for 25 min, then treated with benzyl 
bromide (3 g, 37.5 mmol) and allowed to warm to room temperature. 
After 17 h, the solution was quenched with water (5 mL) and then 
extracted with diethyl ether (3 x 40 mL). The organic fractions were 
combined, dried, filtered and concentrated to give the crude product 28 
as a yellow oil. The crude product was purified by column 
chromatography (hexanes/ethyl acetate 9:1) resulting in 28 in a yield of 
3.9 g (91%) as a white crystalline solid. The spectral data matched those 
reported previously (Nagarajan et al. 1997). 
 
 28) Rf = 0.35 (9:1 hexanes/ ethyl acetate); m.p. 53.5–
55.0 °C (lit.107 m.p. 53– 55 °C); [o]23.4 D −4.90 (c 1.02, 
CH2Cl2); 1H NMR: (500 MHz, CDCl3) δ 7.33–7.23 
(complex m, 15H, Ph) 6.43 (dd, J = 6.1, 1.3 Hz, 1H, H-1), 
4.88 (dd, J = 6.4, 2.7 Hz, 1H, H-2), 4.83 (d, J = 11.3 Hz, 1H, 
PhCH2), 4.640 (d, J = 11.3 Hz, 1H, PhCH2), 4.637 (d, J = 11.8 Hz, 1H, PhCH2), 
4.60 (d, J = 12.0 Hz, 1H, PhCH2), 4.564 (d, J = 12.0 Hz, 1H, PhCH2), 4.562 (d, J 
= 11.8 Hz, 1H, PhCH2), 4.61–4.53 (complex m, 3H, PhCH2), 4.21 (ddd, J = 6.4, 
2.7, 1.3 Hz, 1H, H-3), 4.06 (ddd, J = 8.8, 5.1, 3.0 Hz, 1H, H-5), 3.86 (dd, J = 8.8, 
6.1 Hz, 1H, H-4), 3.80 (dd, J = 10.5, 5.1 Hz, 1H, H-6a), 3.75 (dd, J = 10.5, 3.0 
Hz, 1H, H-6b); 13C NMR: (CDCl3) δ 144.9 (CH, C-1), 138.5 (C, Ph), 138.3 (C, 
Ph), 138.1 (C, Ph), 128.6 (CH, Ph), 128.4 (CH, Ph), 128.1 (CH, Ph), 127.94 
(CH, Ph), 127.89 (CH, Ph), 127.80 (CH, Ph), 127.79 (CH, Ph), 100.1 (CH, C-2), 
76.8 (CH, C-5), 75.9 (CH, C-3), 74.5 (CH, C-4), 73.9 (CH2, PhCH2), 73.7 (CH2, 
PhCH2), 70.6 (CH2, PhCH2), 68.7 (CH2, C-6); IR (Film from CH2Cl2): υmax 3087, 
3064, 3030, 2865, 1648, 1496, 1454, 1239, 1100, 1070, 1027, 735, 697 cm−1. 
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1,5-Anhydro-3,4,6-tri-O-benzyl-2-deoxy-1,2-C-(dichloromethylene)-D-
glycero-D-gulo-hexitol (29) and 1,5-anhydro-3,4,6-tri-O-benzyl-2 
deoxy1,2-C-(dichloromethylene)-D-glycero-D-talo-hexitol (30) 
 As reported by Nagarajan et al. (1997) a solution of 28 (800 mg, 1.93 
mmol) and benzyltriethylammonium chloride (10 mg, 0.04 mmol) in 
chloroform (5 mL) was treated drop-wise with a 33 % aqueous solution of 
sodium hydroxide (10 mL) with rapid stirring. The biphasic mixture was 
stirred at room temperature for 10.5 h, diluted with water (10 mL) and 
extracted with dichloromethane (3 x 20 mL). The organic fractions were 
combined, dried over magnesium sulphate and concentrated to provide 
a crude mixture. Which was purified by column chromatography 
(hexanes/ethyl acetate 14:1) giving 29 as a white solid in 626 mg (62%) 
and 30 as a yellow oil in 61.9 mg (6%) in a combined yield of 68%. Spectral 
data matched those which have been previously reported (Nagarajan et 
al. 1997).  
29)  Rf = 0.40 (9:1 hexanes/ ethyl acetate 
(CH2Cl2); 1H NMR: (500 MHz, CDCl3) δ 7.43–7.22 
(complex m, 15H, Ph), 4.90 (d, J = 11.2 Hz, 1H, 
PhCH2), 4.80 (d, J = 11.7 Hz, 1H, PhCH2), 4.69 (d, J 
= 11.7 Hz, 1H, PhCH2), 4.55 (d, J = 11.2 Hz, 1H, PhCH2), 4.53 (d, J = 12.2 Hz, 
1H, PhCH2), 4.44 (d, J = 12.2 Hz, 1H, PhCH2), 3.89 (d, J = 8.0 Hz, 1H, H-1), 3.84 
(m, 1H, H-5), 3.78–3.76 (complex m, 2H, H-3,4), 3.56 (dd, J = 10.6, 2.8 Hz, 1H, 
H-6a), 3.52 (dd, J = 10.6, 3.7 Hz, 1H, H-6b), 1.79 (m, 1H, H-2); 13C NMR: 
(CDCl3) δ 138.3 (C, Ph), 138.1 (C, Ph), 137.8 (C, Ph), 128.65 (CH, Ph), 128.58 
(CH, Ph), 128.5 (CH, Ph), 128.3 (CH, Ph), 128.04 (CH, Ph), 128.02 (CH, Ph), 
127.93 (CH, Ph), 127.89 (CH, Ph), 127.8 (CH, Ph), 80.0 (CH, C-5), 77.6 and 
75.3 (CH, C-3, and CH, C-4), 74.7 (CH2, PhCH2), 73.5 (CH2, PhCH2), 72.0 
(CH2, PhCH2), 70.3 (CH2, C-6), 61.6 (C, C-7), 59.1 (CH, C-1), 34.4 (CH, C-2); 
IR (Film from CH2Cl2) υmax 3088, 3064, 3031, 2862, 1496, 1454, 1363, 1251, 
1093, 1026, 733, 696 cm-1. 
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30) Rf = 0.25 (9:1 hexanes/ ethyl acetate); 1H 
NMR: (500 MHz, CDCl3) δ 7.46–7.17 (complex m, 
15H, Ph), 4.89 (d, J = 11.7 Hz, 1H, PhCH2), 4.83 (d, 
J = 11.0 Hz, 1H, PhCH2), 4.72 (d, J = 11.7 Hz, 1H, 
PhCH2), 4.64 (d, J = 12.0 Hz, 1H, PhCH2), 4.56 (d, J 
= 12.0 Hz, 1H, PhCH2), 4.55 (d, J = 11.0 Hz, 1H, PhCH2), 4.18 (apparent t, J = 
7.8 Hz, 1H, H-3), 4.00 (d, J = 8.1 Hz, 1H, H-1), 3.86 (dd, J = 10.3, 7.6 Hz, 1H, H-
4), 3.77 (dd, J = 11.0, 1.9 Hz, 1H, H-6a), 3.67 (dd, J = 11.0, 5.3 Hz, 1H, H-6b), 
3.48 (ddd, J = 10.3, 5.3, 1.9 Hz, 1H, H-5), 2.13 (apparent t, J = 8.1 Hz, 1H, H-
2); 13C NMR: (CDCl3) δ 138.3 (C, Ph), 138.2 (C, Ph), 137.9 (C, Ph), 128.7 (CH, 
Ph), 128.6 (CH, Ph), 128.53 (CH, Ph), 128.49 (CH, Ph), 128.2 (CH, Ph), 128.1 
(CH, Ph), 128.0 (CH, Ph), 127.9 (CH, Ph), 127.7 (CH, Ph), 78.6 (CH, C-5), 78.0 
(CH, C-3), 76.8 (CH, C-4), 74.9 (CH2, PhCH2), 73.7 (CH2, PhCH2), 71.4 (CH2, 
PhCH2), 69.1 (CH2, C-6), 62.4 (CH, C-1), 61.8 (C, C-7), 32.9 (CH, C-2); IR (Film 
from CH2Cl2) υmax 3088, 3064, 3031, 2917, 2862, 1496, 1454, 1364, 1091, 1026, 
731, 696 cm-1. 
 
1,5-Anhydro-3,4,6-tri-O-benzyl-2-deoxy-1,2-C-(dibromomethylene)-D-
glycero-D-gulo-hexitol (32) and 1,5-anhydro-3,4,6-tri-O-benzyl-2-
deoxy1,2-C-(dibromomethylene)-D-glycero-D-talo-hexitol (33) 
 As reported by Nagarajan et al. (1997()a solution of 28 (800 mg, 1.93 
mmol) and TEBAC (10 mg, 0.04 mmol) in bromoform (5 mL) was treated 
drop-wise with a solution of 33% aqueous sodium hydroxide (5 mL), and 
potassium fluoride (10 mg, 0.17 mmol) in water (1mL). The biphasic mixture 
was stirred at r.t. for three days. The solution was diluted with water (5 mL) 
and extracted with diethyl ether (3 x 20 mL), then the organic fractions 
were combined and washed with brine (30 mL). The solution was dried, 
over magnesium sulphate and concentrated to provide a crude mixture 
in bromoform and purified by column chromatography (hexanes/ethyl 
acetate 14:1) gave 32 as a white solid in 497 mg (65%) and 33 as a yellow 
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oil in 159 mg (14%) in a combined yield of 79%. Spectral data matched 
those which have been previously reported (Moore 2012). 
32: Rf = 0.40 (9:1 hexanes/ethyl acetate); m.p. 
60.5–62.0 °C 1H NMR: (500 MHz, CDCl3) δ 7.47–
7.22 (complex m, 15H, Ph), 4.90 (d, J = 11.2 Hz, 
1H, PhCH2), 4.81 (d, J = 12.0 Hz, 1H, PhCH2), 4.70 
(d, J = 12.0 Hz, 1H, PhCH2), 4.534 (d, J = 11.2 Hz, 
1H, PhCH2), 5.527 (d, J = 12.2 Hz, 1H, PhCH2), 4.44 (d, J = 12.2 Hz, 1H, 
PhCH2), 3.95 (d, J = 7.8 Hz, 1H, H-1), 3.87 (ddd, J = 7.6, 3.7, 2.7 Hz, 1H, H-5), 
3.79 (dd, 97 J = 9.5, 7.6 Hz, 1H, H-4), 3.68 (dd, J = 9.5, 4.9 Hz, 1H, H-3), 3.55 
(dd, J = 10.5, 2.7 Hz, 1H, H-6a), 3.51 (dd, J = 10.5, 3.7 Hz, 1H, H-6b), 1.87 (dd, 
J = 7.8, 4.9 Hz, 1H, H-2); 13C NMR: δ (CDCl3) C 138.3 (C, Ph), 138.1 (C, Ph), 
137.9 (C, Ph), 128.7 (CH, Ph), 128.6 (CH, Ph), 128.51 (CH, Ph), 128.3 (CH, 
Ph), 128.03 (CH, Ph), 128.01 (CH, Ph), 127.94 (CH, Ph), 127.88 (CH, Ph), 
127.81 (CH, Ph), 80.4 (CH, C-5), 80.1 (CH, C-3), 75.2 (CH, C-4), 74.8 (CH2, 
PhCH2), 73.5 (CH2, PhCH2), 71.9 (CH2, PhCH2), 70.3 (CH2, C-6), 59.4 (CH, C-
1), 35.4 (CH, C 2), 34.1 (C, C-7); IR (Film from CH2Cl2): υmax 3063, 3030, 2860, 
1496, 1454, 1092, 1027, 734, 696 cm-1. 
33) Rf = 0.25 (9:1 hexanes/ethyl acetate); 1H 
NMR: (500 MHz, CDCl3) δ 7.50–7.18 (complex m, 
15H, Ph), 4.92 (d, J = 11.7 Hz, 1H, PhCH2), 4.83 (d, 
J = 11.1 Hz, 1H, PhCH2), 4.72 (d, J = 11.7 Hz, 1H, 
PhCH2), 4.67 (d, J = 12.1 Hz, 1H, PhCH2), 4.57 (d, J 
= 12.1 Hz, 1H, PhCH2), 4.56 (d, J = 11.1 Hz, 1H, PhCH2), 4.18 (t, J = 7.8 Hz, 1H, 
H-3), 4.08 (d, J = 7.8 Hz, 1H, H-1), 3.96 (dd, J = 10.3, 7.4 Hz, 1H, H-4), 3.78 (dd, 
J = 11.0, 1.7 Hz, 1H, 1H, H-6a), 3.68 (dd, J = 11.0, 5.4 Hz, 1H, H-6b), 3.52 (ddd, 
J = 10.3, 5.4, 1.7 Hz, 1H, H-5), 2.29 (apparent t, J = 7.9 Hz, 1H, H-2); 13C NMR: 
(CDCl3) δ 138.3 (C, Ph), 138.2 (C, Ph), 137.9 (C, Ph), 128.7 (CH, Ph), 128.4 
(CH, Ph), 128.2 (CH, Ph), 128.1 (CH, Ph), 128.0 (CH, Ph), 127.83 (CH, Ph), 
127.79 (CH, Ph), 127.7 (CH, Ph), 78.6 (CH, C-3), 78.5 (CH, C-5), 76.6 (CH, C-
4), 74.8 (CH2, PhCH2), 73.7 (CH2, PhCH2), 71.1 (CH2, PhCH2), 69.1 (CH2, C-6), 
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62.8 (CH, C-1), 33.8 (CH, C-2), 30.9 (C, C-7); IR (Film from CH2Cl2): υmax 3063, 
3030, 2861, 1496, 1454, 1091, 1027, 734, 696 cm-1. 
 
3-(prop-2-ynylamino)propan-1-ol (34) 
A solution of 3-aminopropanol (1 g, 0.013 mol) and K2CO3 (1.8 g, 0.013 
mol) in acetonitrile (45 mL) was stirred at r.t. under N2 for 5 min. A solution 
of propargyl bromide (0.158 g, 0.0013 mol) dissolved in acetonitrile (6 mL) 
was added drop-wise with stirring. After stirring for 24 h the solvent was 
evaporated. The residue was dissolved in ethyl acetate (60 mL), washed 
with 10% sodium hydroxide in (3x 25 mL) and dried, over magnesium 
sulphate and concentrated. The crude product was purified by colunm 
chromatography (ethyl acetate to dichloromethane/methanol 4:1) to 
give 34 (146 mg (98.6%). 
34) Rf = 0.20 (4:1 CH2Cl2/MeOH); 1H NMR: (300 MHz, 
CDCl3) δ 3.80 (t, J = 5.4 Hz, 2H, H-1), 3.45 (d, J = 2.5 
Hz, 2H, H-4), 2.95 (t, J = 5.8 Hz, 2H, H-3), 2.45 (bs, 1H, 
OH), 2.23 (t, J = 1.5 Hz, 1H, H-5), 1.73 (p, J = 5.9, 11.2 
Hz, 2H, H-2); 13C NMR: 
 
3-(prop-2-ynylamino)propan-1-ol derivatised sepharose (35) 
To a solution of N-propargyl-3-aminopropanol (126 mg, 1.1 mmol) in 
tetrahydrofuran (3 mL) and dH2O (4 mL) was added epoxy-activated 
sepharose matrix (600 mg). The mixture was shaken at 33 °C for 16 h 
before the mixture was centrifuged down at 2 000 rpm for 1 min. The 
solvent was decanted off, and ethanol (6 mL) was added. The ethanol 
mixture was vortex for 1 min then centrifuged at 2 000 rpm for 1 min, the 
solvent was decanted and replaced with diethyl ether (6 mL). The solution 
was vortex for 1 min then centrifuged at 2 000 rpm for 1 min before the 
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solvent being decanted, this last step was repeated. The resulting matrix 
was further dried under vacuum.  
35) The derivatised resin was not amenable to 
spectroscopic analysis   
 
 
 
 
1,5-Anhydro-3,4-di-O-benzoyl-2-deoxy-6-O-trityl-D-arabino-hex-1-enitol 
(36) and  1,5-Anhydro-4-O-benzoyl-2-deoxy-6-O-trityl-D-arabino-hex-1-
enitol (37) 
To a solution of 2 (4.0 g, 10.3 mmol) in dimethylformamide (32 mL) and 
pyridine (4 mL) at 0 °C was slowly added benzoyl chloride (1.14 g, 8.11 
mmol). The solution was then stirred at r.t. for 4 h, diluted with water (5 mL), 
and extracted with dichloromethane, dried over magnesium sulphate 
and concentrated. The crude product was purified by column 
chromatography (hexanes/ethyl acetate 3:1) to 
 afford 36 in 3.57 g (80%) and 37 in 0.40 g (8%). The spectral data matched 
those reported in the literature (Mariela & Kulkarni, 1988). 
To a solution of 2 (1 g, 2.57 mmol) in dimethylformamide (8 mL) and 
pyridine (1 mL) at 0 °C was slowly added benzoyl chloride (0.9 g, 6.43 
mmol). The solution was then stirred at r.t. for 4 h, diluted water, and 
extracted with dichloromethane, dried over magnesium sulphate and 
concentrated. The crude product was purified by column 
chromatography (hexanes/ethyl acetate 3:1) to afford 37 in 3.66 g (95%).  
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36) 1H NMR: (500 MHz, CD3OD) δ 8.34- 7.06 (m, 25H, Ph), 
6.6 (app dd, 1H, H-1), 5.73 (t, 1H, J = 6.1 Hz, H-4), 5.62 
(ddd, 1H, J = 6.1, 1.8 Hz, H-3), 5.04 (dd, 1H, J = 6.1, 3.2 
Hz, H-2), 4.54- 4.27 (m, 1H, H-5), 3.51- 3.57 (m, 2H, H-6a & 
H-6b); 13C NMR: (CDCl3) δ 168.2 (C, OCOPh),162.6 
(OCOPh), 142.8 (CH, Ph), 134.6 (CH, Ph), 133.1 (CH, Ph), 130.6 (CH, Ph), 
128.8 (CH, Ph), 127.8 (CH, Ph), 127.3 (CH, Ph), 127.0 (CH, Ph), 98.7 (CH, C-
2), 87.1 (C, CPh3), 76.1 (CH, C-5), 68.4 (CH, C-4) 68.2 (CH, C-3), 62.1 (CH2, 
C-6). 
37) 1H NMR: (500 MHz, CD3OD) δ  7.80- 7.10 (m, 20H, 
Ph), 6.55 (dd, 1H, H-1), 5.55 (ddd, 1H, 4.8, 1.8 Hz, H-3), 
4.90 (dd, 1H, J = 6.0, 3.4 Hz, H-2), 3.81-4.0 (m, 2H, H-4, H-
5), 3.33 (dd 1H, H-6a), 3.64 (dd, 1H, H-6b) 2.42 (bs, OH); 
13C NMR: (CDCl3) δ 168.2 (OCOPh), 146.8 (CH, Ph), 144.1 (CH, Ph), 133.6 
(CH, Ph), 130.8 (CH, Ph), 129.1 (CH, Ph), 128.3 (CH, Ph), 128.2 (CH, Ph), 
127.4 (CH, Ph), 99.7 (CH, C-2), 87.4 (C, CPh3), 78.1 (CH, C-5), 73.4 (CH, C-4) 
68.2 (CH, C-3), 63.1 (CH2, C-6). 
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3.0 BIOLOGY 
 
3.1 Aims and objectives 
 
The overall aim of the biology study is to identify the most active 
cyclopropane-containing glycoside and its cellular protein target. To 
achieve this, objectives listed will be completed. 
 Conduct a structure activity relationship (SAR) analysis to determine 
the most active compound against S. cerevisiae (2); 
 Identify potential pathways of interactions by chemical genomics 
(3); and 
 Determine protein targets by mass spectrometry (4). 
 
This chapter describes the biological testing of the compounds synthesised 
in chapter 2. The library of compounds will be subjected to initial dose 
response assays in vivo, (S. cerevisiae) to determine the lead compound, 
which will also give evidence of the mechanism of action. The lead 
compound will be then used in the chemical genomic screen, to 
determine pathways or interactions within the cell. Finally, modifications 
will be made to the lead compound to isolate the biological target.  
Note. Compound 7 will now be called benzose from here on. 
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3.2 Introduction 
 
3.2.1 Structure Activity Relationship 
 
The purpose and importance of a Structure Activity Relationship (SAR) is to 
predict the properties of new compounds from similar known pre-existing 
molecules. 
In the context of bioactive compounds, SARs are relationships between 
the molecular structure and biological activity of chemicals. Similarity can 
be assessed by structure or quantitatively by determining the 
mathematical relationships between molecular descriptors and activity of 
the compound. Studies of the latter are called quantitative structure 
activity relationships (QSAR). This thesis will focus on SAR not QSAR. The 
basic idea of SAR studies originated in the 19th century, when a study by 
Crum-Brown and Fraser (1868) indirectly discovered that it was the 
quaternary ammonium group of curare and other quaternary alkaloids 
that was responsible for their activity of muscular paralysis.  
 
The first direct attempt to identify the relationship between 
pharmacological effect and physicochemical properties was described 
by Richet in 1893. Richet’s study identified the effect of narcotic action on 
tadpoles by a class of organic compounds was related to the solubility of 
these compounds. Since these early studies, the ideas of SAR have stayed 
the same, but the uses have continued to be developed. SAR-based 
studies have been used to great effect in finding new drug candidates 
(Baumert et al. 2012). SAR can also be used to suggest a likely mechanism 
of action; by no means can it definitively determine the mechanism of 
action but it can give supporting evidence. The rationale behind 
determining the mechanism of reaction comes from an in-depth 
knowledge of the chemistry of the substituents. For example, some 
reactions are able to proceed via a chlorine-containing compound 
whereas the reaction is less favourable with bromine at the same position. 
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The rate of the reaction is determined by the stability of the anion 
intermediate; the compound that has the most stabilised intermediate 
can facilitate the reaction most effectively. With an understanding of the 
chemistry it is possible to take a range of similar compounds and 
determine a proposed mechanism; this is further demonstrated in section 
3.5.2.  
 
 
3.2.2 Affinity isolation  
 
The early applications of affinity matrices were related to the use of 
“immunoadsorbents” for the purification of antibodies. These early 
applications have also been used for the purification of nucleotides, 
complimentary strands of nucleic acids, certain species of transfer RNA 
and enzymes (Silman & Katchalski, 1966; Sander et al. 1966; Cuatrecasas, 
1970). It was not until later that enzyme isolation started to have a huge 
impact in this field.  
 
Affinity chromatography matrices attached to bioactive compounds are 
a major tool for finding direct targets. The identification of target proteins 
for bioactive compounds is an essential process of modern 
pharmaceutical drug development because it is a prelude to 
identification of novel drugs with greater selectivity through mechanism-
based and structure-based design. Traditionally for this method, 
compounds that are bound to the matrix interact with proteins by non-
covalent interactions. However, if a matrix-bound bioactive compound 
covalently binds to a target protein, it is believed this protein can be 
removed by trypsin digestion off the matrix-bound protein. The peptide 
fragments can then be identified using MALDI-TOF analysis; an ionization 
technique used in mass spectrometry, allowing the analysis of molecules. 
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The bioactive compound can be either attached to the matrix before or 
after it has interacted with proteins. If attached after, the chemical 
reaction of attaching the molecule and matrix must not affect any 
potential protein targets. Figure 3.1 by Speers & Cravatt (2004) 
demonstrates the binding of a matrix to a compound to identify the 
molecule’s target. The compound, with either an azide or alkyne 
attached can be either added to cells or it can be added to a cell lysate. 
The matrix is then attached in the lysate under the Huisgen Cyclisation 
conditions (copper sulphate, neutralised ascorbic acid).  
 
 
3.2.3 Yeast gene deletion sets (Saccharomyces cerevisiae) 
 
The yeast gene deletion set (YDS) provides one of the most successful 
methods used in the identification of pathways affected by small drug-like 
compounds (Parsons et al. 2004). For S. cerevisiae, deletion mutations 
have been made for all ~6300 known or suspected genes, identifying 
~1000 essential yeast genes and ~4800 viable haploid gene-deletion 
mutants (Tong et al. 2004). These findings show yeast has the ability to 
withstand deletions of a substantial number of individual genes and 
remain viable in standard laboratory conditions (Suter et al. 2006). While 
Figure 3.1. Cartoon representation of an azide-containing molecule binding to an 
enzyme then the attachment to an alkyne-substituted matrix (Speers & Cravatt 
2004).  The biologically active compound is first treated with a protein lysate, 
selectively binding a protein. The bound protein is then removed from the lysate by 
attaching it to a resin through a Huisgen Cyclisation with the alkyne. This resulting in 
the bioactive compound being irreversibly attached to the resin.  
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many single gene deletions cause no change in growth, combinations of 
two such deletions can lead to reduction in, or loss of, viability (Boone et 
al. 2007).  
 
Synthetic non-viable relationships may occur for genes acting in a single 
process, for example, two pathways with the same end point (Boone et al. 
2007). To enable high-throughput synthetic lethal analysis of a bioactive 
compound, a library with a single deletion can be used, while the 
bioactive compound acts equivalently to a second deletion. The deletion 
strains that die or have decreased growth will identify potential pathways 
that are involved in the bioactivity of the compound (Boone et al. 2007). 
Figure 3.2 demonstrates the viability of the deletion strains when exposed 
to the bioactive compound. In some cases an introduced bioactive 
compound shows only low levels of activity due to the cell’s abilities for 
detoxification, for example via efflux pumps (Prasad & Goffeau, 2012). To 
overcome this it is possible to remove the activity of efflux pumps, by 
deletion of the genes that encode for them or their transcription factors 
(Wendler et al. 1997). This provides another example of gene deletions 
that have no effect until treated with a bioactive compound. Removing 
the activity of efflux pumps is not the only method for increasing sensitivity 
of bioactive compounds, for example co-treating bioactive compounds 
with efflux pump inhibitors.  
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Double and triple mutants are also possible. The ∆pdr1∆pdr3∆xxx (where 
xxx donates a single knockout) has been used in our laboratory for drug 
discovery and pathway identification (Coorey, 2012). The PDR1 and PDR3 
genes encode transcription factors for ABC transporters including the 
pdr5p efflux pump, which is able to export a vast range of compounds 
(Talibi & Raymond, 1999; Prasad & Goffeau, 2012). Due to the nature of 
drug-like compounds, the majority of them are substrates for efflux pumps 
because of their hydrophobicity (Prasad & Goffeau, 2012). By removing or 
reducing efflux pump activity, it is possible to identify lead-drug 
candidates that would normally be missed in a drug screen. 
 
The gene SYS1 codes for an integral membrane protein in the golgi and is 
required for targeting of the ARf-like GTPase Arl3p to the golgi. The 
deletion of SYS1 causes increased sensitivities to many different drug-like 
compounds (Setty et al. 2004). The SYS1 gene knock out has no effect on 
cell growth until the cell is put under this type of stress. Gene deletions of 
this sort that sensitise to multiple drugs or conditions are referred to as multi 
drug sensitising, or colloquially “frequent fliers” (Hillenmeyer et al. 2008). A 
Figure 3.2. A chemical genomic approach to identify drug pathways and interactions. 
While the cell is viable when either treated with a biologically active compound or 
related gene is disrupted, it is unable to survive the double insult. By indentifing the 
pattern of phenotype related to treatment with the biologically active compound in 
the chemical genomic screen, target pathways and interactions can be identified. 
(Figure adapted from Parsons et al. 2004) 
Drug  
target Gene  Phenotype 
Viable 
Non-viable 
Viable 
Bioactive  
compound 
Bioactive  
compound 
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paper presented by Hillenmeyer et al. (2008) lists the currently known 
frequent flier genes whose deletion strains are sensitive to many bioactive 
compounds and therefore are generally ignored in chemical genomic 
screens.  
 
In this study the triple deletion mutant library (∆pdr1∆pdr3∆xxx) was used as 
the compounds being tested are exported by ABC transporters in S. 
cerevisiae.  
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3.3 Materials and methods  
 
3.3.1 Chemicals and compounds 
 
The range of cyclopropane-containing glucals were either synthesised by 
myself (chapter 2.0) or donated by Peter Moore of the Organic Chemistry 
Group, School of Chemical and Physical Sciences, Victoria University of 
Wellington, and were purified to >95% pure as assessed by NMR 
spectroscopy. In each case, each study was completed using a single 
batch apart from the lead compound which was identified by batch 
number to keep experiments consistent. All samples were stored at -20 °C 
in DMSO at a concentration of either 10 mM or 50 mM. All other reagents 
were purchased from Sigma-Aldrich unless otherwise stated. 
 
3.3.1.2 Yeast strains and cultures  
 
Yeast strains were either obtained from the ∆pdr1∆pdr3∆xxx knockout 
library, originally prepared by Namal Coorey (within the Chemical Genetic 
Group, School of Biological Sciences, Victoria University of Wellington) or 
from a copy of the yeast gene deletion library, a gift from Charles Boone 
(University of Toronto, Canada).  
 
Strain Genotype 
BY4741 MATa his3∆0/his3∆0 leu2∆0/leu2∆0 met15∆0/MET15 
ura3∆0/ura3∆0 
∆pdr1∆pdr3 MATα pdr1∆::natR pdr3∆::URA3 can1∆::STE2pr-Sp_his5; lyp1∆; 
his3∆1; leu2∆0; ura3∆0; met15∆0 LYS2 
∆pdr1∆pdr3∆xxx pdr1∆::NATpdr3∆::URA3:xxx∆::kanR can1∆::STE2pr-Sp_his5 
Lyp1∆; his3∆1; leu2∆0; ura3∆0; met15∆0 LYS2 
 4xUPRE-GFP  MATα met15∆::4×UPRE-GFP-URA3 can1∆::STE2pr-Sp_his5; 
lyp1∆; his3∆1; leu2∆0; ura3∆0; met15∆0 LYS2 
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3.3.2 Yeast growth conditions 
 
All S. cerevisiae strains were cultured in one of the following media 
supplemented with appropriate antibiotics when required; ClonNat 
(WERNER BioAgents) final concentration of 100 mg/L and geneticin (G418) 
final concentration 200 mg/L. All media were autoclaved at 121 °C for 22 
min before use. 
 
 
Yeast peptone dextrose (YPD) Broth: Was prepared from 8 g yeast extract 
(Becton, Dickinson and Company), 16 g Bacto-Peptone (Becton, 
Dickinson and Company), and 0.096 g adenine (Sigma-Aldrich) mixed into 
760 mL of distilled water. The resulting mixture was sterilised by autoclave; 
once cooled, 40 mL of 40% glucose (Sigma-Aldrich) solution was added 
along with appropriate antibiotics when required. 
Solid YPD media was prepared as above but with the addition of 16 g 
agar (Invitrogen).  
   
Synthetic complete (SC) broth: Was prepared from 1.7 g of yeast nitrogen 
base without amino acids or ammonium sulphate (Becton, Dickinson and 
Company), 1 g of monosodium glutamate (Sigma-Aldrich), and 2 g amino 
acid mixture (see below) was added to 760 mL of distilled water and 
sterilized by autoclave. Once called, 40 mL of 40% glucose (Sigma-Aldrich) 
solution was added along with appropriate antibiotics when required. 
Solid SC media was prepared as above but with the addition of 16 g agar 
(Sigma-Aldrich).  
 
Synthetic Drop out (SD-ura) broth: as above (SC) media with the removal 
of uracil in the amino acid mixture.  
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Amino acid mixture for SC media: 3 g adenine, 2 g uracil, 2 inositol, 0.2 g 
p-aminobenzoic acid, 2 g alanine, 2 g asparagine, 2 g aspartic acid, 2 g 
cysteine, 2 g glutamic acid, 2 g glutamine, 2 g glycine, 2 g histidine, 2 g 
isoleucine, 10 g leucine, 2 g lysine, 2 g methionine, 2 g phenylalanine, 2 g 
proline, 2 g serine, 2 g threonine, 2 g tryptophan, 2 g tyrosine and 2 g 
valine.  
 
 
3.3.3 Initial IC50 assay in Saccharomyces cerevisiae  
 
Liquid phase assay  
The yeast strains BY4741 wild type and ∆pdr1∆pdr3 were used to 
determine the initial IC50 of benzose and compounds 1- 18. 
 
With the initial concentration of 1 mM, serial dilutions in –log(√10 ≈ 3.162-
fold) decrements were made for each of the glucal derived compounds 
by dilution in DMSO (dimethyl sulfoxide). Serial dilutions were transferred to 
wells in a 96 well V-bottom place (KJ511-3, Interlab) along with DMSO 
alone for the negative control to determine the residual growth for each 
yeast strain in the absence of growth inhibitory compound, the residual 
growth is determined from the treated cell growth divided by the control 
cell growth. 
 
A single colony of yeast strain of interest (BY4741 or ∆pdr1∆pdr3) was 
inoculated in 4 mL of each of the three broths (YPD, SC, SD) with the 
appropriate antibiotics. The cultures were incubated on a rotating drum 
(40 rpm) at 31 °C for 18 hours. Cell titre was determined using a 
spectrometer (UNICAM 8625 UV/VIS) and 5x105 cells/mL were inoculated 
into 10 mL of the respective broth for each yeast strain and vortexed. From 
each broth plus cells, 99 µL were delivered into the wells of a 96 well flat-
bottomed plate (TCP-000-096, JET BIOFIL) using a multichannel pipette, for 
each strain in each drug condition in triplicate. Subsequently, 2 µL of half 
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log drug dilutions and DMSO were added to the yeast cells (final DMSO 
concentration 2%).  Individual rows of SC, SD and YPD were included for 
each plate to determine the optical density (OD) of the growth media. 
The contents of the wells were mixed by vortexing the plates at 1000 rpm 
for 30 seconds using the Eppendorf Mix Mate (Krackeler Scientific Inc. 
Albany, New York) and were incubated at 30 °C for 18 hours.  
 
The cultures were resuspended by vortexing at 1000 rpm for 30 seconds 
and the OD in each well was measured at 590 nm using EnvisionTM XciteTM 
2102 Multilabel Reader (Perkin-Elmer, Turku, Finland) with HTS microplate 
reader software version 1.12. The OD in each well was subtracted from the 
average OD for media alone control. The residual growth (OD590Exp/ 
OD590DMSO control x100) was determined and the average residual 
growth plotted using Microsoft Excel (2013). 
 
 
Solid phase assay 
Hot SC-agar (50 °C) was poured into 33 Singer plates (Singer Instruments, 
Somerset UK), with benzose at a range of concentrations from 0 to 200 µM, 
in increments of 20 µM. In triplicate, a single plate from the 
∆pdr1∆pdr3∆xxx library (384 array) was chosen and plated onto each of 
the 30 compound-containing agar plates and along with three DMSO 
alone plates for the negative context by the use of Singer RoToR HDA 
robot (Singer Instruments, Somerset, UK). The plates were imaged 
photographically after 24 hours incubation at 30 °C. Visual inspection and 
use of Colony HT (2006, version 110) were used to identify a concentration 
that led to ~40% reduction in colony size compared to control, allowing 
identification of both resistant and sensitive yeast strains in further assays. 
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3.3.4 Serial dilution assay 
 
The serial spot dilution assay to determine cytotoxic or cytostatic 
behaviours was followed directly from the SC liquid phase IC50 experiment 
of benzose against BY4741 and ∆pdr1∆pdr3 (Methods 3.7.4). One hundred 
µL of culture from the benzose concentrations: 1000, 314, 100, 31, 10, 3.14, 
1.0 and 0.31 µM as well as the 2% DMSO control were transferred into a 96 
well plate from which five sets of 1:4 serial dilutions in dH2O were made. 
The 96 well plates were then transfered onto SC agar plates by pipetting 
1.5 µL of each dilution with a multi-channel pipette. This resulted in four 
lines of five serial dilutions on each half of the SC agar plate as shown 
below. The agar plates were incubated at 30 °C for 36 hours. Photographs 
were recorded at 18, 24 and 36 hours. 
 
 
3.3.5 Mammalian cell experiments 
 
All mammalian cell based experiments were completed by Arun 
Kanakkantharan in the School of Biological Science, Victoria University of 
Wellington.  
 
MTT Cell proliferation assay 
1A9 human ovarian carcinoma cells and HL-60 human promyelocytic 
leukemia cells were seeded in 96-well plates at 1 x 104 cells/well and 
incubated with benzose for 48 hours (for HL-60 cells) and 72 hours (for 1A9 
cells) under normal cell culture conditions. Twenty microlitres of MTT was 
added to each well and incubated for two hours at 37°C. The blue crystals 
were then solubilized at 37°C overnight in 100 μL of solubilizing solution 
containing 10% SDS, 45% dimethylformamide (pH 4.5, adjusted with acetic 
acid), and MTT reduction was measured the following day by absorbance 
at a wavelength of 570 nm in a multiwell-plate reader (Versamax, 
Molecular Devices, Sunnyvale, CA). The half maximal inhibitory 
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concentration (IC50) of the compound was determined from a 
concentration-response curve using Sigma Plot software version 8 (Systat 
Software Inc., Point Richmond, CA, USA). 
 
 
3.3.6 Cell lysate preparation  
 
Glass beads (425-600 μm diameter, Sigma Aldrich) were soaked in 1 M HCl 
for 16 hours then thoroughly rinsed in dH2O, followed by drying for 16 hours. 
The prepared glass beads were chilled in ice before use. 
Fifteen mL of yeast culture was centrifuged at 20 000 rpm (Eppendorf 
centrifuge 5810) and the media was decanted off. The cells were re-
suspended in 2 mL of lysis buffer (50 mM Tris.HCl, pH 7.6, 1 mM EDTA and 10 
µL protease inhibitor mixture). To the buffered culture was added 6 g of 
the prepared glass beads, this was then vortexed at full speed 5 times for 8 
min, between each cycle the cells were kept on ice for 2 min. After the 5 
cycles, the glass beads were removed by pipetting out the media and the 
cell debris was removed by ultra-centrifugation at 4 °C for 30 min at 45 000 
rpm (OptimaTML-100 XP Ultracentrifuge). 
 
 
3.3.7 Bradford protein quantification 
 
Ten µl of the cell lysate was diluted 10-fold with 50 mM Tris.HCl pH 7.5 
buffer, of which 1-5 µl aliquots were taken and made up to 10 µl with the 
appropriate volume of 50 mM Tris.HCl pH 7.5 buffer in a 96 well plate. Two 
hundred µl of Bradford reagent was added. A BSA standard with a 
defined concentration (200-1500 µg/ml) was set up on the same 96 well 
plate. The absorbance was read by (plate reader) at 340 nm and the 
results were graphed with the linear regression of the standards.  
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3.3.8 Affinity matrix preparation 
 
To a solution of 1.26 mg of N-propargyl-3-aminopropanol in 3 mL of THF 
and 4 mL of dH2O was added 600 mg of epoxy-activated sepharose 
matrix (Sigma-Aldrich). The mixture was shaken at 33 °C for 16 hours before 
the mixture was centrifuged down at 2 000 rpm for 1 min. The solvent was 
decanted off, and 6 mL ethanol was added. The ethanol mixture was 
vortexed for 1 min then centrifuged at 2 000 rpm for 1 min, the solvent was 
decanted and replaced with 6 mL of diethyl ether. The solution was 
vortexed for 1 min then centrifuged in an enclosed falcon tube at 2 000 
rpm for 1 min before the solvent being decanted, this last step was 
repeated. The resulting matrix was further dried in a vacuum.  
 
 
3.3.9 Affinity matrix derivatisation  
 
To a solution of 20 mg of 6-[2-(4-azidophenyl)ethyl]azulene in 1 mL of THF  
and 1 mL of cell lysate (S. cerevisiae) was added 5 mg of ascorbic acid 
and sodium hydroxide to neutralise the solution, then 0.1 mL sat. aqueous 
copper sulphate was added. The solution was stirred for 5 min before 300 
mg of the alkyne-substituted sepharose matrix was added. A second 
sample was made as above but with the unmodifed epoxy-activated 
sepharose matrix. The mixtures were shaken at 33 °C overnight. Both 
solutions were then centrifuged at 2 000 rpm for 2 min and the solvents 
were then decanted off. The following wash steps were then carried out 
on both samples: 2x 6 mL water, 2x 6 mL ethanol, 2x 6 mL diethyl ether. For 
each wash, the sample was centrifuged in an enclosed falcon tube at 2 
000 rpm for 1 min then solvent decanted. A solution of 2 M Ammonia was 
then used to dissolve any remaining copper, this was followed by the 
removal of the ammonia by centrifugation at 2 000 rpm the matrix was 
then washed multiple times with dH2O.  
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3.3.10 Huisgen Cyclisation of 24 to the alkyne-substituted sepharose matrix 
 
To a prepared yeast lysate (section 3.3.6), compound 24 was added and 
shaken at 33 °C for 6 h before the alkyne-substituted sepharose matrix was 
added, along with 0.1 mL saturated copper sulphate, and 5 mg of 
ascorbic acid neutralised by aqueous sodium hydroxide. The mixture was 
shaken at 33 °C for 12 h. Centrifugation at 4 000 rpm for 5 min and 
decanting off the supernatant provided the derivatised matrix, which was 
then washed with 1 M Tris.HCl buffer pH 7.5, again centrifuged at 4 000 
rpm for 5 min and the buffer decanted off. The above was repeated with 
the alkyne-substituted sepharose matrix without the copper species 
(Discussion 3.5.4) as a control. 
 
 
3.3.11 Peptide preparation 
 
One hundred µL of 100 mM Tris.HCl pH 8.8 with 0.5 M urea was added to 
the lysate-matrix prepared in section 3.3.10. This was then vortexed. To the 
suspension, 1 µL of NuPage reducing agent (Life Technologies) was 
added, this was then incubated at 55 °C for 35 min. After this time, the 
sample was cooled to room temperature. One µL of freshly made 0.5 M 
iodoacetamide (0.023 g in 250 µL MilliQ water) was added and left for 30 
min in the dark. To the sample, 0.5 µL of 0.5 M calcium chloride and 1 µg of 
trypsin in 20 µL of 100 mM Tris pH 8.8 with 0.5 M urea was added and 
incubated over night at 35 °C with rotation. 
 
The matrix was removed by centrifugation at 2 000 rpm for 3 min, the 
buffer was evaporated by centrivap concentrator. The tryptic peptides 
were re-suspended in 20 µL of 0.1% TFA.  
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3.3.12 ZipTip purification 
 
A PerfectPure C-18 Tip (Eppendorf) was attached to a pipette and 
washed before peptides were attached. The wash consisted of 3x 10 µL 
acetonitrile, 3x 10 µL 50:50 acetonitrile/ 0.1% TFA and then 5x 10 µL 0.1% 
aqueous TFA. Following the wash, the samples of peptides in 20 µL 0.1% 
aqueous TFA prepared in section 3.3.11 were aspirated and expelled 20x 
to attach the peptides to the tip. The tips were then washed with 3x 10 µL 
with 0.1% aqueous TFA. The peptides were then eluted off the tip with 1.5 
µL acetonitrile/ 0.1% aqueous TFA (80:20). The sample was allowed to dry 
in positive air flow. The above was repeated with the alkyne-substituted 
sepharose control sample.  
 
 
3.3.13 Protein identification  
 
Proteins were identified by peptide mass fingerprinting. Proteins were 
cleaved from the alkyne-substituted matrix as described in 3.7.11 and 
3.7.12. The resulting peptide fragments were then subjected to MALDI 
analysis on an AB SCIEX TOF-TOFTM 5800 spectrometer. The sequences 
acquired from this process were then searched against the yeast protein 
database using the MASCOT algorithm. 
3.3.13.1 Preparation of protein spots for MALDI analysis 
The dried peptides from section 3.3.12 were resuspended in 1.5 µL of 
CHCA (alpha-Cyano-4-hydroxycinnamic acid) Matrix (8 mg/mL CHCA, 1% 
aqueous TFA and 50% acetonitrile 1:1). Resuspened samples were 
transferred onto a MALDI plate and left to dry.   
3.3.13.2 MALDI-TOF MS/MS analysis 
MALDI TOF-TOF MS/MS analysis of samples was carried out using an AB 
SCIEX TOF-TOFTM 5800 spectrometer (Applied Biosystems, Foster City, CA) 
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equipped with a diode pulse laser (355 nm, 1 kHz). The spectrometer was 
controlled by TOF-TOFTM Series ExplorerTM software. 
3.3.13.3 Acquisition of spectra for MS 
Spectra for MS analysis were acquired in positive reflector mode with CID 
off. Peptide fragments were collected in the mass range 700- 4000 Da. The 
laser intensity was fixed at 5500 with a pulse rate of 400 Hz. The laser was 
fired in a uniform random pattern. A total of 400 laser shots were collected 
per spectrum. 
3.3.13.4 Calibration of spectra for MS 
MS spectra were internally calibrated using CalMix2 (Applied Biosystems) 
monoisotpic peaks of des-Arg1-Brodykinin (904.4680), angiotensin 1 (m/z 
1296.6770), adrenocorticotropic hormone (ACTH) clip 1-17 (m/z 
2093.0870), ACTH clip 18-39 (m/z 2465.1990) and ACTH clip 7-38 
(3657.9294). Peak matching criteria for calibration included signal to noise 
ratio greater than or equal to five, mass tolerance of ± 0.1 m/z, a minimum 
of three matched peaks, and maximum outlier error of 1 m/z. A list of 
reference masses is shown in appendix 8.0.  
3.3.13.5 Precursor ion selection for MS/MS 
Selection criteria for precursors to undergo MS/MS analysis included a 
signal to noise ratio greater than or equal to 20, mass within the range 800- 
4000 Da, and exclusion of precursor ions within a resolution of 200 of the 
selected precursor ion. Known adduct, calibration and common 
contaminant peaks, such as trypsin were excluded. A full list of exclusion 
masses is shown in appendix 8.0. A maximum of 60 precursor ions were 
selected per spot. MS/MS data were acquired from strongest precursor ion 
first. 
3.3.13.6 Acquisition of spectra for MS/MS 
Spectra for MS/MS analysis were acquired in 1 kV positive reflector mode, 
with CID and metastable suppressor on. The laser intensity was fixed at 
5800 with a pulse rate of 1000 Hz. The laser was fired in a random uniform 
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pattern. Acquisition of spectra was stopped after four sub-spectra were 
collected. A total of 1000 laser shots were collected per full spectrum.  
3.3.13.7 Calibration of spectra for MS/MS 
The monoisotopic angiotensin 1 peak (1296.4680) was selected as a 
precursor ion for calibration. MS/MS spectra were then calibrated using 
known fragment ion masses for this precursor ion (appendix 8.0). Peak 
matching criteria for calibration included a signal to noise ratio greater 
than or equal to 10, mass tolerance ± 0.03 m/z, a minimum of five 
matched peaks, and maximum outlier error of 100 ppm 
3.3.13.8 Comparison of peptide sequences to S. cerevisiae data base 
Peptide fingerprints and MS/MS sequences were imported into Protein 
PilotTM 3.0 software. The MASCOT algorithm was used to search the 
generated peaks list against the NCBI non-redundant data base 
(2008/09/02, 21331 sequences) for S. cerevisiae (905409 sequences) for 
proteins obtained from S. cerevisiae samples. 
 
 
3.3.15 Validation of benzose breakdown in agar 
 
Hot SC-agar (50 °C) containing 60 µM benzose was poured in to five Singer 
plates. At time intervals of four, 10, 14 and 18 h after pouring, the plates 
were pinned by the use of Singer RoToR HDA with plate 10 of the 
∆pdr1∆pdr3∆xxx library. After 24 h of incubation at 33 °C each plate was 
photographed and the growth of each spot was determined by colony HT 
analysis.  
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3.3.14 Genomic screen  
 
The genomic screen used in these studies was modified by Namal Coorey 
within the Chemical Genetic Group, School of Biological Sciences, 
Victoria University of Wellington. The screen was adapted from Tong & 
Boone 2006 to create a library containing the background with null 
mutations in the PDR1 and PDR3 transcription factors. The library was 
maintained as haploid MATa mutants in 1536 colonies per plate format on 
14 plates. Each plate contained 384 strains in quadruplicate with a 
his3∆::kanR control stain border comprising 144 colonies along the side of 
the plate. Since the genomic screen identifies sensitive and resistant strains 
by colony size, the his3∆::kanR border acts as a buffer to prevent strains 
from being susceptible to edge effects such as, more access to media 
and less competition. The his3∆::kanR  was used as the border because it 
does not show any genetic interaction with any query mutations since 
histidine prototrophy is achieved via can1∆:STE2pr-sp-HIS5 in the 
recombinant MATa strains. 
The ∆pdr1∆pdr3∆xxx gene deletion library was copied on to SC agar 
plates in a 1536 arrangement which consisted of four replicates arranged 
in a box formation, as well as a ∆his3 border that consisted of the two 
outer rows and columns of the plates. Fifty six 40 mL SC agar plates were 
poured after autoclaving, with 14 having no drug and 800 µL DMSO as the 
control and the remaining 42 having 60 µM benzose (48 µL of 50 mM stock 
in DMSO) and 752 µL DMSO, both having a DMSO concentration of 2%. 
The DMSO benzose solution was not added until the agar had cooled to 
50 °C. Plating of the 1536 array yeast on to the drug and control plates 
was done using the Singer RoTor HDA. The treated and control plates were 
incubated at 30 °C. At 18, 24 and 36 h, photographs were taken of each 
plate, these were then subjected to Colony HT analysis to determine the 
size of each yeast colony.  
Resistant strains were defined as those where the residual growth of 
benzose-treated strains was found to be above two standard deviations 
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from the total average residual growth in at least one of the technical 
replicates in 2 of 3 biological replicates. Residual growth is defined as the 
average of the quadruplet of benzose treated in each strain divided by 
the average of the corresponding quadruplet of DMSO control. If one of 
the four colonies of the quadruplet was outside of two standard deviation 
points from the average colony was rejected. 
 
Sensitive strains were defined as those where the residual growth of 
benzose treated strains was found to be below two standard deviations 
from the total residual growth average in at least one of the technical 
replicates in 2of 3 biological replicates.  
 
 
3.3.16 Validation of the genomic screen 
 
Each yeast strain that was shown to be resistant in the genomic screen 
was treated to 30, 50 and 70 µM benzose, following the methods 
described for IC50 analysis liquid phase assay (section 3.3.4).  
For each strain, an aliquot of 98 µL of 5x106 cells/ mL was removed from 
the mid log culture and placed into 96 well round bottom plate. To each 
aliquoted yeast strain was added 2 µL the appropriate concentration of 
benzose in DMSO. The samples were sealed by a plastic film and left in an 
incubator for 36 hours. After this time the samples were shaken before 
being read by the plate reader (OD590). To be validated as a resistant 
strain, the strain had to have a residual growth greater than 0.4 at 50 µM 
of benzose, 10 standard deviations above ∆his3 residual growth average 
(0.362 ±0.004). 
This method was also used to validate the sensitive strains but with lower 
benzose concentrations of 10, 30 and 50 µM. To be validated, strains had 
to have residual growth below 0.555 at 30 µM of benzose, two standard 
deviations below ∆his3 residual growth average (0.685 ±0.065). 
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3.3.17 Unfolded protein response element (UPRE) assay 
 
The UPRE assay was carried out by James. H Matthews (within the 
Chemical Genetic Group, School of Biological Sciences, Victoria University 
of Wellington) with the 4×UPRE-GFP (Unfolded Protein Response Element-
Green Fluorescent Protein) strain. A single colony of YCG266 was 
inoculated into 3 mL SC and grown overnight at 30 °C on a rotating drum. 
Cell titre was diluted to 5x 106 cells/mL with SC and resuspended. Fifty µL 
aliquots of this cell suspension were dispensed into a PerkinElmer 384-well 
CellCarrier confocal microscopy plate, with a concentration range of 200, 
100, 50, 25, 12.5, 6.75, 3.85 µM dilutions of benzose and DTT at 0.025 mM. 
ddH2O and 2% DMSO were aliquoted into separate wells as controls. The 
treated cultures were incubated at 30 °C for 4 h, before being read with 
an Opera High Content Screening System confocal microscope 
(PerkinElmer). Excitation and emission wavelengths were 488 and 520 nm 
(GFP), and 561 and 600 nm (RFP) respectively. Data from this assay was 
analysed using Acapella software (PerkinElmer), with Ln(GFP/mCherry) 
being calculated to determine activation of the unfolded protein 
response. 
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3.4 Results  
 
The aim of this study was to determine the potential target of a lead 
compound and to investigate which cellular pathways it affects. To 
identify the lead compound, a structure activity relationship (SAR) assay 
was completed. The SAR assay was also designed to help determine the 
likely binding mechanism that is occurring when interacting with the 
protein of interest (assuming covalent interactions). Identification of 
proteins that interact directly with the lead compound was attempted 
using affinity chromatography and mass spectrometry. A yeast-based 
genetic deletion approach was undertaken using a drug sensitised 
∆pdr1∆pdr3∆xxx genetic mutant array.  
 
 
3.4.1 Benzose is active in ∆pdr1∆pdr3 dual knockout S. cerevisiae 
 
The first synthesised compound (benzose) was subjected to a general 
inhibitory assays against S. cerevisiae BY4741 wild type and ∆pdr1∆pdr3 
dual knock out strains and two stains of human cell lines, HL-60 (human 
promyelocytic leukaemia) and 1A9 (human ovarian cancer) cells. Each 
assay was completed in triplicate. The BY4741 wild type yeast was not 
sensitive towards benzose at any of the concentrations tested, with a 
growth rate within 10% of the non-treated control at each concentration. 
The ∆pdr1∆pdr3 strain had an IC50 of 44 µM; maximal cell death was 
observed at 100 µM (figure 3.3). At the higher end of the concentration 
range the cell survival apparently increased. This was due to benzose 
precipitating in the aqueous solution at these higher concentrations. 
When the DMSO carrier was increased from 2% to 4%, the increase in 
survival was no longer observed.  
 
 
96 | P a g e  
 
 
 
  
 
 
 
 
 
 
 
Figure 3.3. S. cerevisiae ∆pdr1∆pdr3 dual knock out and BY4741 treated with benzose. 
Benzose showed activity against ∆pdr1∆pdr3 with an IC50 of 44 µM, however, no 
activity was found against BY4741 cells. This strongly suggests that benzose is a 
substrate for the membrane ATP-binding cassette (ABC) transporter, which is regulated 
by the PDR1 and PDR3 transcription factors. Results were measured at OD590, in 
triplicates. Values shown are the average of triplicate experiments, with the error bars 
representing the standard deviation.  
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3.4.2 Serial dilution assay 
 
The serial spot dilution assay was undertaken as described in section 3.3.5, 
to determine whether benzose acts as a cytotoxic or cytostatic 
compound. The two strains of yeast were grown in liquid culture at the 
concentrations shown in figure 3.4; cells were serially diluted then 
transferred onto drug-free agar. It was found that at high concentrations 
(314 µM above) benzose is cytotoxic in the initial treatment, leading to no 
growth on the drug-free agar.  At lower concentrations (314 µM and 
below) benzose acts as cytostatic compound, and growth resumed 
unimpeded following transfer. Figure 3.4 confirms that BY4741 is not 
effected by benzose. However, ∆pdr1∆pdr3 at high concentrations is 
showing no growth after the 2nd serial dilution at 314 µM and the 3rd 
dilution at 101 µM. At lower concentrations the ∆pdr1∆pdr3 are able to 
Figure 3.4. Benzose is cytostatic and cytotoxic. Shown here, a double serial 
dilution, the vertical dilution is a decreasing concentration of benzose, and the 
horizontal is a 1:4 dilution of cells. As the concentration is increased, cellular 
growth is decreased showing both cytostatic and cytotoxic characteristics. The 
serial dilution assay was repeated in triplicate, shown here is representative of the 
three replicates. Note, at high concentrations benzose percipates out of solution 
resulting in increased cell growth, BY4741 at 1000 µM  its due to plating error. 
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fully recover at all serial dilutions. It has to be noted that 1000 µM a 
pipetting error occurred due to a defective channel (hence no growth for 
the BY4741 strain) and benzose percipates out of solution resulting in 
decreased toxicity. 
 
 
3.4.3 Identification of the lead compound through SAR analysis 
 
The structure activity relationship study was undertaken as described in 
section 3.3.4. The study was designed to identify the most active 
compound in S. cerevisiae, the study was also designed to identify the 
potential mechanism by which the compounds act on their biological 
target. Structural variations were limited to the groups on oxygen at C-3, 
C-6 and varying the substituent on the cyclopropanes. As discussed in 
section 1.4.2, should these cyclopropanated glycals bind covalently to 
their target protein, they are likely to do so through one of three possible 
mechanisms. 
The compound library consisted of 27 glycals (table 3.1), of which 20 
contain a cyclopropane; 12 of these are chlorine containing and six 
contain bromides; the remaining two cyclopropanes are unsubstituted. All 
glycals were tested under the same conditions as benzose (section 3.3.4) 
against two strains of yeast, the BY4741 wild type and ∆pdr1∆pdr3. Only 
four compounds (7, 11, 15, 25 and 27) were sufficiently active in 
∆pdr1∆pdr3 to permit determination of an IC50. Others were inactive or 
only partially active below their solubility limit in 2% DMSO; only compound 
27 showed activity in the BY4741 wild type yeast.  
The most active compound was then tested against the human cell lines 
HL-60 and 1A9, benzose was inactive in both human cell lines tested. 
 
99 | P a g e  
 
 
 
 
 
 
Compound 
number 
R1 R2 R3 R4 R5 
Cyclo-
propane 
BY4741 
µM 
∆pdr1 
∆pdr3 
µM 
1 CH2OAc Ac Ac - - - - - 
3 CH2OTr H H - - - - - 
4 CH2OTr Bn Bn - - - - - 
5 CH2OTr Bn Bn Cl Cl Down - - 
6 CH2OTr Bn Bn Cl Cl Up - - 
7 CH2OH Bn Bn Cl Cl Down - 40 ± 1.2 
8 CH2OCHO Bn Bn Cl Cl Down - - 
9 CH2OH Bn Bn Cl Cl Up - - 
10 CH2OCHO Bn Bn Cl Cl Up - - 
11 CH2OH Bn Bn Cl H Down - 300 ± 15 
12 COOH Bn Bn Cl Cl Down - - 
13 CH2OTr Bn Bn Br Br Down - - 
14 CH2OTr Bn Bn Br Br Up - - 
15 CH2OH Bn Bn Br Br Down - 150 ± 19 
16 CH2OH Bn Bn Br Br Up - - 
17 CH2OTr Bn Bn H H Up - - 
18 CH2OH Bn Bn H H Up - - 
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24 CH2OH p-N3Bn p-N3Bn H H Down - - 
25 CH2OTr Bn H Cl Cl Down - 200 ± 22 
26 CH2OH H Bn Cl Cl Down - - 
27 CH2OH Bn H Cl Cl Down 500 ± 9 400 ± 24 
28 CH2OBn Bn Bn - - - - - 
30 CH2OBn Bn Bn Cl Cl Down - - 
30 CH2OBn Bn Bn Cl Cl Up - - 
31 CH2OH H H Cl Cl Down - - 
32 CH2OBn Bn Bn Br Br Down - - 
33 CH2OBn Bn Bn Br Br Up - - 
 
 
 
 
 
 
 
 
 
Table 3.1. IC50 analysis of the library synthesised in chapter 2 against 
yeast strains BY4741 and ∆pdr1∆pdr3. All compounds were tested.  
Those with no measurable activity are shown with a dash (-). Five 
compounds were identified as active against ∆pdr1∆pdr3, with one 
showing activity against BY4741. Each compound was measured 
against the two strains of S. cerevisiae at 1, 0.314, 0.100, 0.031, 0.010, 
0.003 and 0.001 mM in three technical and two biological replicates.    
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3.4.4 Matrix derivatisation 
 
The matrix derivatisation was undertaken as described in section 3.3.9 of 
the methods. The study was carried out to synthesise a matrix that would 
have an alkyne that would act as an attachment point to 24, which 
contains an azide moiety which is able to undergo a Huisgen cyclization 
reaction within a cell lysate. This was carried out in two steps, 1) The 
attachment of the alkyne-substituted amine to the epoxide and 2) 
subsequent Huisgen cyclization. An experiment was carried out to confirm 
that the resin can capture the azide derivative, as indicated by a colour 
change since traditional identification techniques (NMR, IR and MS) are 
not suitable for resin-supported chemistry. An azulene-azide derivative (6-
[2-(4-azidophenyl)ethyl]azulene) that is coloured bright blue and contains 
a p-azidobenzyl group was chosen as a substrate to show that cyclization 
is possible. The bright blue colour could not be removed from the matrix 
when washed with multiple solvents (water, ethanol and ether), showing 
the cyclization worked and the 6-[2-(4-azidophenyl)ethyl]azulene was 
attached via the copper-activated Huisgen Cyclization. 
 
 
 
 
 
 
 
 
 
Sepharose 6B matrix 
Figure 3.5. Proposed structure of the azulene-azide derivative undergoing a Huisgen 
Cyclisation, resulting in “staining” of the matrix bright blue. 
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3.4.5 Chemical proteomic analysis 
 
A chemical proteomic analysis study was undertaken as described in 
section 3.3.13. The study was employed to determine the potential 
biological target(s) of benzose. 
An MS/MS analysis was used to determine the identity the peptides that 
were digested off the lysate treated 24-matrix. The control resin (alkyne-
substituted matrix without 24 attached) was shown to have interacted 
with three proteins with a Z-score greater than 56 which was determined 
by Protein PilotTM 3.0 to be the cut off for statistically relevant results. All 
proteins found were part of the glyceraldehyde-3-phosphate 
dehydrogenase family, presumably retained due to residual epoxide 
groups that had not fully reacted with 3-aminopropan-1-ol (McCaul & 
Byers, 1976). The study with the 24-matrix presented four proteins with three 
matching those isolated by the control resin; the glyceraldehyde-3-
phosphate dehydrogenase family. The remaining protein was with a Z-
score of 73, Tef2p, TEF1 encodes the Translational elongation factor EF-1 
alpha, however this was also then identified in the control resin upon 
validations.  Subsequent bioactivity analysis of 24 indicates that the 
compound is inactive, and this is likely to explain the inability of the 24-
derivatised matrix to retain proteins (see section 3.4.3).  Currently no 
biological targets have been identified. 
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3.4.6 Benzose breaks done in agar 
 
The IC50 of benzose in solid agar had to be determined before 
undertaking the chemical genomic screen. The initial experiment 
unexpectedly showed no activity of benzose against any strain of plate 10 
of the ∆pdr1∆pdr3∆xxx library, up to 100 µM. Subsequently a second 
experiment was carried out at concentrations up to 200 µM, in this case 
an IC50 was recorded at 70 µM, which was inconsistent to the previous 
study. It was proposed that the benzose might be breaking down in agar. 
To test this, an experiment was carried out where plates were left for 4, 10, 
14 and 18 hours from pouring. Plates older than 14 hours showed a marked 
decrease in activity of benzose; the change in IC50 with time is shown in 
figure 3.6. On the basis of these results, 4 hours after the plates were 
poured was determined to be the best for the subsequent chemical 
genomic screen, permitting the agar to cool and set, but retain activity. 
Temperature was also determined to be a factor in the breaking down of 
benzose, it was decided to add benzose to the agar directly before each 
plate was poured to limit the contact with heated agar.  
Figure 3.6. Breakdown of benzose in agar. It was found that benzose breaks down 
to unknown products over time, decreasing the activity against ∆pdr1∆pdr3. The 
data points represent average concentration of benzose required to reach the IC50 
at each time point. The error bars equate to the standard deviation between the 
three replicates.  
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3.4.7 Chemical genomic Assay 
 
The PDR1 and PDR3 genes encode transcription factors for elements of the 
pleiotropic drug resistance network including the major efflux pump pdr5. 
The library of ∆pdr1∆pdr3∆xxx modified yeast strains is thus sensitised 
toward drug-like compounds, while also harbouring a different gene 
deletion in each strain of the library. This was tested against benzose to 
identify strains that had elevated sensitivity or resistance to the compound. 
To be classified as resistant, the yeast strain had to show residual growth 
above 0.40 at 50 µM, 10 standard deviations above ∆pdr1∆pdr3∆his (0.36 
±0.004), which was used as a proxy for wild type. For a strain to be classed 
as sensitive it had to show residual growth below 0.36 at 30 µM, two 
standard deviations below ∆pdr1∆pdr3∆his (0.68 ±0.065). 
 The ~4800 strains were tested in a 1536 strain array format (394x four 
replicates per plate) as shown in figure 3.7. The strains that have a square 
box around them have been classified as showing enhanced resistance. 
The screen was performed with three biological replicates as well as two 
technical replicates with four colonies of each strain. 
Figure 3.7. Example of a single resistant gene from plate 8, left DMSO control, right 
benzose (70 µM) treated. The 1536 pinned plate consists of 384x four replicates, 309 
different single deletion mutants, the border consists of his3 (56x four replicates).  
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Of the 4800 strains, 56 were identified as having enhanced resistance. The 
56 strains are presented in table 3.3. Of these, 13 were annotated as 
dubious open reading frames. Notably 25 strains were found to be 
involved in transcription or translation.  
 
A total of 18 ∆pdr1∆pdr3∆xxx sensitive strains were identified (table 3.2). Of 
the 18, (APL5, ATP11, CHO2, CIT1, IRE1, NUP133, OPI3, PDR16, PHO80, RPN4, 
SAP190, SIP3, SSD1, TGL2, TPM1, YJR087w, YKL207w, and YNR021w) three 
(YJR087w, YKL207w, and YNR021w) were annotated as dubious open 
reading frames or uncharacterised; and seven (APL5, CIT1, OPI3, PDR16, 
PHO80, SIP3, and TGL2) were annotated as multi drug sensitising (Hillmeyer 
1997) deletion strains (frequently flyers as described in section 3.2.3). Of the 
remaining eight, five (ATP11, IRE1, NUP133, RPN4 and SSD1) were found to 
be involved in transcription or translation.   
 
 
Systematic name Alias Description of biological process 
YKL207W AIM27 
required for efficient folding of proteins in the 
ER 
YPL195W APL5 
vesicle-mediated transport; protein binding 
AP-3 adaptor complex 
YNL315C ATP11 
protein complex assembly; unfolded protein 
binding 
YGR157W CHO2 
telomere maintenance; 
phosphatidylethanolamine N-
methyltransferase activity  
YNR001C CIT1 
tricarboxylic acid cycle; citrate (Si)-synthase 
activity; mitochondrion 
YHR079C IRE1 
protein amino acid phosphorylation; protein 
serine/threonine kinase activity. 
YKR082W NUP133 
mRNA export from nucleus; structural 
molecule activity; nuclear pore 
YJR073C OPI3 phosphatidylcholine biosynthetic process 
YNL231C PDR16 
response to drug; phosphatidylinositol 
transporter activity; cytoplasm 
YOL001W PHO80 
telomere maintenance; cyclin-dependent 
protein kinase regulator activity  
YDL020C RPN4 
telomere maintenance; transcription factor 
activity 
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YKR028W SAP190 
G1/S transition of mitotic cell cycle; protein 
serine/threonine phosphatase activity  
YNL257C SIP3 
transcription initiation from RNA polymerase II 
promoter  
YDR293C SSD1 
 intracellular mRNA localization; negative 
regulation of translation; regulation of fungal-
type cell wall organization  
YDR058C TGL2 
lipid metabolic process; triacylglycerol lipase 
activity; cellular component 
YNL079C TPM1 
pseudohyphal growth; actin lateral binding; 
bud neck contractile ring 
YJR087W 
 
Dubious  open reading frame that overlaps 
EMC2 which is required for efficient protein 
folding 
YNR021W 
 
biological_process unknown. Localises to the 
endoplasmic reticulum 
 
 
Systematic name Alias  Description of biological process 
YDR524C AGE1 
ADP-ribosylation factor; GTPase activating 
protein effector involved in secretory and 
endocytic pathways 
YDR525W API2 dubious open reading frame 
YDR376W ARH1 
oxidoreductase of the mitochondrial inner 
membrane, involved in cytoplasmic and 
mitochondrial iron homeostasis 
YMR116C ASC1 
G-protein beta subunit and guanine 
nucleotide dissociation inhibitor for Gpa2p 
YLR393W ATP10 
mitochondrial inner membrane protein 
required for assembly of the F0 sector of 
mitochondrial F1F0 ATP synthase 
YFL023W BUD27 protein involved in buD-site selection 
YPL178W CBC2 
possibly to package mRNA for export from 
the nucleous; contains RNA-binding motif 
YER061C CEM1 
beta-keto-acyl synthase with possible role in 
fatty acid synthesis 
YGL019W CKB1 
beta regulatory subunit of casein kinase 2 
has many substrates including transcription 
Table 3.2. Gene deletion strains identified as sensitive in the chemical genomic screen 
treated with Benzose (70 µM). The strains identified as frequent flyers are identified 
by a grey background.  
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factors and all RNA polymerases 
YKL139W CTK1 
catalytic subunit of C-terminal domain of 
kinase I, Phosphorylates both RNA pol II to 
affect transcription and pre-mRNA 3'end 
processing and ribosomal protein 
YBR026C ETR1 a probable role in fatty acid synthesis 
YFL237C HAP2 
subunit of the heme-activated, glucose-
repressed HAP2p/3p/4p/5p CCAAT-binding 
complex, a transcriptional activator and 
global regulator of respiratory gene 
expression 
Control HIS3 
imidazoleglycerol-phosphate dehydratase, 
catalyzes the sixth step in histidine 
biosynthesis; mutations cause histidine 
auxotrophy and sensitivity to Cu, Co, and Ni 
salts; transcription is regulated by general 
amino acid control via GCN4p 
YDR528W HLR1 
regulation of cell wall composition and 
integrity and response to osmotic stress 
YHR187W IPK1 
Inositol 1,3,4,5,6-pentakisphosphate 2-kinase, 
nuclear protein required for synthesis of 
1,2,3,4,5,6-hexakisphosphate (phytate), 
which is integral to cell function; has 2 motifs 
conserved in other fungi 
YGL086W MAD1 
coiled-coil protein involved in the spindle-
assembly checkpoint 
YDR005C MAF1 
highly conserved negative regulator of RNA 
polymerase III 
YRP070W MED2 
subunit of the RNA polymerase mediator 
complex; essential for transcriptional 
regulation 
YFR034C PHO4 
basic helix-loop-helix transcription factor of 
the myc-family; activates transcription 
cooperatively with PHO2p 
YDR276C PMP3 
small plasma membrane, deletion causes 
hyperpolarization of the plasma membrane 
YPL157W QCR2 
subu+A21:D40nit 2 of the ubiquinol 
cytochrome-c reductase complease 
involved in electron transport chain 
YER083C RMD5 
somponent of GID Complex that confers 
ubiquitin ligase (U3) activity; necessary for 
polyubiquitination and degradation of the 
gluconeogenic enzyme fructose-1,6-
bisphosphatase 
YFR048W RMD7 
involved in insertion of proteins into the ER 
membrane; required for the retrieval of HDEL 
proteins from the Golgi and ER 
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YBL027w RPL19b ribosomal 60s subunit protein 
YPR043W RPL43A ribosomal 60s subunit protein 
YLL045C RPL8B ribosomal 60S subunit protein L8B 
YJL191W RPS14b 
protein component of the small (40S) 
ribosomal subunit; required for ribosome 
assembly and 20S pre-rRNA. 
YNL302C RPS1a 
ribosomal protein 10 (RP10) of the small (40S) 
subunit 
YPL090C RPS6A ribosomal 40s subunit protein 
YBL025W RRN10 
protein involved in promoting high level 
transcription of rDNA, subunit of UAF for RNA 
polymerase I 
YNL254C RTC4 
protein of unknown function; null mutation 
suppresses CDC13-1 temperature sensitivity;  
YDL225W SHS1 
component of the septin ring that is required 
for cytokinesis; septins are GTP-binding 
proteins that assemble into rod-like hetero-
oligomers that can associate with other rods 
to form filaments 
YBR289W SNF5 
subunit of the SWI/SNF chromatin 
remodeling complex; involved in 
transcription regulation 
YHR008C SOD2 protects cells against oxygen toxicity 
YGL127C SOH1 
subunit of the RNA polymerase II mediator 
complex; assacoiates with core polymerase 
subunits to form the RNA polymerase II 
holoenzyme; involved in telomere 
maintenance 
YMR179W SPT2 
protein involved in negative regulation of 
transcription 
YER161C SPT21 
protein with a role in transcriptional silencing; 
required for normal transcription at several 
loci including HTA2-HTB2 and HHF2-HHT2, but 
not required at the other histone loci 
YOR247W SRL1 
mannoprotein that exhibits a tight 
association with the cell wall, required for 
cell wall stability in the absence of GPI-
anchored mannoproteins 
YGL024W SST3 
dubious open reading frame unlikely to 
encode a protein that overlaps with PGD1, a 
RNA polymerase II mediator, and STE18 
involved in mating signalling. 
YPR191W TGS1 
trimethyl guanosine synthase; required for 
nucleolar assembly and splicing of meiotic 
pre-mRNAs 
YDR354W TRP4 
anthranilate phosphoriboyl transferase of 
the trytophan biosynthetic pathay. 
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YPR066W UBA3 
protein that acts together with ULA1p to 
activate RUB1p before its conjugation to 
proteins which may play a role in protein 
degradation 
YDR092W UBC13 
ubiquitin-conjugating enzyme involved in 
the error-free DNA postreplication repair 
pathway; interacts with MMS2p to assemble 
ubiquitin chains at the Ub Lys-63 residue; 
DNA damage triggers redistribution from the 
cytoplasm to the nucleus 
YER151C UBP3 
ubiquitin-specific protease involved in 
transport and osmotic response; interacts 
with Bre5p to co-regulate anterograde and 
retrograde transport between the ER and 
Golgi; involved in transcription elongation in 
response to osmostress through 
phosphorylation at Ser695 by HOG1p 
YNL197C WHI3 
RNA binding protein that sequesters CLN3 
mRNA in cytoplasmic foci; Tpk1 (PKA) 
mediated phosphorylation of WHI3 affects 
the G1/S phase transition by modulating 
CLN3 transcription 
YDR250C   
dubious open reading frame unlikely to 
encode a protein 
YGL036W   
dubious open reading frame unlikely to 
encode a protein 
YLR365W   
dubious open reading frame unlikely to 
encode a protein 
YLR366W   
dubious open reading frame unlikely to 
encode a protein which overlaps RPS22B 
YNL170W   
dubious open reading frame unlikely to 
encode a protein. Overlaps with PSD1 
(Phosphatidylserine decarboxylase) 
YPL257W 
 
putative protein of unknown function; 
homozygous diploid deletion strain exhibits 
low budding index 
Table 3.3. Genes deletion strains identified as resistant in the chemical genomic screen 
treated with Benzose (70 µM)  
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3.4.8 Validation of high throughput results 
 
High throughput assays are prone to errors. False positives, where sensitivity 
or resistance is erroneously indicated, can be identified by careful 
validation of the identified deletion strains. Such false positives can arise 
from a number of sources. Competition can cause a decrease in growth, 
when normal growing yeast is situated next to fast growing strains or an 
apparent increase when neighbouring a slower growing stain. Also 
mispinnings lead to colonies where fewer cells were collected during 
pinning, leading to apparent reduced growth across a quadruplet for a 
strain. Finally it is unclear if the breakdown product(s) observed in section 
3.4.6, may have an effect on some strains of yeast. For these reasons it was 
decided to validate the resistant and sensitive strains in liquid SC culture. 
 
3.4.8.1 Validation of Resistant strains  
The validation of the resistant strains were undertaken as described in 
section 3.3.16 of the methods. Of the 56 validated strains assessed, 34 
strains showed enhanced resistance compared to the Δhis3 control to 50 
µM benzose in SC culture, shown in graph 3.9 and an example of the 
resistance against HIS control is shown in figure 3.8. No further studies were 
completed to determine the precise IC50 of any resistant strain. 
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3.4.8.2 Validation of sensitive strains 
The validation of the sensitive strains was carried out as described in 
section 3.3.16 of the methods. All 18 strains that were identified as sensitive 
in the high throughput screen validated as sensitive in SC media (OPI3, 
CIT1, APL5, YKL207w, TGL2, PHO80, SIP3, PDR16, SAP190, YNR021w, 
YJR087w, CHO2, IRE1, ATP11, TPM1, RPN4, SSD1 and NUP133). The 
validation of these sensitive strains was undertaken with lower benzose 
concentrations; 50– 10 µM. The results showed that four of these strains 
were sensitive below 10 µM.  
 
ΔTGS1  ΔHIS3 
DMSO 
control 
30 µM  
Benzose 
50 µM  
Benzose 
70 µM  
Benzose 
Figure 3.8. Sample of resistant validations from the chemical genetic screen. Each 
strain was subjected to three concentrations of benzose (30, 50, 70 µM). Strains that 
showed residual growth greater than 0.400 at 50 µM treatment of benzose (10 stdev 
of ΔHIS3 control average) were classed as resistant. ΔTGS1 shows resistance against 
benzose at all concentrations of benzose, at 50 µM ΔTGS1 has an average (three 
replicates) residual growth of 0.932 ±0.016 at least 0.5 greater than ΔHIS3.  
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3.4.9 Benzose has no effect on the unfolded protein response 
 
In order to determine if the unfolded protein response (UPR) was activated 
by benzose treatment, YCG266-4xUPRE-GFP yeast cells were treated with 
the compound and examined for UPR activation via confocal 
microscopy. Benzose treated cells were compared to cells treated with a 
known UPR inducer, dithiotheritol (DTT). No evidence was seen for 
induction of the UPR by treatment with benzose.  
 
 
 
 
 
 
 
 
 
 
 
 
3.4.10 Antibiotic assay 
  
Current experiments have shown no activity in bacteria (E. coli DH5a and 
Psa-V 18800). 
Figure 3.10. UPR assay to determine protein misfolding, benzose showed no increase 
in protein folding. DTT was used as a control, as it is a known protein misfolding 
inducer. Whole cell GFP intensity, measured at 520 nm, increases with concentration 
in DTT treated cells, indicating UPR activation. GFP intensity remains relativity 
constant in benzose treated cells, indication a non-existent response. 
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3.5 DISCUSSION 
 
This project identified a range of biologically active compounds. The 
library of compounds synthesised consisted mainly of cyclopropane-
carbohydrates with a range of glucal precursors and by-products. This 
library was screened for inhibitory biological activity for mechanism and 
mode of action studies in S. cerevisiae. Twenty-seven compounds were 
synthesised and screened for inhibitory activity, producing five active 
compounds. 
Of the synthetic compounds identified as active, the most potent was 
found to be benzose, therefore, was selected for further study. 
 
 
3.5.1 Dose response assays 
 
A series of dose response assays were carried out in SC broth against S. 
cerevisiae BY4741 and ∆pdr1∆pdr3 strains to determine the characteristics 
of the studied compounds with regards to general toxicity. 
A liquid phase response assay showed that benzose, and compounds 11, 
15, 20 and 27 inhibited yeast growth in the low to mid micromolar range. 
Benzose inhibited all cell growth with an IC50 concentration of 40 µM in the 
∆pdr1∆pdr3 strain, but was inactive against BY4741, identifying efflux 
pumps as having an effect on toxicity. Benzose was shown to have no 
activity against human cell lines HL-60 and 1A-9. Furthermore benzose was 
also found to have no activity as an antibacterial agent. 
The ∆pdr1∆pdr3 strain has a reduced ability to efflux xenobiotics through 
ATP-binding cassette (ABC) transporters (Taibi & Taymound, 1999). The 
major ABC transporters are able to export a wide range of substrates 
(Jungwirth & Kuchler, 2006) and the structure and hydrophobicity of 
benzose fits the character of an ABC transporter substrate. For many 
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drugs, including benzose, the PDR1 + PDR3 combined deletions are 
sufficient to increase the sensitivity of the cell (Nourani et al. 1997; Rogers 
et al. 2001). PDR1 and PDR3 are genes that produce transcription factors 
that are considered to be master regulators of the pleiotropic drug 
resistance systems, which includes the major ABC efflux pumps (Onda et 
al. 2004). These multideleted knock-outs are therefore sensitive to a wide 
array of compounds and can be used for screens to identify weakly-
active lead structures which can often be missed by classic drug 
screening (Rogers et al. 2001). The yeast ∆pdr1∆pdr3∆xxx library was used 
as it is a valuable tool for the genomic screening, coupling its increased 
sensitivity with the utility of a deletion library for revealing chemical genetic 
profiling to probe benzose’s mode of action (Ferrari et al. 2010; Coorey, 
2012). The ∆pdr1∆pdr3 and BY4741 dose response was further utilised to 
identify whether benzose acts in a cytostatic or cytotoxic manner. 
3.5.1.1 Cytostatic and cytotoxic  
In the initial dose response assays with benzose, only partial inhibition of 
growth was observed for the PDR-deficient strain ∆pdr1∆pdr3 between 0.1 
µM to 1000 µM (section 3.4.2). Growth was only observed at 0.1 µM to 100 
µM concentrations while 314 µM showed no signs of growth beyond the 
second cell dilution. This may be due to irreversible inhibition of growth at 
high concentrations but a reversible inhibitory effect at lower 
concentrations. This has been previously reported in literature (Van 
Goietsenoven et al. 2012; Dumont et al. 2007). For example, narciclasine, 
a potent eEF1a inhibitor, induces cytotoxic mitochondrial apoptosis at 
≥200 nM whereas cytostatic impairment of actin cytoskeleton organisation 
is induced at 50 nM (Van Goietsenoven et al. 2012; Dumont et al. 2007). 
The results above suggest that, like narciclasine, benzose is exhibiting both 
cytostatic and cytotoxic effects.  
The remaining compounds did not show activity or have any effect at low 
enough concentration to be considered as further lead compounds. 
However, the dose response assay was able to give insight into the 
biological mechanism through structure activity relationships. 
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3.5.2 Structure activity relationship of cyclopropanated carbohydrates 
 
The structures and properties of each of the five active compounds 
(benzose, 11, 15, 20 and 27) against ∆pdr1∆pdr3 were analysed to assess 
why they have different levels of biological activity. Five of the 27 
compounds synthesised were active against ∆pdr1∆pdr3, with benzose 
being the most active (40 µM). However only one, 17 (0.4 mM) was active 
against BY4741 (S. cerevisiae), as described in section 3.4.1. To understand 
the activity the compounds will be discussed in turn based on the three 
proposed mechanisms discussed (section 1.4.2).   
The following assumptions are also made in this analysis; 
I) All compounds share the same target; and  
II) the compounds function through covalent interactions with their 
target or, must be covalently modified prior to interaction with their target. 
Given a proteins’ ability to catalyse reactions, the inherent activity of an 
individual substrate may be masked. Thus activity will arise from a 
combination of a compound’s ability to bind to the target and its ability to 
undergo the appropriate transformation. 
 
3.5.2.1 Mechanism 1 
As introduced in sections 1.4.1 and 2.2.1, the cyclopropane is a strained 
three-membered ring that is susceptible to nucleophillic attack. Of the 
active compounds (benzose, 11, 15, 20, 27), all have a cyclopropane and 
all can undergo the proposed ring breaking mechanism (scheme 3.1). For 
a compound to go via this mechanism it must be able to stabilise a 
carbanion, and have a good leaving group on the cyclopropane (Hewitt 
& Harvey, 2008). All five active compounds are able to fulfil these 
attributes. Compound 15 is the only one of the five active compounds 
that has a dibromocyclopropane. Bromines are large halogens that act as 
very good leaving groups (Bartoli & Todesco, 1977), however their ability to 
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stabilise a carbanion, is not to the same degree as chlorine (Bickelhaupt et 
al. 2005). It has computational been shown computationally by 
Bickelhaupt et al. (2005) that -stabilization of the carbanion by CH2X- is 
strongest for fluorine and become less so along the series X= F, Cl, Br and I. 
This is shown to follow the observed decrease in basicity of CH2X- along this 
series, the reduced basicity corresponds to a decrease in proton affinity of 
CH2X-. When applying this computational model to the anion stabilisation 
proposed in mechanism 1, it would be expected that the dibromine will 
be less active than the dichlorocyclopropane-carbohydrate. This is seen in 
the difference in activity between benzose and 15. The 
monochlorocyclopropane 11 is eight-fold less active than benzose. This 
change in activity can be attributed to the removal of one of the two 
chlorides from benzose. The loss of a chloride would reduce the effect of 
carbanion stabilisation (Brinkman et al. 1994), resulting in lower activity. 
Furthermore, the activity of 11 is less than 15, which adheres to the 
stabilisation of the carbanion effect, two bromines have a greater 
stabilisation effect over a single chlorine. 
Scheme 3.1. Mechanism 1 
H+
Base
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3.5.2.3 Mechanism 2  
The two proposed ring opening mechanisms may be operating, however 
the evidence is presently against this. Scheme 3.2 shows the loss of a 
substituent of the cyclopropane in a Ferrier-like rearrangement, for this to 
occur the substituents on the cyclopropane must be good leaving groups, 
this is the case. However a bromine is a much better leaving group than 
chlorine (Alonso & Rossi, 1980) so it would be expected 15 would be more 
reactive then benzose, this is not the case as shown in section 3.4.3. 
Therefore, it is doubtful that this is the mechanism of action.  
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.2. Mechanism 2 
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3.5.2.2 Mechanism 3 
The mechanism shown in scheme 3.3 is similar to the above, however in 
this case the leaving group is on the C-3 position. Compounds 11, 15 and 
benzose all have an OBn, which can act as a leaving group when 
activated by an electrophile (Rooseboom et al. 2004). However two of the 
five compounds have a hydroxyl group, which is a very poor leaving 
group (Qin et al. 2007). Although catalytic activation by the protein target 
may permit this transformation, it remains less likely. 
 
At this point the evidence discussed here is pointing towards the 
carbanion intermediate mechanism, as depicted in scheme 3.1. 
 
The orientation of the cyclopropane proved to be important for activity as 
all five active compounds had the cyclopropane in the “down” position 
(ie on the same face as the C-6 substituent of the pyran), whereas the 
stereoisomers in the “up” position showed no activity. This effect could be 
caused by multiple factors. Sterics play an important part of all drug 
design. If the structure does not fit with the target it will not be active. For 
example a study by Carotti et al. (2002) demonstrated that removing the 
methyl group in the 3’ position of geiparvarin increased its level of 
inhibition of monoamine oxidase. This was due to reduction in the steric 
hindrance. Todoroki et al. (1996) showed that the “down” unfunctionalised 
cyclopropane of abscisic acid analogues was inactive against the 
Scheme 3.3. Mechanism 3 
:Enzyme
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stomatal opening of the epidermal strips of spiderwort, lettuce seed 
-amylase induction by gibberellin A-3 in barley half-seeds 
and elongation of the second leaf sheath of rice seedlings, whereas the 
“up” cyclopropane was active, the difference in activity was contributed 
to the stereochemistry of the cyclopropane in a tight binding pocket. 
 
3.5.2.4 C-6 hydroxyl is needed for activity 
Benzose has a C-6 hydroxyl, it was found that when this was protected by 
either a trityl 5, formate ester 8 or benzyl 29 the activity is completely lost 
(exluding 25 for reasons later discussed). This suggests either an 
unfavourable steric interaction or that H-bonding is required for activity. 
Interestingly, 25 which retains OTr but lacks a C-3 OBn is somewhat active, 
albeit at a five-fold higher concentration than benzose. This may be 
because of hydrogen bonding within the pocket as both the C-3 hydroxyl 
and C-6 hydroxyl may be able to interact with the same hydrogen bond 
acceptor shown in figure 3.11. The enzyme acts as a hydrogen bond 
donor and the compound the acceptor because compound 9 with the 
formate esters would be able to accept a hydrogen bond, however it is 
Figure 3.11. Proposed hydrogen bonding in the active site with C-3 and C-6 hydroxyl. 
A: represents the hydrogen acceptor in the hydrogen bond formation. The blue 
hydrogen bond represents compounds; 9, 11, 15, 16, 18, 24, 27, 26 and benzose, the 
orange hydrogen bond represents compounds; 25, 27 and 26.  
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inactive. 
Surprisingly, 24 was found to be inactive due to the addition of an azide in 
the para-position of the benzyl group. This suggests that the benzyl 
protecting groups are situated inside the active site pocket.  
In all cases of activity the cyclopropane was in the “down” position and 
the “up” was always found to be inactive. It is proposed that benzose is in 
a tight-binding enzymatic pocket, and the enzymatic nucleophile is 
attacking the anomeric centre (C-1), and is positioned so it can undergo 
nucleophillic attack at the required angle as shown in figure 3.12. 
However, in the proposed position with compound 8 the nucleophile 
would be unable to attack the “up” cyclopropane, resulting in inactivity.  
 
 
 
 
 
Figure 3.12. Proposed nucleophilic attack of the aromatic centre of compound 9 and 
benzose. Benzose is active, whereas 9 is inactive suggesting steric hindrance as a 
factor, or the nucleophile is situated at an angle that can attack the “down” 
cyclopropane but not the “up” cyclopropane. A: represents the proton acceptor in 
the hydrogen bond formation (Nitrogen or Oxygen), Nu: represents the nucleophile 
attacking the aromatic centre.  
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3.5.3 The chemistry of benzose 
 
It is possible, as we have seen in the structure activity relationships of the 
cyclopropanated-carbohydrates and their precursors, to predict their 
chemistry within a cell. There are several determinations that can be 
made about benzose in this manner. Benzose (1,5-Anhydro-3,4-di-O-
benzyl-2-deoxy-1,2-C-(dichloromethylene)-D-glycero-D-gulo-hexitol) is a 
non-polar, cyclopropanated carbohydrate. The apparent affinity of the 
compounds for ABC transporters suggests that the toxicity of benzose is 
limited by the detoxification pathways of the cell. This was expected as 
benzose had been designed to be highly selective with its target. The 
proposed mechanism of benzose (scheme 3.4) shows that ring breaking 
will not occur unless the structural requirements are met. This is further 
backed up by the SAR analysis that shows the addition of either an azide, 
C-6 hydroxyl protecting group, or “up” cyclopropane results in full loss of 
activity.  
The mechanism proposed in scheme 3.4 would see the nucleophile within 
the targets active site being irreversibly bound to benzose. The nucleophile 
attacks at C-1, results in ring breaking and the formation of a stabilised 
anion, which is stabilised by the two chlorines. Through acid-base catalysis, 
the anion attacks a proton, a base attacks the C-2 proton with results in 
the formation of an alkene and elimination of chlorine. However, this 
mechanism can stop once C-7 has been protonated.  
This reaction could have a range of deleterious effects including covalent 
modification of the proteins structure, blocking the active site, or 
interfering with protein-protein interactions (Way, 2000; Johnson, 2004; 
Stadtman, 1990). Covalent modification may not be occurring if the 
protein is attacking the cyclopropane via an activated water molecule 
(Liu et al. 1995). This mechanism will still occur although benzose will not 
irreversibly bind to the protein. 
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Benzose is non-polar with a polar alcohol region, which is likely to form 
hydrogen bonds within the active site of the enzyme. Non-polar drugs are 
able to diffuse through the phospholipid bilayer membrane (Schwendener 
& Schott, 2010), meaning they are able to be incorporated into the cell 
without the need of active transport. Hydrophobic compounds are more 
likely to be “drug-like” as they have a high ligand-lipophilic efficiency 
score which is associated with drug-likeness (Leeson & Springthorpe, 2007). 
Ligand-lipophilic efficiency is a parameter used to link potency and 
lipophilic nature associated with a compound to estimate its potency as a 
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drug.  
The proposed mechanism of benzose suggests a likely pathway of how 
the compound acts to inhibit yeast survival. The primary biological effect 
of toxicity suggests that inhibition of cellular growth is a result of selective 
inhibition of an essential protein. 
 
 
Scheme 3.4. The proposed enzymatic step of benzose within the 
active site of an unknown protein, where a nucleophile is present 
that is able to attack the C-1 (anomeric) position. The addition of 
the nucleophile causes the cyclopropane to break resulting in the 
rearrangement of bonds forming a stabilised anion, which is then 
able to attack a proton then elimination of H-2 by a base and 
elimination of Cl. 
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3.5.4 Alkyne-substituted sepharose matrix  
 
This study was undertaken to identify possible methods of attaching 
benzose to a resin in order to create a tool for identification of potential 
benzose-interacting proteins. The investigation yielded a possible method 
of attachment and also a method to identify whether the chemistry was 
viable, as described in results section 3.4.4.  
Through testing a range of cyclopropane-containing glycosides and 
glucals for activity against ∆pdr1∆pdr3, benzose was found to be the most 
promising candidate for pull-down studies due to the low micromolar 
activity. However there were no suitable points of attachment on benzose 
for the matrix attachment, as any modification to the C-6 hydroxyl would 
most likely cause loss of activity as shown by 6, 9 and 30 in the SAR as 
previously mentioned in 3.5.2. 
Therefore a strategy was proposed to add the attachment point to the C-
3 or C-4 hydroxyl. A viable option was the use of p-azidobenzyl as it is 
already similar to the benzyl on the C-3 and C-4 hydroxyl and has been 
previously used to attach a photoaffinity probe (Young, 1983). Additionally 
the p-azidobenzyl could undergo a Huisgen Cyclisation reaction, within a 
cell lysate, to a corresponding alkyne resin leading to identification of the 
biological target (Wang et al. 2009). By doing so it would overcome the 
problem of binding benzose to a matrix. Azides are small and have no 
biological effect and was anticipated to have little effect on the binding 
of benzose. Compound 24 was therefore synthesised as a tool to identify 
the likely target(s) of benzose.  
It was decided to modify an epoxy-activated sepharose 6B resin to an 
alkyne-substituted sepharose resin. The epoxy-activated sepharose resin 
has an advantageous 13-atom spacer which is linked to an epoxide 
through which an alkyne can be attached. It has also been reported that 
alkyne-modified probes display suitable stability for profiling enzyme 
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activities in cells (Speers & Cravatt, 2004), as they can undergo the 
Huisgen Cyclisation with azide-containing compounds such as 24.  
The epoxide matrix was treated with three different alkyne derivatives to 
determine which would lead to a desired alkyne-substituted sepharose 
matrix. The short optimised synthesis of the alkyne- substituted sepharose 
6B resulted from the propargylation of 3-aminopropan-1-ol with propargyl 
bromide. Two other amines were also tried but they did not present a 
viable option. The amines were too volatile, which resulted in their loss 
under the reaction conditions required with the propargyl bromide. The 3-
(prop-2-ynylamino)propan-1-ol was subsequently reacted in a vast excess 
with the epoxy-activated sepharose 6B matrix to give an unknown yield 
(scheme 3.5). Traditional chemical identification techniques are not 
amenable to quantifying the outcome of matrix derivatisations of this sort, 
therefore a proof of principle using colour was used to identify the 
product.  
 
propargyl bormide,
K2CO3, MeCN
Scheme 3.5. Synthesis of the alkyne-sepharose matrix. 
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A fellow chemist in the School of Chemical and Physical Sciences (Victoria 
University of Wellington) has been working on azulene derived compounds 
that are densely coloured even at nanomolar concentrations (Bevan, 
2010). Given its colour and availability, 6-methylazulene was reacted with 
p-azidobenzyl bromide. The product 6-[2-(4-azidophenyl)ethyl]azulene 
was then reacted under Huisgen Cyclisation conditions (Speers & Cravatt, 
2004) in a cell lysate with the alkyne-substituted sepharose 6B matrix. No 
yield was recordable. However, when compared to a control reaction 
with the click conditions and underivatised epoxide activated resin, it was 
clear the p-azidobenzyl azulene substituted the alkyne-substituted matrix, 
giving a persistent blue colour. As figure 3.13 shows, there is retention of 
colour on the azulene substituted matrix. Ammonia was used to remove 
any copper species, by forming tetraamminecopper(II) sulphate, ensuring 
the only remaining blue colour could come from immobilised azulene. The 
Huisgen Cyclisation conditions lead to a blue sepharose matrix and 
without the click conditions a white speharose matrix was present. While 
these results were only an indication that the matrix was undergoing a 
Huisgen Cyclisation reaction via the alkyne of the modified matrix, it was 
believed to be strong enough evidence to proceed. The azulene capture 
Figure 3.13. Demonstrates visual results for azulene-sepharose matrix compared to 
the alkyne-sepharose matrix; for proof of principle purposes. Two samples of alkyne-
sepharose matrix was subjected to azulene-azide; one with the Huisgen Cyclisation 
condition one without, to determine if azulene will “click” to the alkyne matrix.  Both 
the alkyne-sepharose matrices were multiple solvent washes, then to an ammonia 
wash followed by multiple water washes. The sample treated under the cyclisation 
conditions lead to a blue matrix, while the other lead to white matrix, indication the 
reaction was successful.  
Azulene-sepharose 
matrix (blue) 
Alkyne-sepharose 
matrix (white) 
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from the cell lysate proved the principle, and the approach may be 
valuable in other cases (ie attempts to identify targets of other bioactive 
compounds).  
Unfortunately, 24 has been shown to have no activity against ∆pdr1∆pdr3 
(S. cerevisiae). However, pull-down from lysate was attempted as weak 
binding, metabolic degradation or reduced cell entry could have been 
the cause of the lack of activity. It could also indicate whether 24 is 
binding to proteins that do not lead to cell death.  Unfortunately, and in 
line with the lack of activity, no proteins were selectively isolated using the 
affinity matrix, which indicates substantial constraints operating with this 
part of the target’s binding pocket.  Future work may identify a 
compound that can utilise the alkyne-modified matrix. 
 
3.5.5 Chemical genomic screen gives insight to the biological role of 
benzose 
 
During this study it was identified that benzose breaks down in agar 
(section 3.4.6), but through careful preparation of benzose-containing 
agar plates, the ∆pdr1∆pdr3∆xxx deletion library was screened identifying 
53 resistant and 18 sensitive strains.  All sensitive strains were verified in 
liquid culture, along with 34 of the 53 resistant strains. 
Benzose belongs to a class of cyclopropanated carbohydrates which 
have been shown to have activity against cancer cell lines (Sanhueza et 
al. 2007). Benzose may bind and inhibit a protein synthesis related protein 
via one of the proposed mechanisms (section 1.4.2) as indicated by the 
genomic screen results, and so inhibit growth in ∆pdr1∆pdr3 cells. 
However, no inhibition was observed in the HL-60 and 1A9 mammalian cell 
lines or the bacterial strains Psa-V 18800 and E.coli DH5a, suggesting that 
the role of benzose in inhibition is selective to S. cervisiae. Compound 29 
showed no activity in ∆pdr1∆pdr3 cells however, literature showed 29 as 
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having an IC50 in the low micromolar range against HeLa (Sanhueza et al. 
2007).  
 
A number of benzose-resistant deletion mutants were identified in the 
chemical genetic screen, but failed to show functional enrichment by 
Gene Ontology (GO) analysis. However, a very high proportion of genes 
whose deletion lead to resistance encode for proteins involved in 
ribosomal transcription or translation (CKB1, CTK1, MED1, RMD7, RPL19b, 
PLR43a, RPL43a, RPS14b, RPS1a, RPS6a, RRN10, SNF5, SPT2, SPT21, UBP3, 
SIP3, IRE1, ATP11, and RPN4). The deletion of these genes could cause 
impairment in protein synthesis. Limiting protein synthesis has been 
identified as a method of increasing cell growth under pressures of toxicity 
such as an increase in misfolded proteins caused by bioactive 
compounds (Ding 2007; Steffen et al. 2012).  
A previously reported chemical genetic screen using tunicamycin, a 
known N-linked glycosylation inhibitor in the ER, is often used to prompt the 
unfolded protein response. Yeast strains with ribosomal protein knockouts 
treated with tunicamycin have been shown to result in resistance, the 
associated resistance varied dramatically depending on the 
corresponding ribosomal protein knock out. Tunicamycin resistance was 
found to be partially Hac1 independent. Hac-1 independent resistance to 
ER stress in yeast is thought to activate transcriptional response to ER stress. 
The stress is reliant on the contact between RNA Pol II and the core 
promoter of ER chaperone genes (Schroder et al. 2003). Interestingly, a 
majority of the hits found in the genetic screen identify ribosomal protein 
Figure 3.14. Compound 29 and benzose (7) 
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knock outs, resulting in resistance. Also, RNA Pol II related knockouts were 
identified as sensitive and resistant, with suppressors as sensitive and up 
regulators as being resistant.  
Wild-type yeast was co-treated with tunicamycin and cycloheximide to 
determine whether reduced translation generally resulted in tunicamycin 
resistance, this was found to be true (Steffen et al. 2012). If this holds true 
as a comparison to benzose, a strain that has a decreased rate of protein 
synthesis will show resistance. Reducing the rate of protein synthesis will 
allow the cell to “keep up” with the increased misfolding. To identify 
whether decreased protein synthesis is causing resistance it would be 
advisable to co-treat with benzose and a known protein synthesis inhibitor. 
Recently, benzose was subjected to a protein misfolding assay.  
These results suggest that benzose like Tunicamycin may induce the 
unfolded protein response, to determine this, the UPR assay was 
conducted. 
3.5.6.1 The effect of benzose on the unfolded protein response UPRE   
Benzose may have one or more roles in protein synthesis. For example, it 
may lead to production of misfolded proteins. Misfolded proteins are 
degraded and recycled to prevent toxic effects (Das et al. 2013; 
Goldberg, 2003). If benzose is causing an increase in misfolding of proteins, 
the cell’s protein recycling pathways will be unable to keep up with the 
increased workload. Amongst the sensitive hits were ∆ire1, ∆YJR087w 
(overlaps emc2), and ∆aim27, all of which are associated with protein 
misfolding, indicating this as a potential function of benzose which will 
likely trigger the unfolded protein response (UPR) (Rao et al. 2004; Lin et al. 
2007; Jonikas et al. 2009). The primary causes of UPR in a cellular context 
are elevated synthesis of secretory proteins, expression of mutant proteins 
prone to misfolding, and altered glycosylation (Kaufman, 2002). However, 
inhibition of proteins essential to protein folding will also lead to 
upregulation of the UPR system. 
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An assay was conducted to assess the ability of benzose to perturb protein 
folding. The UPR assay uses a strain of yeast in which the expression of a 
red fluorescent reporter protein (RFP) is controlled by the unfolded protein 
responsive element (UPRE). An increase in RFP levels acts as an indicator 
of UPR activation (Jonikas et al. 2009; Bernales et al. 2006; Okamuraa et al. 
2000).  Unfortunately, this UPR assay strain does not have the ∆pdr1∆pdr3 
background, and so it was recognised that the efficient efflux of benzose 
that ablates growth inhibition in the presence of a functioning PDR system 
could also lead to a negative response in this UPR assay system.  Whilst a 
positive result in the assay would have confirmed an effect on protein 
folding, unfortunately the negative result obtained in this assay is not 
informative.  Work is ongoing to place the UPR reporter construct into the 
∆pdr1∆pdr3 background.  
 
The primary causes of UPR in a cellular context are elevated synthesis of 
secretory proteins, expression of mutant proteins prone to misfolding, and 
altered glycosylation (Kaufman, 2002). In this experiment, benzose did not 
produce a response from the UPR GFP reporter expression.  
 
3.5.6.2 Deletion mutants sensitive to benzose 
The 18 benzose hypersensitive strains were subjected to the same analysis 
as the resistant strains. However, eight of these strains have been 
previously identified as multidrug sensitising (Hillemeyer et al. 2008). The 
term multidrug sensitising is given to a gene deletion that leads to 
sensitivity to multiple drugs of diverse structure and activity. For example, a 
gene that encodes for a protein involved in cell wall synthesis, when 
removed may allow for a higher concentration of drug to diffuse into the 
cell, making the cell more susceptible to cell death (Hillemeyer et al. 2008; 
Parsons et al. 2004; Parsons et al. 2006). Of the 10 genes that are not 
multidrug sensitising, three were found to be involved in RNA localisation, 
one in the negative regulation of transcription from RNA polymerase II 
promoter in response to stress and three were found to be involved in the 
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negative regulation of cellular protein biosynthesis. Therefore, as observed 
with the resistant genes, the majority of sensitive genes are found to be 
involved in transcription and/or translation.  
There were no statistically significant enriched processes relating to these 
sensitive strains, although removing multiple hypothesis test corrections 
(such as the Bonferroni correction), results in the phospholipid biosynthesis 
pathway being noted as enriched, albeit on the basis of only two strains 
(CHO2 & OPI3). Interestingly, IRE1, CHO2 and OPI3 genes result in a 
Yeastmine (www.yeastmine.org) publication enrichment for an article 
“The membrane stress response buffers lethal effects in disequilibrium by 
reprogramming the protein homeostasis” (Thibault et al. 2012). 
3.9.6.3 Mutants effected by benzose 
Fifteen of the gene deletion strains identified as either benzose sensitive or 
resistant encode ribosomal subunits or proteins involved in the regulation 
of protein synthesis, five of which were directly associated with RNA-
polymerase I and II. The yeast ribosome consists of 78 ribosomal proteins, 
encoded by 137 genes, two per ribosomal protein. Twenty of the 30 most 
abundant mRNAs encode ribosome proteins. The mRNAs from these 
genes have significantly shorter half-lives compared to other mRNAs, and 
an estimated 50% of the RNA-polymerase-II-mediated transcription events 
involve ribosomal proteins (Warner, 1999). S. cerevisiae utilises transcription 
as its primary means of regulating ribosomal synthesis, whereas eubacteria 
utilise translation, albeit in very different ways.  
To date benzose has only been found to be active in S. cerevisiae. It can 
therefore be suggested that benzose may have an effect on a step in 
translation or subsequent processing of, for example, a ribosomal subunit; 
however the exact biological mechanism through which benzose acts 
remains open for further investigation. 
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4.0 Overall discussion  
Over the course of this study benzose has been developed as the most 
potent glycal inhibitor of growth in the S. cerevisiae strain ∆pdr1∆pdr3, 
from the library synthesised. The genomic assay suggests a role within 
transcription and/or translation. It is currently believed benzose has a 
direct or indirect role on ribosomal proteins. Selective covalent binding 
may have occurred, this remains to be investigated, and there are many 
questions still to be answered. 
 
4.1 Assessment of experimental strategies and protocols 
 
The overall strategies and protocols described in this thesis were designed 
to identify a lead compound and its biological mode of action in a 
rational manner. The SAR analysis allowed the bioactive compounds to be 
identified and a lead found. However, a larger library of glucosides needs 
to be tested to add more scope to the study.  
The chemical genomic screen using benzose was able to identify some 
likely pathways and processes that are being affected. The major problem 
found here was the breakdown of benzose and the associated activity 
reduction of benzose in agar. This could be repeated in liquid culture to 
determine if the lack of reactivity limited the genetic screen. The 1536-
format agar-based high throughput is efficient from the perspective of 
compound use, practical simplicity and internal replication. The amount of 
benzose required for a liquid-based high throughput screen would not act 
as a deterrent, as benzose is synthesised in four steps from D-glucal.  
A limitation in the chemical proteomics was found to be the lack of 
activity of 24. Attaching a probe to benzose on the C-6 hydroxyl of 
benzose would most likely lead to loss of activity, as evident in the SAR 
analysis which showed that the formate ester exterminated all activity 
against the ∆pdr1∆pdr3 strain. Further investigations are required to 
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identify a method of attaching a biological probe to benzose in order to 
identify the target, without the loss of activity. 
Within the chemistry section of this thesis it was determined that the 
synthesis of each compound was achieved in the fewest steps currently 
known. Methods of dihalocyclopropanation without the need for a fully 
protected glucal would lead to a much easier synthesis of further 
compounds destined to join the SAR. A method of 
dichlorocyclopropanation of an alkene via a dichlorocarbene, 
magnesium and ultrasonication, had been previously presented by Lin et 
al. (2003). Scheme 3.6 demonstrates this reaction on 3,4-dihydro-2H-pyran 
resulting in the 7,7-dichloro-5-oxabicyclo[4.1.0]heptane, in an impressive 
yield of 95%. This high yield would reflect the lack of competing 
functionality in this system, no compounds with C-3 functionality have 
been described at present in the literature. However, it would be worth 
invesitagating this cyclopropanation method on D-glucal. This method 
may offer a way of synthesising novel dichlorocyclopropanated 
carbohydrates.  
 
 
 
 
 
 
 
 
 
CCl4, Mg
ultrasound
Scheme 3.6. Synthesis of 7,7-dichloro-5-oxabicyclo[4.1.0] heptane via a 
dichlorocarbene, magnesium and ultra-sonication with a yield of 95%.  
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4.2 Assessment of the aims and objectives 
 
The overall aim of this project was to determine whether cyclopropanated 
sugars that can undergo ring opening or ring expansion reactions have 
ideal characteristics for suicide inhibitors. In this respect, it was partially 
successful. Of the four objectives set out in this thesis, three were 
achieved.  
Objective one was to design and synthesise a range of compounds that 
would allow identification of bioactivity, and to give an idea of the 
mechanism of action. A range of compounds were synthesised consisting 
of cyclopropanated carbohydrates and their glucal precursors.  
With a range of compounds synthesised, objective 2 was to identify a lead 
compound, which was benzose. The library allowed identification of the 
most likely chemical mechanism through which the compound might 
covalently modify a target protein.  If covalent modification occurs, it is 
proposed to go via a stabilised carbanion. Again the objective was met, 
the lead compound was then subjected to a chemical genetic screen. 
Objective three consisted of trying to identify the likely mode of action of 
the selected lead compound within the biological environment. This 
objective was completed with benzose, which was found to be both 
cytostatic and cytotoxic depending on concentration. It appears to 
interact specifically with translation and transcription pathways.  
The final objective was to identify the likely protein target(s) of the lead 
compound. A modified matrix and a benzose-like compound 24 were 
synthesised to achieve this target. However, compound 24 was found to 
be inactive, which raises the questions of the ability to use a chemical 
proteomic approach for these compounds. With the lack of time, 
objective four has yet to be accomplished.  
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Figure 5.1. A cyclopropanated carbohydrate showing all possible stereo isomers, 
showing the use of multiple 6-carbon sugars. 
R1, R2 = Cl, Br, I, H, NHR, CONH2, CONHR, 
R3 = OH, OBn, OBz, Me, Ac, alkyl chain, NHR, 
R4 = OH, OBn, OBz, OMe, OAc, alkyl chain, NHR, 
R5 = OH, OBn, OBz, OMe, OAc, alkyl chain, NHR, 
 
5.0 Future directions  
 
A considerable amount of progress has been made towards the 
application of mechanism-based inhibitors, consisting of a cyclopropane 
on a carbohydrate backbone. While many structures have been 
synthesised, many more could be made for further investigations. 
Identification of the biological target would be a major step forward in 
presenting the “big picture” in which benzose has its effect.  
5.1 SAR where to now?  
The development of a range of cyclopropanated derivatives has yielded 
a varying degree of activity, however there is a large area of 
stereochemistry yet to be investigated. Allose and galactose offer differing 
stereochemical arrangements compared to glucose, and would offer a 
good starting point to extend the structure activity relationship. The 
substituents on the C-3 and C-4 hydroxyls also offer an area that warrant 
more investigation. As discussed in section 3.5.2, the most likely mechanism 
of action is through the carbanion intermediate, although this remains to 
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be proven. The research into benzose has proposed two methods of 
moving forward with the SAR studies. Firstly, ignore the protein target and 
make more cyclopropanated carbohydrates (figure 5.1) to try and 
increase the toxicity on the whole cell, or secondly focus on identifying the 
biological target and design potent, benzose-like compounds for this 
target. 
Benzose its self may never offer a biologically relevant compound, 
however the ring breaking mechanism offers a novel mechanism-based 
inhibition that warrants more research. The use of the cyclopropane with 
the carbohydrate backbone has been shown to be active, most likely 
through the ring breaking mechanism, which answers the question “Will 
cyclopropanated carbohydrates undergo the slow ring 
breaking/expansion in the presence of proteins, and are we able to 
identify what of three types of mechanisms the reaction is going through?” 
The question can now be changed to further identify key aspects of 
activity, “will modifications to the structure provide selective binding to a 
biologically relevant target?” 
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6.0 Conclusion 
 
We set out to identify the potential in drug discovery of known and novel 
cyclopropanated-carbohydrates.  With the background knowledge of 
known chemistry that is well precedented in the literature, we proposed 
that this known chemistry could be catalysed by a selective protein. 
Over the course of this project, a library of cyclopropanated 
carbohydrate based compounds has been synthesised, with regio- and 
stereoselective chemistry in mind. Five compounds (all cyclopropane-
containing) were found to display cytotoxic activity against S. cerevisiae 
(∆pdr1∆pdr3), with the most active being benzose. A derivative of 
benzose was then synthesised to act as a molecular probe to give a tool 
to identify the protein target. However, this compound lacked activity and 
failed to pull down any proteins for identification. The current mechanism 
through which benzose acts in S. cerevisiae is unknown, but it is believe to 
be involved in transcription or translation, potentially via a ribosomal 
target, further investigations are needed. 
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8.0 Appendix  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exclusion masses for MALDI TOF-TOF MS/MS  
m/z monoisotopic NAME TOLERANCE (m/z) 
659.384 Trypsin 0.03 
805.417 Trypsin 0.03 
861.060 CHCA 0.10 
877.000 Polyethylene glycol 0.10 
906.505 Trypsin 0.03 
1020.503 Trypsin 0.03 
1153.574 Trypsin 0.03 
1175.523 Trypsin 0.03 
1296.680 Angiotensin 1 0.03 
1433.721 Trypsin 0.03 
1493.599 Trypsin 0.03 
1676.777 Trypsin 0.03 
1774.851 Trypsin 0.03 
2093.080 ACTH (clip 1-17) 0.03 
2163.057 Trypsin 0.03 
2193.003 Trypsin 0.03 
2193.995 Trypsin 0.03 
2273.160 Trypsin 0.03 
2289.155 Trypsin 0.03 
2305.150 Trypsin 0.03 
2465.190 ACTH clip (18-39) 0.03 
2514.339 Trypsin 0.03 
2550.233 Trypsin 0.03 
2612.181 Trypsin 0.03 
2613.350 Trypsin 0.03 
3211.475 Trypsin 0.03 
3227.400 Trypsin 0.03 
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m/z monoisotopic NAME TYPE CHARGE 
904.468 des-Arg1-
bradykinin 
 
r +1 
1296.685 
 
Angiotensin 
 
r +1 
1570.677 
 
Glu1-
fibrinopeptide 
 
r +1 
2093.087 
 
ACTH (1-17) 
 
r +1 
2465.199 
 
ACTH (18-39) 
 
r +1 
3657.929 
 
ACTH (7-38) 
 
r +1 
 
 
m/z monoisotopic NAME TYPE CHARGE 
255.1090 B2-17(-NH3) 
fragment ion 
r +1 
354.1780 B3-17(-NH3) 
fragment ion 
r +1 
784.4110 B6 fragment ion r +1 
1181.6580 Angiotensin Y9 
fragment ion 
r +1 
1183.6010 Angiotensin 
fragment ion 
r +1 
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